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Abstract
The oestrogen receptor (ER) mediates both normal and malignant breast
development. The ER can exert its ligand-dependent gene regulatory functions
directly by association with target genes and subsequent dynamic formation of a
transcription complex through its oestrogen response element. The complex receptor-
ligand signalling network has received much interest as a potential therapeutic target.
Endocrine agents, such as tamoxifen, have been developed to reverse oestrogen (E2)
stimulated gene transcription and tumour growth, however progression to endocrine
resistance provides a major obstacle in breast cancer treatment. This study
investigates changes in endocrine response and ER transcription activation during the
acquisition of endocrine resistance.
Breast cancer cell lines were selected that encompassed the range of oestrogen
and anti-oestrogen sensitivities from the E^-dependent and tamoxifen-sensitive MCF-
7 cell line through the less sensitive LCC-1 and LCC-2 lines to the insensitive LCC-9
and independently derived LY2 line. All lines had been derived from MCF-7 cells.
These models represent different endocrine phenotypes and were designed to reflect
sequential changes in the clinical progression from hormone sensitive to hormone
insensitive and antioestrogen resistant. MDA-MB-231 breast cancer cells were used
as ERa negative controls. Growth assays confirmed these phenotypes and
proliferative behaviour in response to Et and tamoxifen.
To help evaluate the role of the ERa in the development of endocrine resistance,
quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western
blot analysis was carried out to assess transcriptional and translational receptor status
for each phenotype. All resistant lines possessed greater levels of ERa mRNA than
wild-type MCF-7 cells. E2 downregulated ERa mRNA and protein. Results suggest
ERa functionality in these cell lines. Analysis of mRNA levels of several ER target
genes (pS2, progesterone receptor (PR), cathepsin D and MYC) indicated
informative differences between lines. pS2 was highly expressed in resistant lines as
was PR in most lines compared to MCF-7 cells. E2 and tamoxifen produced
attenuated or no effects in pS2 expression compared to the marked induction
produced by E2 in MCF-7 cells. Minor changes were also observed in the expression
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levels of various coactivators (SRC-1, SRC-2, SRC-3) and corepressors (NCoR,
SMRT and RIP140) investigated by qRT-PCR and Western blot.
A subset of three cell lines (MCF-7, LCC-1 and LCC-9) was used to examine
transcription complex assembly at the pS2 promoter in response to E2 utilizing
chromatin immunoprecipitation. This identified a dynamic cycle of increasing H4
acetylation (indicative of active transcription) and ERa as well as cofactor
recruitment upon E2 addition in MCF-7 cells. A distinctive H4 acetylation pattern
was revealed for LCC-1 and LCC-9 cells. While ERa recruitment was similar to
MCF-7 cells, particularly strong SRC-1 and SRC-3 recruitment was detected in
LCC-1 but most markedly in LCC-9 cells, implying altered pS2 transcription
complex assembly.
The data suggest that a functional oestrogen receptor may remain in these
endocrine resistant models. Cell proliferation and E2 target gene expression in LCC-1
cells proved to be oestrogen and antioestrogen independent but responsive in the
presence of the ligand whereas LCC-9 cells manifest complete endocrine resistance.
In addition, changes have been detected in the assembly of a gene transcription
complex at the pS2 promoter. Taken together, this is evidence for modified ER
mediated transcription activity. These results may help to identify potential
mechanisms of endocrine resistance.
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Breast cancer is a common disease with 1 in 9 woman in the UK developing
this illness during their lifetime. It is a disease with a high level of public awareness
and one of the best-funded areas of research in the world. Remarkable insights into
the biology of this cancer have been gained and significant progress has been made
in terms of treatment and outcome. However, many patients become resistant to
treatment or never respond at the outset. 'Further research is needed' is the phrase
included in many publications summarizing the underlying mystery that still
surrounds this disease.
1.1.1 Breast cancer classification
The normal female breast develops fully between the ages of 12 and 19 years.
It consists of lobules or glands grouped together into 15-20 lobes. Ducts emanate
from each lobule forming a lactiferous duct which merge beneath the nipple to form
a lactiferous sinus. Milk is secreted during pregnancy in the terminal duct lobular
unit in response to the hormone oxytocin. The breast also consists of adipose and
connective tissue (see figure 1.1).
A normal ductular epithelial cells
B basement membrane
C lumen (center of the duct)
A duct system
B lobules




F pectoralis major muscle
G chest wall/ rib cage
Breast profile:
Enlargement:
Figure 1.1: Schematic representation of the female breast (Source: www.breastcancer.org).
J
Introduction
Breast cancers can be classified as either in situ (non-invasive) or invasive cancers
(Sainsbury, J.R.C. et al., 2000). Most cancers develop in the lining of the ducts but
they can also arise in the lobules or the stroma. The most common form of pre¬
invasive breast cancer, ductal carcinoma in situ (DCIS), evolves only in the milk
ducts while invasive ductal carcinoma (IDC) spreads through the duct walls. Similar
classifications are made for lobular carcinoma in situ and invasive lobular carcinoma.
Less common forms of breast cancer include inflammatory cancers or medullary
carcinomas (which originates in the central breast tissue). Figure 1.2 shows a
mammogram of a normal breast and a mammogram of a breast showing an
abnormality later confirmed to be a malignant lesion.
Figure 1.2: Mammogram of a normal breast (left) and a breast showing an abnormality (Source:
Interactive Mammography Web Tutorial. McGill University Faculty of Medicine).
1.1.2 Incidence, mortality and epidemiology
(i) Worldwide
There are an estimated 10 million new cases of cancer occurring each year
(Parkin D.M. et al. 2001 (a), (b) and(c)). Breast cancer, with l.lmillion (10.4%)
cases, is the second most common cancer overall after lung cancer (12.3%) and
remains by far the most common cancer in woman. However, the disease only ranks
4
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fifth with 370 000 deaths (6%) of 6.2 million death caused by cancer. This
favourable trend is considered to be due to improving treatment options compared to
lung or stomach cancer. Age standardized incidence and mortality rates for the
disease vary greatly between different countries. Generally high rates of incidence
can be found in Northern America, Europe and Australia (GLOBOCAN 2000 in
Parkin, D.M. et al., (a)), which indicates a strong link between more affluent areas
and high numbers of breast cancer cases.
(ii) In the UK
In the UK, 41,000 new cases of breast cancer and 13,000 deaths due to the
disease occur every year. The number of new cases accounts for more than 1 in 4 of
all cancers diagnosed in woman. Over the course of the last 25 years and up to 2000,
the UK has seen a steady increase of age standardized female breast cancer incidence
rates rising from 79 to 114 per 100 000 women. This increase can partially be
attributed to more frequent screening and more thorough national case registration
over these years. The lifetime risk of developing breast cancer in the UK is 1 in 9
across all ages. The age-standardized 5 year relative survival rate (taking into
account the underlying rates of death in woman of the same age) has increased from
about 52% between 1971-1975 to about 77% between 1996-1999 as documented in
table 1.1 (Cancer Research UK (CRUK), 2004).
1971-1975 1976-1980 1981-1985 1986-1990 1991-1995 1996-1999
52% 59% 62% 67% 73% 77%
Table 1.1: Age standardized 5-year survival rates for female breast cancer patient's diagnoses
1971-1999, England and Wales (Source: http://www.cancerresearchuk.org/aboutcancer/
statistics/statsmisc/pdfs/factsheet_breast_feb2004.pdf).
1.1.3 Aetiology
Most risk factors associated with a greater chance of developing breast cancer
are the consequence of higher exogenous or endogenous oestrogen levels in the cell




The strongest risk factor for breast cancer is age. The incidence of breast
cancer in woman increases considerably up until menopause. In the UK in 2000, 587
new cases were diagnosed at the ages of 30-34 years compared to 5586 new cases
between the ages of 50-54 years (CRUK, 2004). Once menopause is reached the rate
of increase in developing the disease slows down. Breast cancer under the age of 30
is rare (CRUK, 2004).
(ii) Age at menarche and menopause
Early onset menarche as well as late onset of menopause have both long been
related to an increased risk of breast cancer. Woman who reach menopause after the
age of 54 years are subject to a twofold increase in the risk of breast cancer. A
threefold increase is likely for women who reach menarche before the age of 11
years (McPherson, K et al., 2000). Both factors could be based on prolonged
exposure to endogenous oestrogen during regular ovulatory cycles (Pari, F.F., 2000).
(iii) Family history
A genetic predisposition is widely acknowledged as a risk factor in this
disease. Hereditary factors account for an estimated 5-10% of all breast cancers
(Ellison E.W., et al., 1998). Several genes have been demonstrated to be linked with
susceptibility to breast cancer including tumour suppressor genes BRCA1 and
BRCA2 located on chromosome 17q21 and 13q 12-13, respectively. Women carrying
mutations of BRCA1 and BRCA2 are estimated to have an 85% lifetime risk of
developing breast cancer. Mutations occur at almost any position (McPherson K. et
al., 2000: Dumitrescu. R.G. and Cotarla, I. 2005). Complete loss of function for both
genes is a result of carriers exhibiting the loss of the wild-type allele. There is a very
high probability for this loss, when carrying a germ line mutation in one of the two
alleles of the gene. BRCA1 and BRCA2 are considered 'caretaker genes', one of two
groups of cancer susceptibilty genes responsible for maintaining genomic integrity
(reviewed in Venkitamaran, A.R. et al. 2002). Mutations of these genes causes
accumulation of altered 'gatekeeper genes', the gene group whose changed functions
alters regulation of cell cycling, cell proliferation and cell death.
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Much effort has been spent on determining how wild-type BRCA proteins
play a role in preserving chromosome structure. BRCA1 function has been linked to
several aspects of DNA damage repair as well as the regulation of transcriptional
events (reviewed in Wang, Q. 2000). For example, co-localization has been reported
with DNA repair and recombination protein RAD50 or RAD51 protein complexes,
suggesting that BRCA1 might be directly involved in repair-work of double-stranded
DNA breaks (Scully, R. et al. 1997(a) and (b); Zhang, H. et al. 1999). BRCA1 has
been shown to associate with chromatin remodelling complexes containing HDAC as
well as CBP/p300 proteins to modulate gene transcription in breast and ovarian
cancer (Yarden, R.I. and Brody, L.C. 1999; Pao, G.M. et al. 2000). BRCA1 and
BRCA2 genes have been suggested to play a role in cell cycle control with one or
both proteins able to regulate cell cycle arrest and/or apoptosis (reviewed in
Venkitamaran, A.R. et al. 2002). Most mutations linked to breast cancer show little
evidence to be familiar rates of mutations but are in fact sporadic forms, for example
mutations found on the tumour suppressor genes p53 and PTEN/MMAC1 (reviewed
in Feki, A. and Irminger-Finger, I. 2004; de Jong, M.M. et al. 2002). p53 is located
on chromosome 17p 13.1 and is thought to play a role in DNA repair as well as
prevention of replication of damaged DNA. Mutations of p53 are common and
identified in approximately 50% of all human cancers including breast, ovarian and
lung cancer. The risk of developing breast cancer for women carrying a p53 mutation
decreases with age but is estimated to be 18 fold higher compared to the general
population.
(iv) Life style
Much debate has been sparked by the fact that breast cancer incidence is
much higher in Western European countries or the US than African or Asian
populations (Parkin, D.M. et al. 2001). This is thought to be due to geographical as
well as lifestyle factors such as income, education or housing which are linked to a
higher incidence of breast cancer. For postmenopausal woman, being overweight
increases the risk of breast cancer by around 50% most likely by increasing the
exposure to endogenous oestrogen (reviewed in Key, T.J. et al., 2002). However, this
does not appear true for pre-menopausal woman where obesity is associated with a
slight decrease in breast cancer incidence (reviewed in Hankinson, S.E. et al. 2004).
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As with early pregnancies and breastfeeding in younger women, these factors
decrease the risk longterm as the number of ovalutory cycles and therefore the levels
of endogenous oestrogen are reduced. Also, an increased alcohol intake might be
associated with an increased risk for breast cancer (Petri, A.L. et al. 2004. and
others). The mechanisms for this association are unknown but might include the
hypothesis that alcohol induces genome instabilities such as chromosome 17
aneuploidy (Benassi B. and Fenech M., 2004) or increases in oestrogen concentration
in the serum (Dorgan, J.F. et al. 2001). Taken together, evidence for any dietary or
other lifestyle risk factors remains controversial and their effects are likely to alter
the balance of circulating oestrogen and other hormones (Key, T.J. et al., 2002).
(iv) Hormone replacement therapy
When analysing evidence for the risk of breast cancer as a result of hormone
replacement therapy (HRT), a clear distinction is made between current and never or
no-longer users as well as long-term and short-term users. In general, the incidence
risk increases most significantly for women who are currently and have been using
HRT for more than 5 years. A study by the Collaborative Group on Hormonal
Factors in Breast Cancer (Collaborative, 1997) which included 51 studies in 21
countries demonstrated that the relative risk of being diagnosed with breast cancer
for woman currently using or having used 1 -4 years previously, increases by a factor
of 1.023 per year of use. The risk for woman having used HRT for 5 years or longer
is increased by a factor of 1.35. Interestingly, this increase diminishes when HRT
usage has been stopped for more than five years. The risk for women who never have
or have ceased using HRT is reduced or disappears. One of the largest studies to
demonstrate the increased risk for current HRT users to develop and die from breast
cancer for was the so called 'Million Women Study" (Beral, V. et al. 2003). This
study also established that continuous HRT combining oestrogen with progestagens
carries a greater risk than other HRT combinations or oestrogen alone (Beral, V. et
al. 2003; Tjonneland, A. et al. 2004). When evaluating the HRT associated breast
cancer risk, it has to be taken into account that combined HRT can decrease
sensitivity for mammography. Combined oestrogens and progestogens can increase
breast density, a fact that reflects negatively on the efficacy of breast screening.
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Risk factor High risk group
Gender Female
Age Elderly
Genetic predisposition BRCA1/2 mutation carriers
Geographical location Developed country
Family history BC in first degree maternal relative
Reproductive span Early age at menarche
Late age at menopause
Age of pregnancy Late age at first pregnancy
Parity Null parity
Previous benign disease Atypical hyperplasia
Endogenous hormones Current use of oral contraceptives
Long-term hormone replacement therapy
Height Tall individuals
Diet High fat intake
Benefit factors: Physical activity
Long duration of lactation
Table 1.2: Possible risk factors for breast cancers as suggested by a literature review.
(Dixon, J.M. 2003). A certain number of breast cancers might therefore remain
undetected or will not be be detected until later stages. Overall, interpretation of
results in these studies, regarding the effects of HRT on breast cancer, is difficult. It
is often commented that, particularly in large cohort studies, clear subgroups of HRT
users and information on the length and the hormone combination is not consistently
known. In addition, when comparing breast cancer incidences, HRT users are more
likely to be seen regularly by a physician than non-users, which might increase their
chance of being diagnosed with breast cancer. Known and suspected risk factors
contributing to an increased risk of breast cancer as reviewed in the literature are
summarized in table 1.2.
1.1.4 Screening and diagnosis of breast cancer
Breast cancer screening aims to detect any malignancy as early as possible
and before any spread has occurred to increase the potential for a cure. Many
women detect palpable malignancies by self-assessment. However, the most
effective screening method is mammography particularly for women aged 50-70
years which can reduce mortality from breast cancer for up to 40% in those who
9
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attend (Blarney, R.M. et al., 2000). The National Breast Cancer Screening
Programme in the UK currently advises every woman between the age of 50 and 64
years to take part in mammographic screening every 3 years. The program is being
extended to include women up to the age of 70 years in 2004 nationwide.
Mammography can detect palpable as well as non-palpable abnormalities since
carcinomas generally display a greater density than the surrounding tissue. If an
abnormality has been detected or is suspected by mammography, a tissue sample can
be extracted for further investigation by the cytopathologist. Fine needle aspiration or
core biopsies remove smaller lesions or draw tissue samples from the affected area
which can then be examined for the presence of malignancy and other diagnostic
factors such as their ER/ PR status determined through immunoperoxidase staining.
The tumour is staged and graded as described in the next section and a treatment plan
is established based on the combined results of these diagnostic procedures.
In addition to the primary detection methods, genetic testing is offered for
women who are at a particularly high risk of developing breast cancer. Among these
are women who have had several cases of breast cancer within the family, especially
on the same side. Familial breast cancer is also suspected when cancers occur at
younger ages or other forms of cancer have evolved such as ovarian or bowel cancer,
cancers that have shown to be linked to the occurrence of breast cancer.
1.1.5 Treatment of breast cancer
(i) Staging and grading of breast cancer
The choice of treatment for breast cancer is strongly influenced by the stage
and grade of the tumour as well as the overall health and the wishes of the patient.
The stage of a breast cancer categorizes tumours according to their size and degree of
spread where stages I-III are considered primary breast cancers with possible
regional (nodal) metastases and stage IV implies secondary cancers, tumours of any
size with involvement of distant metastases (see table 1.3). Grading breast cancer is
based on the histology of the tumour. Grade 1 to 3, corresponding with high to lower
survival rates, are assigned using histological characteristics such as tubule formation
or mitotic counts of the carcinoma.
10
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Stage Tumour diameter Involvement of regional spread Evidence of distant spread




II 5cm or greater no no
III 5cm or greater Yes (skin, lymph nodes, pectoral and
chest wall fixation)
no
IV Any size Yes or no yes
Table 1.3: Staging system for breast cancer tumours.
(ii) Chemotherapy
The systemic forms of breast cancer treatment used are either neoadjuvant
(before surgery) or adjuvant (supplemental, after surgery). Neoadjuvant
chemotherapy is given to reduce tumour size and determine the tumours response to
this form of treatment for subsequent treatment. Adjuvant chemotherapy is given in
addition to other forms of treatment such as surgery to reduce the chances of cancer
recurrence by eliminating metastatic forms of the disease. Chemotherapy is
administered either orally or, more commonly, intravenously in cycles
(administration over several days followed by 3-4 week breaks) and can last up to 6
month (Cancer Research UK Website). The most commonly used drugs include
cyclophosphamide (cytoxan), Epirubicin (Ellence), 5-Fluorouracil (5 FU/Adrucil) or
Methotrexate (Amethopterin/ Mexate/ Folex). Drugs are often used in combination to
maximize efficacy. Most common combinations include CMF (cyclophosphamide,
Methotrexate, 5-Fluorouracil) and FEC (5-Fluorouracil, Epirubicin,
cyclophosphamide). The nature of such systemic therapy leads to a variety of side
effects experienced by patients. More temporary side effects include nausea and
vomiting, hair loss, fatigue and anaemia while potential permanent effects include





Most patients are ultimately offered surgical procedures to remove
carcinomas and obtain a lymph node sampling. Surgery can involve removing
localized carcinomas (lumpectomy) or the removal of the carcinoma, surrounding
affected tissue or lining of the chest muscle (partial mastectomy). The most common
form of surgery involves the removal of the breast in addition to lymph nodes and
affected chest wall lining or muscles (modified radical mastectomy). Surgery is often
combined with internal or external radiation therapy or chemotherapy to eliminate
any remaining cancerous cells and reduce the chances of recurrence (see 1.4 (ii)).
(iv) Hormone therapy
Hormone therapy is primarily used for oestrogen and progesterone receptor
positive cancers. Various endocrine agents are designed to reverse oestrogen
stimulated tumour growth in different ways. They can be divided into two major
groups: (a) 'Classical' antioestrogens: Triphenylethylene derivatives such as
tamoxifen and other non- steroidal compounds such as 'Fixed ring' structure
Raloxifene; and the more recently developed (b) Steroidal and non-steroidal
aromatase inhibitors such as Letrozole.
Tamoxifen, an oestrogen derivative, with its relatively low toxicity has
proven to be a significant part of breast cancer chemoprevention and treatment
(Clarke, R. et al. 2003) (figure 1.3). It is generally associated with an increase in
disease free and overall survival and used long term for up to 5 years in adjuvant
therapy. Tamoxifen prevents oestrogen stimulated gene transcription by competition
with oestrogen for ER binding. However, many tumours eventually grow resistant to
this antioestrogen. Tamoxifen's known partially agonistic effects also result in
unwelcome side effects. This lead to the development of other strategies including
anti-oestrogenic agents ICI 182,780 (Fulvestrant/Faslodex) and ICI164,384.
Oestradiol analogues are steroidal ER inhibitors regarded as pure antagonists because
of their lack of oestrogenic activity (reviewed in Osborne. K. et al. 2000). ICI
182,780 is primarily used in advanced forms of the disease after tamoxifen failure



























Figure 1.3: Chemical structure of selected 'classical' antioestrogens and aromatase inhibitors (source:
Flowell, A. et al. 2001).
the receptor which might avoid cross-resistance to tamoxifen. ((Howell, A. et al.
2001; Gradishar, W.J., 2004). However, purely antioestrogenic also implies
therapeutic disadvantages as the use of these agents increases bone loss. The
mechanism of action of antioestrogens as well as the antioestrogen resistance is
discussed in more detail in chapters 1.4.1 and 1.4.2.
Benzothiophenes, such as Raloxifene (keoxifene, LY 156,758), are
structurally similar to triphenyl-ethylenes. Both groups are non-steroidal
antioestrogens and considered competitive ER inhibitors with partial agonistic
activities. The three-dimensional structure of Raloxifene inlcudes a 'fixed ring'.
Raloxifene significantly reduced the risk of ER positive breast cancer development in
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postmenopausal women (Cauley, J.A. et al. 2001). Compared to tamoxifen, it
showed substantially less oestrogenic activity in the endometrium (Cummings, S.R.
et al. 1999). Raloxifene also shows beneficial effects on bone density and was further
developed for the prevention and treatment of osteoporosis (Delmas, P.D. et al.
1997).
A more recent option is aromatase inhibitors such as anastrazole or letrozole
offering a more potent and better tolerated form of treatment to postmenopausal,
hormone sensitive breast cancer. Unlike antioestrogens, aromatase inhibitors prevent
the conversion of androgens to oestrogens actively removing a primary source of
oestrogens available to the receptor. In the so-called Anastrazole, Tamoxifen Alone
or in Combination (ATAC) trial, the largest of its kind so far, anastrazole, as
adjuvant treatment for postmenopausal woman, demonstrated enhanced efficacy as
progression-free survival time was increased by 19% and the incidence for new
contra-lateral tumours decreased by 58% compared with tamoxifen (Buzdar, A.U.;
ATAC Trialists' Group, 2003 and Dowsett, M. and Howell, A. 2002). In addition,
patients seem to tolerate treatment with anastrazole generally much better although
nausea and muscoskeletal pain are common side effects. Results of these studies are
likely to lead to the use of aromatase inhibitors as the preferred choice of therapy in
early breast cancer although the use of agents in sequence for the optimal treatment
might always include antioestrogens. The continuous withdrawal of oestrogen is
likely to cause adverse effects on other systems such as bone metabolism and
cardiovascular functions (Dowsett, M. and Howell, A. 2002; Haynes, B.P. et al.
2003). The ATAC trial showed that patients receiving anastrazole have a greater
incidence of bone fractures reflecting a possible increase in bone mineral loss
(ATAC Trialists" Group, 2002). Letrozole has shown to increase urinary and plasma
markers of bone resorption (Heshmati, H.M. et al. 2002; Harper-Wynne, C. et al.
2002). Further research assessing long-term effects of aromatase inhibitor is needed
to ensure the agents beneficial effects outweigh the side effects.
Aside from antioestrogens and aromatase inhibitors, pituitary down regulators
(such as 'goserelin'), ovariectomy or radiotherapy targeting the ovaries are
sometimes considered in pre-menopausal woman as strategies to suppress hormone
production and reduce exposure to endogenous levels of oestrogen.
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(v) Other forms of treatment
A more recently developed form of breast cancer treatment is a monoclonal
IgGl class- humanized antibody Herceptin (trastuzumab) designed to the
extracellular domain of the HER2/neu receptor. The HER2/neu receptor is a member
of EGFR/HER/erb family of transmembrane receptor tyrosine kinases which also
includes the epidermal growth factor receptor HER1 (EGFR, erbBl), HERS (erbBS)
and HER4 (ErbB4)(figure 1,4)(Arteaga, C.L. 2003; Ross, J.S. et al. 2004). HER
receptors are involved in signal transduction via phosphorylation and
dephosphorylation of transmembrane proteins or signalling intermediates of several
pathways such as the Ras/mitogen activated protein kinase (MAPK) or
Figure 1.4: The HER2/ neu family of transmembrane receptor tyrosine kinases (source: Ross, J.S. et
al. 2004)
phosphatidylinositol 3-kinase (pl3K)/ Akt pathways which affect cell proliferation,
survival, motility and adhesion. Activation of HER receptors follows ligand binding
and dimerization with another receptor of the family. HER2 is the only receptor for
which there is no known ligand, however, it is the preferred binding partner
providing the most stable and potent combination of dimers (Tzahar, E. et al. 1996;
Craven, R.J. et al. 2003).
HER2 has been found to be overexpressed in 20-30% of breast cancers
mostly the result of amplification of the HER-2 gene (Slamon, D.J. et al. 1987;
Pauletti, G. et al. 1996). The overexpression of HER-2 has been positively correlated
15
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with a poor breast cancer prognosis involving several parameters such as disease
recurrence, metastasis, short term survival and resistance to chemotherapy and
hormone therapy (reviewed in Harries, M. and Smith, I. 2002). In vitro and in vivo
studies have shown that herceptin has a significant antiproliferative effect in HER-2
overexpressing breast cancer, however, the mechanism of action remains elusive
(Harries, M. and Smith, I. 2002; Ross, J.S. et al. 2004). It is likely that the
mechanism involves receptor degradation preventing HER2/neu dimerization or a
pro-apoptotic effect inhibiting PI3K/Akt signalling (De Santes, K. et al. 1992; Yakes,
F.M. 2002). Herceptin is most widely used as a first- and second-line agent in HER-2
overexpressing metastatic breast cancer. It is used as a single agent or in combination
with chemotherapeutic drugs such as paclitaxel (Arteaga. C.L. 2003; Ross, J.S. et al.
2004).
1.2 Oestrogens, Oestrogen Receptor and Breast Cancer
Oestrogen is classically defined as one of the natural steroids, a female sex
hormone responsible for the stimulation of the development of female secondary sex
characteristics and the promotion of the growth and maintenance of the female
reproductive system. Oestrogens also play a role elsewhere in the human body, for
example the male reproductive system, the cardiovascular and immune systems and
in the development of diseases such as colon cancer and arthritis. The role of
oestrogen in the development of breast cancer is complex and the subject of diverse
intensive research.
1.2.2 Oestrogen synthesis and metabolism
All oestrogen molecules are a product of cholesterol metabolism and consist of
an aromatic ring, a phenol hydroxyl group and a methyl group. In premenopausal
women most oestrogen is biosynthesised in the theca and granulosa cells of the
ovaries. This hormone synthesis is known as the 'two-cell' concept. Androgenic
precursors, testosterone and androstenedione, originate in a multistep enzymatic
reaction in the theca interna cells and are then aromatised into oestradiol (E2) and
estrone (Ei) in the granulosa cells. The synthesis of progesterone and testosterone is
mediated by the luteinizing hormone (LH), the aromatisation to oestradiol and
16
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estrone by the follicle-stimulating hormone (FSH). Hormone synthesis also takes
place in the adrenal cortex and peripheral tissue, and adipose tissue. Oestrogen levels
are maintained in the breast tissue by hormone uptake from the serum and local
synthesis (Miller, W.R. and O'Neill, JS. 1987; Pari, F.F. 2000 (b)).
Once women reach menopause, non-ovarian oestrogen production is
predominantly responsible for the maintenance of hormone levels in breast tissue.
The steroids androstenedione and estrone sulfate circulate in an inactive form in
breast tissue and are both converted to estrone by P450 aromatase and estrone
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Figure 1.5: Oestradiol synthesis in breast tissue (Estrone sulfatase (Ei -STS), Interleukin-I/6
(IL-1/6), Tumour-Necrosis Factor a (TNF).
HSD) converts estrone into the biologically active estradiol (see figure 1.5).
Aromatase is encoded by the CYP19 gene. The gene contains multiple promoters.
The expression of CYP19 is thought to be influenced primarily by promoter 1.4
stimulated by cytokines such as IL-6 and TNF-a in normal tissue (Purohit, A. et al.
2002, Suzuki, T. et al. 2003). However, in malignant tissue, expression is mainly
stimulated by promoter 1.3 and II. Its regulation remains unclear but might be
influenced by cAMP and Prostaglandin E2 (PGE2) (Purohit, A. et al. 2002).
The proposal of a local synthesis of oestrogen is based on the observation that
after menopause there is a change in the ratio of E2 concentration in plasma
circulation compared to the concentration in the breast tissue. After menopause,
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oestrogen levels decrease in the circulating serum but remain the same in malignant
breast tissue (van Landeghem, AA et al. 1985). Hence oestrogen levels are actually
much higher in the tumour compared to the level in the serum but also compared to
normal surrounding tissue as summarized by Pasqualini, J.R. (2004). The local
oestrogen source is the key in the development of newer treatment forms for breast
cancer using aromatase inhibitors. The development of breast cancer is dependent on
increased oestrogen exposure. The blockade of this synthesis pathway is thought to
prohibit tumour progression in postmenopausal women. Not unexpectedly, even
complete aromatase inhibition does not withdraw all oestrogen from the breast tissue
and plasma. Alternative pathways must be available to synthesize oestradiol locally
under the influence of enzymes such as STS and 17(3-HSD Typel or oestrogens
entering through the diet.
1.2.3 Oestrogen receptor
Oestrogen mediates its actions by binding to the oestrogen receptor, a
member of a large protein family consisting of nuclear receptors for vitamin A,
testosterone and progesterone as well as orphan receptors to which specific ligands
have not yet been identified.
(i) Oestrogen Receptor Structure
The oestrogen receptor a (ERa) gene is a 140kb gene located at 6q25.1
(Gosden, J.R. et al. 1986). It encodes a 595aa protein expressed primarily in the
uterus, the liver, the kidney and the heart. A second oestrogen receptor gene, ER(3, is
located at 14q22-24 and spans about 40kb (Enmark, E. et al. 1997). The ERp protein
consists of 485aa and is primarily found in the ovary, the prostate, lung,
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Figure 1.6: Percentage amino acid identiy between human ERp and human ERa. Numbers above note amino acid position




gastrointestinal tract, bladder, haematopoietic and central nervous systems. In
addition, both receptor forms are also found in certain areas of the brain, the
mammary gland, the thyroid and the bone. The human ER(3 shows about 47%
identity overall to the human ERa in its translated region (Enmark, E. and
Gustafsson, J.-A. 1999)(Figure 1.6). Exact amino acid positions as well as the degree
of amino acid homology vary slightly between publications (figure 1.7).
Both steroid receptors consist of six main functional domains but with
varying homology. The N-terminal domains A and B encode one of the two-ligand
binding domains (LBD), activation domain (AF-1) associated with ligand -
independent (constitutive) activity involved in protein-protein interaction and
transcriptional activation of oestrogen target genes (figure 1.7). Here one of the
striking functional differences between the two-receptor forms can be found reflected
in the low degree of homology of only about 16% within the N-terminal region. In
ERa, oestrogen mediates transcription of several oestrogen responsive genes by
activation of the AF-1 domain but fails to have an impact on this domain in ER(3.
Furthermore, two separate regions within the AF-1 domain of ERa, which are not
found in ER(3, are necessary for the agonistic effect of oestradiol. Synthetic
antioestrogens such as tamoxifen or raloxifene show a partial agonistic effect as
opposed to a pure antagonistic effect in ER(3 (reviewed by Nilsson, S. et al. 2001).
This might be one functional variation contributing to the different response of
specific tissues to oestrogens and antioestrogens. The highest degree of homology
between the two receptors with 97% identity is observed at the
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Figure 1.7: Schematic diagram of oestrogen receptor a protein and its structural and functional
domains. Numbers note amino acid positions within protein. Note: Exact amino acid positions vary
between publications (figure adapted from Sommer S. and Fuqua, S.A.W., 2001).
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Figure 1.8: Positioning of helix H12. a: ER LBD-E2 complex, b: ERLBD-RAL complex.
H12 is drawn as a cylinder and coloured blue (E2 complex) or green (RAL complex). The remainder
of the ER LBD is shown in red.Dotted lines indicate unmodelled regions of the structures.
Hydrophobic residues located in the groove between H3 and H5 (yellow) and Lys 362 (K362, pink)
are depicted in space-filling form. The locations of Asp 538. Glu 542 and Asp 545 are highlighted
(brown spheres) along with the helices that interact with H12 in the two complexes (source:
Brzozowski, A.M. et al. 1997).
DNA binding domain (DBD), the C-domain of the receptor, with only two aa
differing (reviewed in Pari, FF (c) 2000). This domain contains two zinc fingers to
mediate conformational changes in the receptor and the binding of the receptor to the
promoter of the ER responsive gene. As a result of the structural resemblance,
receptor binding shows similar specificity and affinity for the ERE binding to the
promoter. Regions D-F at the COOH-terminal are the most important for ligand
binding, receptor dimerization and nuclear translocation. This region includes a
ligand-binding pocket, which harbours the functionally critical activation domain
AF-2. Crystallographic structures have revealed that the LBD contains an interacting
surface composed of aa spanning helices 3-12 (Pari, FF (c) 2000). The AF-2 region
stretches over helices 3, 4, 5 and 12 where helix 12 (HI2) is specifically altered
depending on the ligand bound to the receptor (figure 1.8) (Brzozowski. A.M. et
al. 1997; Shiau, A.K. et al. 1998). When agonists oestradiol or diethylstilbestrol
(DES) are bound to the LBD, HI2 positions itself in a way that seals the binding
cavity, generating an interacting surface for coactivators necessary for the
transcription initiation of target genes. In contrast, when antioestrogens such as
raloxifene or tamoxifen bind to the LBD, their long side chains prevent HI2 from
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covering the binding cavity as with oestradiol binding. Instead, H12 occupies helices
3,4 and 5 while blocking the coactivator binding sites at H12 and preventing the
activation of transcription. Distinct receptor conformations caused by different
ligands and specific H12 positioning serve as molecular evidence for agonistic or
antagonistic response. Such conformational changes have been observed for liganded
states at the activation domains in both ERa and ERP (Pike, A.C. et al. 1999).
(ii) Oestrogen receptor isoforms/ splice variants
There is an abundance of splice variants that have been identified for the ER
receptor including mRNA variants with duplications, insertions or deletions of
alternative exons at either the NEE or the COOH terminus, the DNA or ligand-
binding domains. The nomenclature and classification for the identified isoforms
varies to a great extent. Here, non-coding region and coding region variants will be
differentiated. The same nomenclature as suggested by Flouriot, G. et al. (1998) is
used (detailed review of ER mutations by Herynk, M.H. et al. (2004). The described
mRNA isoforms described are all products of non -mutated genes. Other variants
generated from genes altered by nucleotide substitutions and deletions have also been
identified.
The ERa gene spans eight exons. The coding region is comprised of exons 1-
8 where the DBD is encoded by exons 2-3 and the LBD by exons 4-8 (reviewed in
Hirata, S. et al. 2003). Variants with any of these individual exons or a combination
deleted have been found as well as an additional exon S between exons 3 and 4
(Hirata, S. et al. 2002). One of the most frequently observed variants in breast cancer
is an ERa exon 7 deletion (A7) (McGuire, W.L. et al. 1991). As with most variants,
the A7 variant is co-expressed with the wild-type ERa mRNA. It makes up about
30% of total ERa mRNA although only 2 of 23 tumours expressed the protein
product of this variant (Fuqua, S.A. et al. 1992). Similarly, despite high mRNA
levels of this variant in several antioestrogen resistant ER positive MCF-7 cell
sublines, a corresponding protein has not been detected (Madsen, M.W. et al. 1997).
Furthermore, expression differences for the A7 mRNA variant could not be revealed
between the wild type MCF-7 cells and the different resistant lines suggesting that
this variant plays no significant role in the development of antioestrogen resistance.
Studies of the predicted proteins from the various mRNA isoforms are rare. There is
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still insufficient information as to whether proteins are expressed from the isoforms
and whether they fulfil any biological role.
In addition to the coding region, multiple untranslated 5'-exons in the
upstream region of exon-1, the promoter region, have been identified (Herynk, M.H.
et al. 2004). The encoding for an ER mRNA transcript appears to use different
promoters employing alternative exons in the 5' untranslated region (UTR). Even
though various mRNA isoforms are generated, they only differ in their UTRs. The
translation-initiation codon is located downstream from the UTR within the exon-1
region and consequently, all promoters encode the same 66kDa ER protein. The
main ERa exon-1 variants identified have been named promoter A-l to F-l. More
recently two new exons have been identified for the ERa promoter called T-l and T-
2 expressed mainly in the testis and epididymis (Brand, H. et al. 2002). Isoforms A-F
have all been shown to be present in MCF-7 cells as well as benign and malignant
breast tissues to varying degrees with A-l as the most abundant isoform (Flouriot, G.
et al. 1998; Pari, FF (c) 2000). As with the coding region variants, the function of the
5'UTR variants remains unclear. The alternative exons may be responsible for the
control of ER synthesis by regulating the turnover or translation efficiency of the ER
mRNA isoforms. This suggestion is based on the thermodynamic principle that the
5'UTR sequences of the mRNA could be folded in the more stable secondary
structures (Flouriot, G. et al. 1998).
One shorter 46kDa ERa isoform (hERa46) has been isolated in human
osteoblasts and the MCF-7 cell line but not in human tissue samples (Flouriot, G.
2000). This mRNA isoform is identical to hERa66 aside from the absence of the first
173aa. It lacks the A/B domain at the N-terminus and consequently the AF-1 region.
The hERa46 protein is thought to both homodimerize with itself- and also
heterodimerize with hERa66 competing for the ERa DNA binding site. It is able to
repress AF-1 dependent transcription indicating a possible mechanism to alter ERa
dependent gene transcription.
Similar to ERa, multiple variants have been detected for ER|3. The coding
region of the ERP gene consists of exons 1-7 with several untranslated exons in the
upstream region of exon-1 (reviewed in Hirata, S. et al. 2003). Like the ERa, ERP
mRNA is a product of a complex transcription initiation using different promoters.
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Single as well as multiple exon deletions or duplications have been identified for
each of the coding region exons. For example, ERPA5, an exon 5 variant lacking part
of the LBD has been identified (Inoue, S. et al. 2000). This isoform might act as a
dominant negative receptor, blocking oestrogen stimulated transactivation by ERa as
well as ERp. An inserted exon M has also been located between exons- 4 and 5
(Shoda, T. et al. 2002). It remains to be seen whether any of these isoforms and their
possible products give any insight into the function of ERp, the coexistence and
interaction between the two receptor forms and the development of breast cancer.
1.2.4 ER co-regulatory proteins
The oestrogen receptor associates with the promoter of the target gene but
also a host of other proteins to mediate transcription. Among those proteins are co-
regulatory proteins classified into nuclear receptor (NR) coactivators and NR
corepressors, which by definition, enhance and inhibit transcription, respectively.
(i) Coactivators: SRC-1
Among the best-studied coactivators in NR-mediated gene transcription is the
pi60 protein family with its three closely related members SRC-1 (also termed
NcoA-1/ ERAP-160), SRC-2 (also termed TIF2/GRIP1) and SRC-3 (also termed
AIB1/ ACTR/ RAC3/TRAM-1). The functionally most interesting similarity in
structure is the common central nuclear receptor-interaction domain (NRD)
consisting of three LXXLL motifs or NR-boxes, and a common PAS domain (Figure
1.9). The LXXLL motifs account for the coregulator's ability to bind to the LBD of
the receptor whereas the PAS domain is known to be involved in protein-protein
interaction. Several groups have produced evidence that the pi60 family is involved
in NR dependent gene transcription. SRC-3 was detected at high levels in the cytosol
as well as in the nucleus of MCF-7 cells and has been shown to form an endogenous
complex with hER after oestrogen treatment (Tikkanen, M.K. et al. 2000). This
complex formation also took place to a lesser extent in MCF-7 cells treated with
monohydroxytamoxifen, an indication of the involvement of SRC-3 in the agent's
partial agonism. However, this experiment failed to detect SRC-1
coimmunoprecipitation with hER. It was suggested that this is partially due to a low
level of SRC-1 in the nuclear fractions as opposed to high levels only in cytosolic
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Similarity (Identity): hSRC-1/2, 54% (46%); hSRC-1/3, 50% (43%); hSRC2/3, 55% (48%)
hSRC-1/2: 73% (64%) 55% (48%) 42%(36%)
hSRCl/3:67% (59%) 55% (45%) 45% (38%)
hSRC2/3:71% (63%) 64% (58%) 52% (46%)
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Figure 1.9: Structural and functional features of p 160 proteins. The similarity (and identity) of amino
acid sequences for full-length human SRC proteins and their specific conserved regions are indicated
above the bars. The letters below the bars indicate structural domains, and the lines underneath the
bars indicate domains that interact with different factors or nuclear receptors (NR) (adapted from Xu,
J. and Li, Q. 2003).
fractions. Other groups demonstrated that pi60 proteins are essential and sufficient
for the initiation of transcription of the E2 dependent CTSD promoter (Shang, Y. et
al. 2000). SRC-1 family members were also identified as being recruited to the pS2
promoter in MCF-7 cells as part of an intricate transcription complex assembly
leading to gene activation (Metivier, R. et al. 2003).
As for all pi60 proteins, SRC-1 enhances ERa-mediated gene transcription,
but it also mediates full ERa activation by integrating N and C terminal AF-1 and
AF-2 functions of the receptor (reviewed in Klinge, C.M. 2000). Specific amino
acids in helix 12 within the LBD of ERa have been identified to interact with the
conserved LXXLL motif of SRC-1 for cofactor-ER binding. Other coactivators
employ different amino acids within the LBD of the receptor indicating the
involvement of multiple cofactors at any one time in a transcription complex. SRC-1
has shown to directly interact with other transcription factors such as Fos, Jun, NF-
kB and cyclin Dl. The activation domains AD1 and AD2, likely to be present in all
SRC proteins, recruit CBP/p300 and acetyltransferases, and coactivator-associated
arginine methyltransferase (CARM). respectively (reviewed in Nilsson, S. et al.
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2001). SRC coactivators are thought to primarily accomplish their gene regulatory
functions by recruiting such histone modifying enzymatic activities to the receptor.
For both, SRC-1 and SRC-2, NR-box 2 has been shown to have the highest affinity
for the agonist-bound ERa (Chen, J.D. et al. 1995) while NR-box 1 appears to have
the highest affinity for SRC-3 (Suen, C.S. et al. 1998). SRC-1 is known to have
histone acetyltransferase activities stimulating the acetylation of lysine residues on
histones H3 and H4 in the receptor chromatin resulting in more extended DNA that
is readily available for transcription.
(ii) Coactivators: SRC-2
SRC-1 and SRC-2 show a 54% overall amino acid identity (Xu, J. and Li, Q.
2003). Like SRC-1, SRC-2 has been shown to stimulate E2 dependent gene
transcription. Both activation domains of the receptor, AF-1 and AF-2, are involved
in E2 bound ERa - SRC-2 interaction but only the AF-2 region for ERP- SRC-2
binding (reviewed in Klinge, C.M. 2000). As with SRC-1, there is an ongoing debate
as to whether SRC-2 is involved in not only the oestrogen bound but also the
antioestrogen associated receptor gene transcription initiation. Evidence suggests that
SRC-1 enhances E2 as well as 4-OEIT stimulated gene transcription by direct
association with AF-1 and AF-2 (Smith, C.L. et al. 1997; Webb, P. et al. 1998). GST
pull-down assays have shown that in the presence of SRC-2, the AF-2 region has
strong activity when the receptor was bound to E2 or no ligand while the AF-1 region
was activated in the presence of E2 and tamoxifen (Webb, P. et al. 1998). This
independent AF-1 tamoxifen initiative has been demonstrated to be due a glutamine
rich domain near the C-terminus of SRC-2, a region that is well conserved within
pi60 proteins, and an extended region of the ERa AF-1 AB domain. However, in
MCF-7 cells, SRC-1 did not interact with AF-1 when antioestrogen bound
(Halachmi, S. et al. 1994). The fact that SRC-2 association with the LBD/AF-2
region might be restricted to the E2 bound receptor has been reported previously
(Cowley, S.M. and Parker, M.G. 1999; Voegel, J.J. et al. 1996). Ribbon
presentations have been produced to illustrate the structure of the agonist and
antagonist associated receptor and its binding to SRC-2. When ERa is bound to E2
(or another agonist diethylstilbesterol (DES) whose conformation to ERa resembles
that of E2), a peptide derived from the NR box II region of SRC-2 associates with a
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Figure 1.10: Structures of the DES-ERa LBD SRC-2 NR box II complex and of the OHT-ERa LBD
complex. A. Two orthogonal views of the DES-ERa LBD-SRC-2 NR Box II peptide complex. The
coactivator peptide and the LBD are shown as ribbon drawings. The peptide is coloured gold, helix 12
(H12) is coloured magenta, helices 3,4,5 (H3,H4,H5, respectively) are coloured blue. DES is coloured
green. B: Two orthogonal views of the OHT-ERa LBD complex. The ligand binding domain is
pictured as a ribbon. HI2 coloured magenta, H3, H4 and H5 blue. OHT is coloured red.
hydrophobic groove on the surface of the LBD (aa at helices 3,4.5,12) (figure 1.10
(A)) (Shiau, A.K. et al. 1998). When ERa is 4-OHT occupied, the SRC-2 binding
site on the receptor appears to be blocked by helix 12, inhibiting any transcription
initiation by interaction of the ERa LBD with SRC-2 (figure 1.10 (B)). These data
indicate that SRC-2 does play a role in transcriptional mediation of oestrogen and
antioestrogen bound receptor but direct association might be restricted to the AF-1
region of ERa.
(iii) Coactivators: SRC-3
Coactivator SRC-3 has been shown to enhance gene transcription of several
nuclear receptors including PR and ERa but not ER(3 (Suen, C.S. et al. 1998). As
mentioned in section 1.2.3 (i), SRC-3 is thought to mediate transcription via
interaction of the first of the three binding motifs, NR-box 1, and the AF-2 domain of
ERa (reviewed in Nilsson, S. et al. 2001). Uniquely, an additional interaction site, a
region in the COOEl-terminal of the coactivator, has been identified to associate with
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the AF-1 domain of the receptor (Webb, P. et al. 1998 and others). SRC-3 shows an
overall amino acid identity of 50% to SRC-1 and 55% homology to SRC-2. SRC-3
directly interacts with transcription factors pCAF and CBP/p300 and shows intrinsic
HAT activity similar to SRC-1. Much research effort has been devoted to SRC-3,
also known as AIB-1 (Amplified In Breast cancer 1), since it has been identified as
having a prominent role in the development of breast cancer. Overexpression of
AIB1 has been detected in in vitro and in vivo breast cancer. Amplification and high
levels of AIB1 expression have been demonstrated in ER-positive MCF-7, BT474
and ZR75-1 cells (Anzick et al. 1997). However, elevated expression of AIB1
mRNA in ZR75-1 cells was not confirmed in a different study (Thenot et al. 1999).
T47D and ER-negative MDA-MB-231 cells expressed low levels of the coactivator
(Thenot et al. 1999). In a panel of 105 primary breast tumours, 64% of were found to
have a high AIB-1 gene expression relative to expression in normal mammary
epithelium and about 10% showed a high AIB-1 mRNA expression by amplification
(Anzick et al. 1997). Another study demonstrated that the AIB-1 gene was amplified
in 4.8% of breast cancers. Its amplification was correlated with ER and PR positivity
as well as tumour size (Bautista, S. et al. 1998). AIB-1 protein was found to be
overexpressed in only 9.8% of breast tumours indicating that high levels of the AIB-
1 gene do not necessarily translate into elevated protein levels (List, H.J. et al. 2001).
(v) Coactivator and corepressor: RIP 140
Other ER interacting cofactors include Receptor Interacting Protein
(RIP 140) with a molecular weight of 140kDa which interacts with several NRs
including ERa in a promoter dependent way. Two regions have shown to interact
with the ER, an LXXLL motif at the N-terminal region and a C-terminal domain.
RIP 140 is a distinct coregulator perhaps of its own category because of its ability to
act as a coactivator or corepressor. In MCF-7 cells, RIP140 shows increased binding
interaction with the AF-2 domain of ERa in the presence of 17P-oestradiol but not 4-
OHT (Cavailles, V. et al. 1995). This interaction has been correlated with stimulation
of hormone-regulated gene transcription.
Much research on the regulatory role of RIP 140 has focused on interactions
with NRs other than the ER such as retinoid acid receptors (RAR) or retinoid-X-
receptors (RXR) to explain its negative effect on transcription. Nuclear receptor 5A1
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(NR5A1/SF-1), a Ftz-Fl member of the NR family involved in endocrine
development, steroidogenesis and gonad differentiation, interacts with RIP 140
through the AF-2 domain. RIP 140 has shown to be a potent corepressor of
transcription from a variety of SF-1 responsive promoter genes and acts as an
inhibitor of the stimulatory effects of the SRC proteins (Mellgren, G. et al. 2003).
RIP 140 itself is thought to have histone deacetylase (HDAC) activity as one of the
means by which it exerts gene repression effects. Unlike classical corepressors,
RIP 140 interacts with agonist but not antagonist bound receptors. This suggests that
this cofactor also does not require antagonist-occupied receptors for its corepressor
activities. An example of that is the interaction of RIP 140 with retinoid receptors
RAR and RXR, which only takes place with the agonist-occupied dimers (Lee, C.H.
and Wei, L.N. 1999).
However, RIP 140 might indirectly inhibit several nuclear receptors by
ligand-dependent transactivation. RIP 140 is thought to compete with other
coactivators such as SRC-1 for AF-2, the receptor binding domain, to exert its
transcription repression effect. This is illustrated in a study utilizing peroxisome-
proliferator-activated receptor (PPAR) responsive reporter gene assays (Treuter, E. et
al. 1998). The PPAR belongs to a subgroup of NR receptors expressed in MCF-7 and
T47D cells (amongst others) and involved in inducing cell differentiation. PPARs
bind to DNA bound retinoid X receptors to regulate gene transcription.
Figure 1.11: Model of RIP 140 mediated retinoid acid receptor regulation of gene expression
illustrating negative feedback mechnisms (source: Kerley, J.S. et al. 2001).
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Increasing amounts of RIP 140 expression vectors cotransfected with SRC-1
expression vectors showed that RIP 140 antagonizes SRC-1 mediated gene
transcription. This experiment confirms SRC-1 -RIP 140 modulation of PPAR
transcription but assigns coactivator functions only to SRC-1 not RIP 140. Plasmid
transfected RIP 140 has been reported to inhibit retinoic acid dependent AR promoter
activity in human embryonal carcinoma cells (NT2/D1) (Kerley, J.S. et al. 2001). In
addition, the RIP 140 gene itself is a direct target of retinoid acid being rapidly
induced by RA in the same system adding further complexity to RIP 140 mediated
gene expression. Together with other findings, a model of negative feedback
signalling is suggested where RIP 140 acts as mediator of cell growth stimulation and
suppression (Figure 1.11).
(vi) Corepressors: SMRT and NCoR
Differential recruitment of co-regulatory proteins to the ER transcription
complex includes corepressors like Nuclear CoRepressor (NCoR) and Silencing
Mediator of Retinoid and Thyroid receptors (SMRT) that have been shown to
distinctively interact with the ER in the absence of a ligand and in the presence of an
antagonist. This was recently demonstrated in MCF-7 and T47D cells as well as
primary breast cancer cell cultures (Fleming, F.J. et al. 2004). Beta-oestradiol
increased ERa and ERP -ERE interaction and coregulators SRC-1 and SMRT were
identified at the transcription complex. Cells treated with 4-OHT showed increased
SMRT expression and ER-ERE binding. Most interestingly, oestradiol treatment lead
to preferred SRC-1 binding to the transcription complex whereas with 4-OHT, both
oestrogen receptors bound SMRT.
Several isoforms of the 168kDa SMRT protein have been isolated including a
longer 270kDa version termed SMRTe or SMRTa (Park, E. -J. et al. 1999). Isoforms
for the 270kDa NCoR protein include RIP13A1 with a deletion in the nuclear
receptor interaction domain (ND) 3 and RIP 13a with a deletion in the repression
domain (RD) 3. A recent comprehensive review published by Privalsky, M.L. (2004)
compares structure and functionality of corepressors SMRT and NCoR. The two
corepressors show a common molecular structure with a 45% aa identity (Ordentlich,
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Figure 1.12: Schematic diagram of hSMRTa/e and its structural and functional features. The locations of the nuclear receptor
interaction domains (NRDs). repression domains (RDs) and the interaction sites of other possible components of the
transcription corepressor complex are shown below. Histone DeACetylases=HDACs; Nuclear Receptor=NR; Transducin-Like
protein=TBLl; mammalian Switch independent 3 protein=mSin3A; G Protein Pathway Suppressor 2=GPS2 (source: adapted
from Privalsky, M.L. 2004 and Klinge, C.M. 2000).
repression domains for SMRT and NCoR, respectively, while the C-terminal
includes two and three nuclear interaction domains (figure 1.12). Similar to NRD
functions in the structure of pi60 coactivators, NRDs in SMRT and NCoR are
responsible for the interaction of the corepressor directly with the receptor. NRDs
contain a L/IXXI/VI sequence embodied in a motif named CoRNR box comparable
to coactivator NR-boxes (Hu, X. and Lazar, M. 1999). CoRNRs are the sites that
build contact between the corepressor and specifically structured helices 3.5. and 6 at
the receptor (reviewed in Dobrzycka et al. 2003). As mentioned, the NR docking site
at the receptor is thought to be accessible only in the non-iiganded or antagonist
bound state. NRs including ER, PR and AR bind SMRT and NCoR with binding
affinities of varying degree. Binding of the corepressor to the receptor gives a
distinct conformation leading to a cascade of events and to recruitment of other
transcription factors at the repression domains. NCoR and SMRT have shown to
interact with numerous proteins such as HDACs 3/4/5 and 7 to deaccess DNA for
transcription (Guenther, M.G. et al. 2001; Yu, J. et al. 2003). Both corepressors have
been identified as part of large transcription complexes to regulate transcription
(Shang, Y. et al. 2000; Fischle, W. et al. 2002). Transducin-like proteinl (TBL-1)
may assist to recognize chromatin substrates and stabilize the quaternary complex
structure. G-protein pathway suppressor 2 (GPS2) is thought to bind to TBL-1 and
NCoR and further mediate transcription complex assembly (Privalsky, M.L. 2004).
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The mechanism of cofactor recruitment and transcription complex assembly is
discussed in more detail in subsequent chapters.
As a result of the multiplicity of transcription factors recruited by
corepressors, SMRT and NCoR are often referred to as 'platform proteins' acting as
the base for many different proteins to display their functions. Corepressors are then
able to exert their function by different mechanisms utilizing functions of the
docking proteins, such as chromatin remodelling functions or effects on the basal
transcription apparatus. In addition, corepressors directly compete for NR binding
sites, similar to coactivators.
(vii) Other corepressors
There is a growing list of additional corepressors such as Repressor of
Estrogen receptor activity (REA) and BRCA1, a protein product of the breast cancer
susceptibility gene, LCoR and MTAl/ls but they are less well studied (reviewed in
Privalsky, M.L. 2004). Semiquantitative PCR analysis showed varied expression of
REA mRNA in normal and neoplastic breast tissue (Dotzlaw, H. et al. 1999).
Moreover, expression might positively correlate with estrogen receptor levels and
inversely with tumor grade (Simon, S.L.R. et al. 2000). The REA gene encodes a
small 37kDA protein. It interacts with the E2 or 4-OHT bound ER receptor through
direct association with the ER -LBD as well as indirectly through binding to other
transcriptional factors to repress receptor activity (Delage-Mourroux, R. et al. 2000).
Similar to RIP-140, REA interacts with SRC-1 actively competing with the
coactivator preventing it from exerting its stimulatory effect on transcription
initiation. Supporting this mechanism, an LXXXLL motif within REA has been
identified to associate with SRC-1 but not the oestrogen receptor. REA enhances the
antagonistic activities of antioestrogens such as 4-OHT-bound to ER but also
suppresses the agonist activities of oestrogen bound to the receptor (Montano, M.M.
et al. 1999). Furthermore, suppression of hormone liganded-ER mediated
transcription could be due to REA association with PTa, a chromatin remodelling
protein (Martini, P.G.V. and Katzenellenbogen, B.S. 2003). The direct and indirect
binding to other cofactors or the receptor enables REA to modulate hormone and
antihormone mediated transcription in a cofactor and ligand specific manner in breast




1.3.2 ER mediated genes
The number of identified ER regulated genes is constantly increasing. The
complexity of E2 action is reflected in a multi gene expression profile and their tissue
specific, ligand and ligand-dose dependent expression. Investigations mostly using
microarray analysis have been carried out to identify genes which are overexpressed
in breast cancer cell models and primary cancer cells and can be associated with
disease outcome or prognosis and classifications of primary tumours. The large scale
investigation of ER linked genes is demonstrated in a global approach using
microarrays containing probes representing approximately 19.000 human genes (Lin,
C.Y. et al. 2004). The study identified 386 oestrogen sensitive genes in T47D cells of
which 137 were ER -regulated when treated with either E2 or E2 in combination with
ICI 182,780 or protein synthesis inhibitor cycloheximide; 89 of which were proposed
to be direct target genes as opposed to downstream targets. ER- regulated genes were
defined by being responsive to oestrogen but blocked by ICI 182,780. The direct
target genes were further categorized as being 59 E2 up-regulated and 30 E2 down-
regulated genes. The list contains targets such as cell signalling proteins adenylate
cyclase 1 (ADCY2), transcription regulation proteins such as nuclear receptor
interacting protein 1 (NRIP1), cell cycling proteins such as CTSD and multiple
proteins with unknown functions.
In a different study, the effect of the antioestrogens raloxifene, trans-
hydroxytamoxifen (4-OHT) and ICI 182,780 on 40 E2 up- and 89 down-regulated
genes in MCF-7 cells, revealed fundamentally different expression profiles
indicating distinct biological mechanisms for each agent (Frasor. J. et al. 2004). For
both, E2 up- and down-regulated genes, ICI 182,780 produced the most potent
antagonistic effect on 95% and 91% of genes, respectively. Raloxifene and 4-OHT
also act as antagonists of E2 up-regulated genes (67% and 47%), but act as partial
agonist/ antagonists in the majority of the down-regulated genes, 63% and 43%,
respectively. Most agonistic activity was found for 4-OHT in 23% of the up- as well
as 31% of the down-regulated genes. This study identified single oestrogen regulated
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genes like the transcription factor c-fos or DNA synthesis regulator CDC6 showing
unique expression patterns in response to ICI, raloxifene and 4-OIIT and
demonstrates that E2 mediated transcription is part of a vast number of pathways.
Several oestrogen -regulated genes have been extensively studied and those include
the progesterone receptor, pS2 and cathepsin D.
(i) Progesterone Receptor
Also a steroid hormone, progesterone mediates most of its known effects by
binding to a further member of the nuclear receptor family, the progesterone receptor
(PR) whose expression and regulation is highly influenced by oestrogen.
Progesterone action has been shown to play a key role during normal female
reproduction. This includes functions in the uterus and the ovary with the control of
ovulation and maintenance of pregnancy; proliferation and differentiation, control of
lactation in the mammary gland; or the brain where progesterone mediates signal
transduction required for the expression of sexual responsiveness (Graham, J.D. and
Clarke, C.L 1997). The intricate mechanisms of progesterone action and its complex
interaction with other steroid receptor pathways has been demonstrated in phenotypic
studies of the progesterone knockout mouse model (PRKO) (Lydon, J.P et a!. 1995).
Severe physical reproductive abnormalities and impaired sexual behavior were
exhibited as a result of the absence of the PR gene in these organisms.
The two progesterone receptor isoforms hPR-A and hPR-B have been identified
as functionally different receptors. The two proteins show 100% aa homology with
the exception of an additional 164 aa at the N-terminal end of hPR-B (Clarke, C. and
Sutherland, R.L. 1990). Both isoforms are generated from transcripts from a single
gene but encoded by separate oestrogen responsive promoters resulting in either the
94kDa hPR-A protein or a 115 kDa hPR-B protein. (Giangrande, P.H. and
McDonnell, D.P. 1999). Structural and functional features of both progesterone
receptor isoforms resemble other nuclear receptor family members (Figure 1.13)
(Mulac-Jericevic-B. and Conneely, O.M. 2004). Within the six main functional
domains, the A/B region plays a key role in mediating gene activation of target genes
by recruiting coactivators and corepressors in a ligand independent manner to the
transactivation domain AF-1. Unique to hPR-B, its extended N-terminal region
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Figure 1.13: Schematic diagram of progesterone receptor protein and its structural and functional domains. Numbers note amino
acid positions within each protein (adapted from Graham, J.D. 1997 and Mulac-Jericevic. B. 2004).
contains an additional transactivation domain. AF-3 (Sartorius, C.A. et al. 1994;
Huse, B. et al. 1998). This region might be responsible for the stronger activation
potential of hPR-B, augmenting activity of hPR-B and preventing inhibitory
functions of hPR-A on itself (Graham, J.D. and Clarke, C.L 1997). The inhibitory
function of hPR-A is the result of an inhibitory domain (ID) within the A/B region of
progesterone receptors. Both receptors contain this region but it is only active in the
hPR-A isoform where it can act as a repressor of hPR-B and possibly other receptors
(Huse, B. et al. 1998). The inhibitory domain has also been identified to serve as a
docking site for transcriptional corepressors (Giangrande, P.H. et al. 1997). The
ligand binding domain, located within the E-region of the protein towards the
carboxyl-end. is responsible for hormone binding but also contains a transactivation
domain, AF-2, specifically associating with coactivators in a hormone dependent
manner. The DNA binding domain within region C enables the receptor to directly
bind to its specific target genes.
Known direct or indirect progesterone target genes include growth factors




as cyclin D1 and c-myc (Mulac-Jericevic-B. and Conneely, O.M. 2004). Although
both PR isoforms bind progestins, their transactivation functions are different and are
promoter as well as cell specific. While hPR-B is thought to primarily activate
transcription of target genes, hPR-A has shown to transcriptionally repress
progesterone target genes. Moreover, hPR-A can inhibit the stimulatory actions of
hPR-B if coexpressed indicating differential cofactor binding of both isoforms
(Giangrande, P.H. and McDonnell, D.P. 1999). This allows for transrepression of
other pathways such as that of the oestrogen or the androgen receptor. Corepressor
SMRT has been demonstrated to preferrentially interact with the inhibitory domain
of hPR-A over hPR-B. When PR is antagonist bound, hPR-A becomes inactivated
while hPR-B becomes a strong transcriptional activator.
Whilst progesterone decreases, oestrogen increases PR expression. In other
words, progestins oppose E2 mediated action, which is thought to be the basis for the
main effects of PR. This is thought to be due to a downregulation in ER transcription
as decreased ER protein but also mRNA have been found in response to progesterone
treatment in breast cancer cells (Graham, J.D. and Clarke, C.L 1997). During normal
mammary gland development, progesterone plays particularly vital roles during two
specific developmental phases, puberty and pregnancy. Cells expressing the
progesterone receptor segregate from proliferating cells. Normal breast development
shows characteristic changes in PR expression pattern from an undifferentiated, even
expression in puberty to an epithelial clustered concentration in the adult. During
pregnancy, progesterone exposure has an increased proliferation effect on ductal
epithelium and differentiation effect in alveolar lobules. This response also results in
activation of growth factors of PR negative cells. However, in breast cancer the
distinctive separation of PR containing cells from normal proliferative cells no longer
takes place (Graham, J.D et al. 1996). Some research effort has been made to
identify the role of the PR isoforms in breast cancer with inconclusive results. While
the isoform expression ratio appears approximately even in non-malignant tissue,
ratios seem to vary to a great extent in tumours and might be linked to tumour stage
and invasiveness (Graham, J.D et al. 1996 and Mote, P.A. et al. 2002). Predominant
expression of one form or the other might indicate alternative pathways in endocrine
response and potential antihormone resistance mechanisms.
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This has sparked an ongoing discussion as to whether PR testing has its place
in the modern breast cancer diagnostic regime as a therapeutic indicator. A recent
correspondence between two research groups published in The Journal of Clinical
Oncology outlines the main arguments. It is reasoned that testing has been used to
identify a relatively small group of about 3-5% of patients with ER- and PR+
tumours who might benefit from endocrine therapy (Olivotto, I.A et al. 2004).
Further, in ER+ patients, PR testing is not necessary given that most ER+ patients
receive endocrine therapy regardless of their PR status. However, PR testing can
identify a subgroup of ER+ tumours. ER+/PR-, which are less likely than ER+/PR+
groups to respond well to hormone therapies (Fuqua, S.A. et al. 2005). In addition, it
is argued that studies have recognized a generally poor response to adjuvant
tamoxifen in the ER+/PR- patients. This subgroup of about 30% might therefore
benefit from testing. In the light of more recent therapy options, preliminary studies
also indicate potential differences in response when comparing tamoxifen treatment
Clinical evidence Scientific evidence
ER- tumours
ER-/PR+ tumours respond better to
endocrine therapy
(Robertson, J.F. et al. 1996)
ER- tumours
ER-/PR+, no evidence of intact ER
signalling
ER+ tumours
ER+/PR- benefit less from hormonal
therapy, part.tamoxifen
(Osborne, C.K. et al. 1980)
ER+/PR- benefit from anastrazole more
than tamoxifen
(ATAC trial: Baum, M. et al. 2002; Dowsett. M.
2003)
ER+/PR+ might benefit from tamoxifen
therapy followed by anastrazole
ER+/PR- might benefit from anastrazole
followed by tamoxifen
ER+ tumours
In ER+/PR- tumours, evidence of altered
ER signalling and enhanced growth
factor signalling
(Cui, X. et al. 2003)
PR+ tumours
hPR-A rich tumours might benefit less
from tamoxifen therapy
(Hopp, T.A. et al. 2004)
PR+ tumours
hPR-A rich tumours show increased
aggressiveness
(Mote, P.A. et al. 2004)
Table 1.4: Scientific and clinical issues in the controversy surrounding the usefulness of progesterone
testing in breast cancer treatment as argued by Olivotto, I.A et al. 2004 and Fuqua. S.A.W. et al. 2005.
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with anastrazole treatment for ER+/PR+ and ER+/PR-tumors. And lastly, it is argued
that based on a pilot study, tumours expressing the PR isoform hPR-A in abundance
might benefit less from tamoxifen therapy (Fuqua, S.A.W. et al. 2005). PR testing
would therefore identify a subgroup of PR expressing tumours for whom endocrine
therapy is not the preferred treatment. The key issues of this debate are highlighted in
table 1.4 comparing clinical and scientific arguments. The role of the progesterone
receptor in the development of breast cancer remains unclear. Known complex
interaction between hormone receptor pathways, newly identified receptor isoforms
and their differential functions indicates enormous potential in alternative endocrine
signalling during malignant breast development. Whether progesterone testing
should become obsolete may have to be re-evaluated as research progresses.
(ii) Trefoil factor 1/ pS2
The function of trefoil factor family (TFF) proteins in breast cancer remains
unknown. As TFF proteins are predominatly expressed in the mucus in the
gastrointestinal tract (GI), they are thought to be involved in the maintenance and
organization of the mucous layer lining. They have also been identified, in several
but not all, normal and malignant breast epithelial cell lines and tumours at varying
levels of expression (May, F.E.B. and Westley, B.R. 1997; May, F.E.B. et al. 2004).
It has been suggested that motogenic characteristics of TFFs detected in the repair of
gastric tissue could also play a role in directing the invasion and expansion of breast
cancer cells. The original observation was made in tissue surrounding gastric ulcers
in rat models (Taupin, D.R. et al. 1994). A strong increase in trefoil factor expression
led to the proposition that the migration of cells over the damaged surface was
mediated by such peptides. A recent study has indeed shown that TFF2 could
stimulate breast cancer cell movement (May, F.E.B. et al. 2004).
Three human trefoil factor proteins have been identified: pS2 (TFF1/ pNR-2/
BCEI), the first and best studied 60-residue protein; TFF2 (spasmolytic peptide -
hSP) a 106-residue protein; and TFF3 (intestinal trefoil factor -hITF), another small
of 60-residue protein (reviewed in Ribieras, S. et al. 1998). A small 42-43 residue
'trefoil sequence'characterizes the family. pS2 and TFF3 contain a single trefoil
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Figure 1.14: (A) TFF gene cluster at on human chromosome 21q22.3, kb =kilobases. (B) pS2/TFFl
gene structure: bp= base pairs; AP1= jun/fos responsive element; ERE= Estrogen response Element;
TATA- TATA box. (C) pS2/TFFl protein structure: aa= amino acids; PRE= signal peptide domain;
TFF domain and AC= carboxy-terminal acidic domain (adapted from Ribieras, S. et at. 1998).
located in close proximity on chromosome 21q22.3 spanning a genomic DNA
fragment of 55kb. pS2 is positioned 12.5Kb upstream TFF2, which is found 30Kb
upstream of TFF3 (Figure 1.14 (A)).
The promoter of the 4.5kb pS2 gene contains an imperfect 13-base pair
oestrogen response element between positions —405 and -393, a jun/fos responsive
AP-1 site as well as DNA enhancer elements responsive to the epidermal growth
factor, the tumor promoter TPA or the c-Fla-ras oncoprotein (Berry, M. et al. 1989;
Nunez, A.M. et al. 1989) (Figure 1.14 (B)). The small 6.5kDa pS2 protein is encoded
by three exons translating into the amino-terminal signal peptide (exon 1), the TFF
domain (exon 2) and the carboxy -terminal acidic motif (exon 3) (Figure 1.13 (C)).
The highly conserved pS2 trefoil sequence includes six cysteine residues that form
three intramolecular disulphide bonds resulting in three loops within the TFF
sequence (May, FEB et al. 2000 and Polshakov, V.I. et al. 1997) (Figure 1.15). A
seventh cysteine residue near the C-terminus can form intermolecular disulphide
bonds (reviewed in May, F.E.B et al. 1997). The loops are stacked into the
characteristic cloverleaf -like disulphide structures. This compact structure is stable
and resistant to proteases and thiol agents. Structural analysis has suggested that
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Figure 1.15: (A) Amino acid sequence of TFFl/pS2 protein. Cysteine residues involved in disulphide
bonding are indicated in red. (B) TFFl/pS2 2D protein structure. Red and blue residues indicate
conserved aa of trefoil domain. Three disuiphide bonds are shown (=). C7 and green aa represent Ac
domain. (Figure (A) Polshakov, V.I. et al. 1997 and Figure (B) Ribieras, S. et al. 1998).
exposed surface residues could serve as binding sites for receptors and ligands
(Polshakov, V.I. et al. 1997).
pS2 is highly expressed in ER positive breast cancer cell lines and malignant
breast cancers. Low-level pS2 mRNA and protein have also been detected in normal
mammary tissue (Predine, J. et al. 1992 and others). A study involving 172 primary
breast cancers found that 68% of the tumours expressed pS2 protein (Henry, J.A. et
al. 1991). It has been firmly established that pS2 mRNA and protein expression is
induced by oestrogen (Masiakowski, P. et al. 1982 and May, F.E.B and Westley,
B.R. 1986). The hormone induction of pS2 is thought to be a primary response to
oestrogen and based on the ER binding to the ERE within the promoter of the
sequence (Berry, M. et al. 1989). Antioestrogens reverse the effect of oestrogens on
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pS2 expression. Non-steroidal antioestrogens act as partial oestrogen agonists (May,
F.E.B 1987and Westley, B.R. 1987). In addition, pS2 mRNA levels have been
positively associated with the presence of ER and PR (Henry, J.A. et al. 1991 and
others) and inversely associated with histological grade and size of some tumour
forms (Predine, J. et al. 1992). There is evidence that a high pS2 expression is
generally associated with a good prognosis. This observation might be based on the
association of pS2 expression with ER/PR expression where tumours have better
response rates to anti-hormonal treatment and hence a better prognosis. The
expression of pS2 has shown to be an indicative tool for therapy success in
neoadjuvant hormonal therapy for postmenopausal breast carcinomas (Soubeyran, I.
et al. 1996 and others). Consistent correlation remains absent for the association of
pS2 status and other breast cancer factors such as cell type, patient age, lymph node
status or overall survival time. Consequently, the prognostic value of pS2 expression
with regards to disease progression and therapy response is limited.
(iii) Cathepsin D
Similar to pS2, Cathepsin D (CTSD), a lysosomal protease, is a potential
prognostic factor for breast cancer when not only the presence in MCF-7 and ZR75-1
breast cancer cell lines was established but its oestrogen inducibility confirmed in
ER+ cells (Rochefort, H. et al. 1987). It has since been confirmed that high or
moderate levels of CTSD expression in primary tumours correlate with an increased
risk of relapse and overall survival independent of histological grade, ER status or
tumour size (Foekens, J.A. et al. 1999). proCTSD is a 56kDa precursor of the CTSD
protein that associates with the mannose 6-phosphate/ insulin like growth factor-II
receptor (M6P/ IGF2R) (detailed review by Rochefort, H. et al. 2000). Release of the
protein from its receptor leads to the synthesis of a 48kDa intermediate and a mature
form of CTSD consisting of a 30 kDa and a 12 kDA protein. It is the mature form
that has been shown to play a role in breast cancer metastasis.
As a protease, cathepsin D degrades proteins but has also been shown to play
a role in the development of newborns in protection from intestinal necrosis and
thymic apoptosis. In breast cancer, it has been suggested that CTSD has motogenic
characteristics facilitating the invasion and spread of cancer cells. Abundant
proteases in tumour cells are released and mediate extracellular matrix digestion in
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surrounding tissue to allow cancer cells to invade connective tissue or the blood
stream. Thus, there is an ongoing controversy as to whether it is the intracellular
levels of CTSD stored in lysosomes and phagosomes, or the extracellular levels
secreted by the cells that are of prognostic value. It has been shown that breast cancer
cells produce high levels of CTSD, which is not stored but released into extracellular
space (Capony, F. et al. 1989). A recent study compared the effect of oestrogen and
tamoxifen on intracellular and extracellular CTSD activity (Dabrosin, C. et al. 2004).
Oestrogen was shown to stimulate intracellular proteolytic activities and secretion of
CTSD, whereas tamoxifen stimulated intracellular levels but decreased CTSD
secretion. Opposing effects of both ligands were observed for the M6P receptor.
Receptor levels were decreased with oestrogen exposure and increased with
tamoxifen indicating that the secretion of CTSD might be M6P receptor regulated.
The authors conclude that it might be vital to measure CTSD levels at different sites
to determine its biological role and usefulness as prognostic marker.
1.3.3 ER -ERE interaction
Traditionally, ER mediated gene transcription was thought to be based on a direct
contact between the oestrogen-bound ER and the oestrogen response element (ERE)
within the promoter. However, experiments have shown that ligand binding and
direct ER-ERE interaction present just small elements of transcriptional initiation
and are part of a much more complex mechanism.
The ERE, a 13bp palindrome located mainly within the promoter of an oestrogen
responsive gene, serves as DNA binding site for the receptor (reviewed in Klinge,
C.M. 2001). The ERE consensus 5'GGTCA nnn TGACC 3', where n serves any
nucleotide, can confer oestrogen responsiveness to a reporter gene when transfected
into cell lines (Klein-Hitpass, L. et al. 1988). A specific additional nucleotide on
either side of the palindrome extends the ERE to a 15bp palindrome (5'AGGTCA
nnn TGACCT 3'). The number, spacing and nucleotide sequences immediately
adjacent to the ERE vary frequently between genes and can increase or decrease the
ER binding affinity (Klinge, C.M. et al. 1992; Driscoll, M.D. et al. 1998). The ER is
able to adapt competently and bind to individual nucleotide changes and resulting
asymmetries. The receptor binds to one half side of the single or double stranded
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ERE with its conserved element and tolerates variability in the other non-
corresponding half sequences (Pari, F.F. (c) 2000). Experiments have shown that the
binding affinity and transcriptional activity is inversely proportional to the number of
nucleotide changes from the consensus within one of the ERE halfsites (reviewed in
Klinge, C.M. 2001). It remains controversial as to whether the ER binds simply as a
homodimer to the halfsites of the ERE, or also as a heterodimer. The ER might bind
as a heterodimer when bound to coregulatory proteins while the two flanking
dinucleotides on both sides stabilize the complex. The extended 5' half site of the
ERE is also recognized by other receptors such as RAR. Thyroid Receptor (TR) or
vitamin D3 receptor (VDR). Orientation and spacing of the sequence is what assures
specificity of receptor- response element binding.
The ER exerts its gene regulatory function through direct association with the
ERE activated by oestrogen, through complex formation with other regulatory
Peptide growth Protein kinase
factors activators
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Figure 1.16: Simplified schematic representation of different pathways of ER-mediated gene
transcription. (A) Classical pathway involving direct E2-bound ER -ERE interaction. After E2
binding, the receptor forms homo- or heterodimers and associates with the ERE of the target gene. (B)
Non-classical ERE -independent pathway involving the interaction of the E2 bound ER with other
transcription factors such as Jun and Fos to their response elements (AP-1). (C) E2 independent
transcription involving the ER activation by signalling from extracellular growth factors such as IGF
or protein kinase activators such as cAMP (adapted from Pari, F.F. (c) 2000).
factors one of which will directly associate with its response element (RE), or direct
association with the ERE but activated by a ligand other than oestrogen (see figure
1.16). The indirect or steroid-independent mechanism involves activation through
peptide growth factors such as epidermal growth factor (EGF) or transforming
growth factor a (TGFa) via tyrosine kinase receptors; and protein kinase activators A
and C such as cyclic AMP (cAMP)(Figure 1.16 (C)). There is extensive evidence to
suggest crosstalk between the oestrogen and growth factor pathways, and the ER's
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ability to be activated by phosphorylation (Lannigan, D. 2003). Phosphorylation of
the receptopr by growth factors can activate the oestrogen receptor (Hermanson, O.
et al. 2002 ). The combination of oestrogen and growth factors can mediate gene
transcription synergistically.
ER signalling by association with another transcription factor bound to its
response element, also called 'tethering', has been demonstrated with the ubiquitous
transcription factors Spl or AP-1 (Figure 1.16 (B)). The response element for Spl,
SplRE, is found close to EREs in multiple genes such as CTSD, c-myc or RARa
(reviewed in (Pari, F.F. (c) 2000). Two AP- pathways have been proposed (Webb, P.
et al. 1995 and Kushner, P.J. et al. 2000). ERa with oestrogen or tamoxifen utilizes
the AF pathway to activate AP-1 by association with AP-1 ligands Jun and Fos and
the recruitment of additional cofactors. Proteins such as the pi60 family and
CBP/p300 might serve as a link between Jun/Fos and AF-1/ AF-2 domains of the
receptor leaving the ER -DBD dissociated and unoccupied from the ERE. ERP and
AF-1 deleted ERa activate AP-1 in an AF independent manner in the presence of
antioestrogens raloxifene and ICI 182,780. Here, the receptor binds nuclear
corepressors as mediators and the ER -DBD is directly involved.
1.3.4 Mechanism of ER -ERE action
The functions of the ER mediated network are determined by the cellular context.
The specific action of the ER depends on the subtype and isoform of the receptor
itself, the ligand, the target gene and more specific, the gene regulatory DNA site
(ERE) and the availability and characteristics of a host of coregulator proteins.
Recent evidence suggest a dynamic process where large transcription complexes are
assembled to initiate or repress gene transcription in an ordered and combinatorial
manner.
(i) Assembly of ER transcription complexes to mediate gene transcription
There are a number of approaches to describe the molecular actions of the E2
dependent ER activation. The assembly of different transcription complexes in a
sequential, combinatorial or parallel manner forms the basis for most mechanisms
(detailed review by Glass, C.K. and Rosenfeld, M.G. 2000; and Hermanson, O. et al.
2002). Members of the complexes initiate transcription by reorganizing the
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chromatin structure and/ or modifying and recruiting additional transcription factors,
basal transcription factors and RNA polymerase II (figure 1.16). Two forms of
chromatin remodelling complexes are thought to be crucial. The ATP dependent
BRG (SWI/SNF) complex reorganizes local nucleosome structure and mediates
assembly of further complexes by attracting sequence specific transcription factors to
the DNA. Complexes involving P/CAF, CBP/p300 and pl60 protein possess histone
acetyl transferase (FIAT) activities. Transcriptionally active chromatin fractions are
enriched in acetylated histones. This altered nucleosome structure permits access for
the RNA polymerase II (pol II) machinery initiating transcription. The level of
acetylation of the genome is then linked to the level of transcription. The P/CAF
complex might be composed of numerous proteins; amongst them so called SAGA/
ADA proteins and a group of TATA -binding -protein (TBP) related proteins called
Spt proteins. Coactivators CBP/p300 are involved in many signalling pathways.
They show HAT activities and facilitate other protein complexes. Despite their ER
binding sites, it is unknown whether they directly associate with the receptor, pi60
family proteins might primarily serve as platform proteins via their highly conserved
PAS domains. Protein-protein interactions have been demonstrated with other
transcription factors such as CBP or CARM1. As mentioned earlier, SRC1 and SRC-
3 also show HAT activities. In addition, a large coactivator complex, the
TRAP/DRIP/ARC complex, might directly connect the ER to the basal transcription
machinery containing RNA polymerase II (Pol II) with basal transcription factors
(Glass, C.K. and Rosenfeld, M.G. 2000).
Corepressors form multiunit complexes opposing the effects of coactivators.
NCoR and SMRT are thereby thought to act predominantly as recruitment and
bridging proteins attracting factors with histone deacetylase (HDAC) functions as
both corepressors lack intrinsic deacetylation domains (Klinge, C.M. 2000). HDACs
maintain chromatin in a condensed inaccessible state. Factors found to be associated
with NCoR and SMRT include mSin3, HDAC 1/2/3/4/5/7, BRG-1 transducin (3-like
protein 1 (TBL-1). Repressive functions are thought to be a result of corepressors
mediating NRs in directly repressing target genes or by antagonizing coactivators
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Figure 1.17: pS2 gene activation: Proteins assembled in six different transcription complexes
identified at the pS2 promoter, (source: Metivier, R. et al. 2003).
complexes are recruited in the presence or absence of ligands, bind to the ER -ERE
and facilitate chromatin condensation. Indirect repression, also called
transrepression, involves activation of the receptor, which induces the upregulation
of corepressors. Corepressors have also been shown to compete actively with
coactivators to alleviate transcriptional activation. Overexpression of coactivator
proteins CBP/p300 has been shown to reduce transrepression by NR (Glass, C. and
Rosenfeld, M.G. 2000). As with coactivators, distinct complex compositions
incorporating one or more of these factors have been identified and suggest
corepressor associations are promoter and cell-type specific.
Promoter specific protein complexes have been demonstrated in a recent
study examining transcriptional activation at the pS2 promoter (Metivier, R. et al.
2003). Six different combinations of cofactors have been identified after re-analysis
of samples initially used to identify cofactors via chromatin immunoprecipitation
analysis (ChIP) (see figure 1.17). The ERa is required in all complexes but other
factors are not always part of the complex. For example, complex II contains ElATs
and HMTs crucial for chromatin modulation making the promoter available for
transcription. Protein complex VI containing RNA pol II or DNA elongators Elpl
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and Elp2 appears to be part of the actual transcriptional initiation where chromatin
remodeling enzymes are no longer needed. These results suggest a certain functional
specificity for each cofactor and underline the hypothesis that an alternate and
combinatorial assembly of transcription complexes determines the transcriptional
output.
(ii) Dynamics of ER mediated transcription
The identification of this large number of cofactors involved in ER-mediated gene
transcription led to studies analyzing the dynamics of events leading to gene
activation. One of the first groups to describe the kinetics of the transcription
complex assembly based on ChIP experiments was that of Shang,Y. et al. (2000).
The oestrogen receptor was found to bind to the promoter and the sequential
recruitment of pi 60 coactivators, CBP, p300, pCAF, and PBP shown after oestrogen
binding. It was demonstrated that the target promoter is continuously involved in
complex binding and dissociation providing evidence for a cyclic model of
transcription in response to oestrogen. This analysis was taken one step further
utilizing a-amanitin cell cycle synchronized MCF-7 cells (Metivier, R. et al. 2003).
Three different transcription cycles were identified. During an initial
transcriptionally unproductive and shorter cycle, the nucleosome is opened and
histones H3 and H4 become modified to steady state levels. Only in the following
two productive cycles where histone acetylation and dimethylation increases
dramatically, are p68 RNA helicase, pi60, HAT and a host of other cofactors
recruited to phosphorylate RNA Pol II and initiate trancription. A different set of
cofactors was shown to be involved a SWI/SNF complex to deacetylate histones and
dissociate the ERa from the promoter to repress transcription.
The kind of cofactors and the sequence of events differs according to the
promoter and cell type. However, general features are thought to apply to the






Figure 1.18: Schematic representation of coactivator and corepressor complexes in classical NR
mediated transcription activation. ATP dependent coactivator complex BRG1; HAT activity
possessing complexes CBP/p300, P/CAF and pi60. TRAP/DRIP complex enhances chromatin
independent transcription. Corepressors NCoR and SMRT attract a corepressor complex containing
mSIN3 and HDACs (source: Glass, C.K. and Rosenfeld, M.G. 2000)
C.K. and Rosenfeld, M.G. 2000) (see figure 1.18). The ligand such as
oestrogen enters the nucleus via passive diffusion or active mediated transport to
bind to the receptor. The ligand unbound receptor resides in the nucleus as well as
the cytosol most likely stabilized by either a protein complex containing heat shock
protein 90 (hsp90), a chaperone known to be involved in folding and activating of
NR, or by corepressors such as NCoR and SMRT. After hormone binding,
geneactivation involves roughly two steps:
A. The liganded receptor undergoes a conformational change forming homo- or
heterodimers and dissociates from its chaperones. Subsequent binding of ER to
the ERE in the promoter attracts HAT containing coactivators complexes
including pi60, PBP/p300and pCAF components. HAT complexes modify local




B. The DNA is now readily accessible for additional, basal transcription factors. A
transcription preinitiation complex is assembled at the transcription start site, the
TATA box of the promoter involving the recruitment of TATA box binding
protein (TBP), TBP-associated factors (TAFs) and RNA II.
Alternative activations such as ERs interaction with other DNA bound transcription
factors for example AP-1 or Spl may follow a similar model where ER-associated





1.4.2 Antioestrogens: mechanism of action
Tamoxifen has been the most widely used antioestrogen for many years. About two-
thirds of ER-positive metastatic breast tumours respond to this form of treatment
(Dowsett, M. and Howell, A. 2002). Binding of tamoxifen results in altered receptor
dimerization and prevents AF-2 mediated transactivation while AF-1 mediation
remains functional (Dowsett, M. and Howell, A. 2002). In addition, tamoxifen
induced receptor conformation results in changed coactivator and corepressor
availability for transcription complex assembly influencing transcriptional outcome.
The differential effect on the receptor activation domains gives rise to tamoxifen's
partial agonism in addition to its antagonistic actions. Its two major metabolites N-
desmethyltamoxifen and trans -4 hydroxytamoxifen have a similar affinity for the
ER as 17-P oestradiol (Osborne, C. K. et al. 2000). Oestrogens are thought to
agonize tumor growth mainly by stimulating progression from Gi to S phase,
increasing cell numbers in S and G2/M stages, as well as activating non- cycling Go
cells into the cell cycle (Pari, F.F. 2000(d)). On the other hand, tamoxifen, like many














Figure 1.19: Mechanism of action of classical antieostrogens such as tamoxifen and of aromatase
inhibitors such as anastrozole (source: Dowsett, M. and Howell, A. 2002).
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blocking progression from the active Go/Gi cell cycle phase. There is also evidence
that it might also have the ability to induce apoptosis and cause cell death.
Antioestrogens could initially show cytostatic and then progress to cytotoxic effects
(Clarke, R. et al. 2003). Oestradiol analogues ICI164,384 and ICI 182,780
(Fulvestrant/Faslodex) are steroidal ER inhibitors regarded as pure antagonists
because of their lack of oestrogenic activity (Osborne, K. et al. 2000). ICI 182,780 is
thought to inhibit ER-AF-1 and AF-2 mediated transactivation and stimulate ER
degradation. The ER binding affinity of ICI 182,780 is similar to that of oestrogen
but 100 fold stronger than tamoxifen.
A different class of antieoestrogens, steroidal and non-steroidal aromatase
inhibitors such as Formestane or Letrozole, do not directly interfere with oestrogen
binding to the receptor but prevent the synthesis of oestrogens by directly inhibiting
the conversion of androgens into oestrogen, a step catalyzed by aromatase enzymes,
to withdraw the hormone from the environment (Haynes, B.P. et al. 2003, Miller,
W.R. 2004) (see figure 1.19). Steroidal and non-steroidal aromatase inhibitors both
associate with the substrate binding site of the enzyme but inactivate by different
mechanisms (Howell, A. et al. 2001). Steroidal compounds (type I) bind irreversibly
to the active site of the aromatase enzyme, competing with the natural androgen to
inactivate the enzyme. Nonsteroids (type II) interact with the active site in a
reversible manner but also associate with the heme molecule prothetic group
(cytochrome P45o part) of the enzyme. The reversible association requires the
continued presence of the inhibitor to prevent aromatase function. Different
mechanisms of action for aromatase inhibitors might be the basis for their differential
potency and potential non-cross-resistance.
Strictly speaking, 'classical' antioestrogens like tamoxifen are not plain
antioestrogens. More appropriately the term Selective Estrogen Receptor Modulators
(SERMs) is now used for such agents, which directly bind the ER to interfere with
gene transcription but may also have agonistic characteristics in the same or other
tissues. Separate categories are assigned to pure antioestrogens, also called Selective




1.4.3 Mechanisms of antioestrogen resistance
Interestingly, tamoxifen treatment beyond five years has not proven to be
beneficial. The drug shows an increase in oestrogenic side effects and loss of anti-
tumour action (Lewis, J.S. et al. 2004). This is thought to be predominantly due to
the development of antioestrogen resistance. Most tumours initially responsive to
tamoxifen eventually become resistant to the drug. Resistant phenotypes are one of
two types: intrinsic/de novo or acquired. The former is a pre-existing resistance in
mostly ER -negative but also ER -positive tumours whereas the latter refers to ER -
positive tumours developing drug resistance over time. Efforts have been made to
understand the molecular mechanisms behind the evolution of antihormonal
resistance. It has been shown that the loss of ER expression is uncommon and
therefore not a prerequisite to develop ICI 182, 780 and tamoxifen resistance
(Briinner, N et al. 1993 (a) and 1997). Most tumours remain ER+ and some
responsive to pure antioestrogens indicating that the ER remains intact but loses its
foremost position in E2 dependent transcription. The cell is able to develop alternate
pathways affecting apoptosis and proliferation functions. With the discovery of a
second ER as well as several ER splice variants emerged a potential alternative route
where a switch from ERa to ER(3 mediated pathway might lead to resistance.
Although both receptors show distinct functionalities, a change in receptor ratios
reflecting phenotype progression has not clearly been demonstrated (Clarke, R. et al.
2003). Mounting evidence of altered coactivator and corepressor expression and
activation of as well as involvement of other growth factor and cytokine pathways
hint at a more complex shift in the signalling network of antioestrogen sensitivity and
resistance.
A recent model for acquired resistance suggests a roughly three phase
progression to antihormone resistance based largely on T47D and MCF-7 xenografts
(Schafer, M.J. et al. 2003; Lewis, J.S. et al. 2004). During initial tamoxifen
treatment, phase I sees oestrogen stimulation and anticipated SERM inhibition in
breast tissues. Progression to phase II and III is the result of long-term treatment. In
phase II any SERM as well as E2 will maintain growth. After about 5 years, SERMs
will continue to stimulate growth in Phase III but E2 will become tumoricidal. The
tumor is essentially able to grow independently. There is also evidence that E2 not
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only fails to stimulate growth after long-term antioestrogen treatment but also may
induce apoptosis at physiological concentration. Estrogens are generally thought to
agonize tumor growth by increasing cell numbers in S and G2/M stages as well as
reducing cells in G0/G1 stages to stimulate. As mentioned earlier, antioestrogens are
thought to stimulate G0/G1 cell cycle arrest. This observation has been made in breast
cancer cells long-term (lyear) -deprived of oestrogen and designed to mimic
prolonged antioestrogen treatment and hence, E2 withdrawal.
Increasing attention has been drawn to potential cross-talk of the ER with cell
surface signalling pathways in the development of antioestrogen resistance.
Overexpression of the tyrosine kinase gene ElER2/neu (erbB-2) has been correlated
with a shorter overall and disease-free survival and associated with a reduced ER
expression. Interestingly, experiments have also shown that overexpression of
HER2/neu in breast cancer cells in vitro results in tamoxifen resistance. This can be
reversed by blocking the HER2/neu pathway (Kurokawa, H. et al. 2000). A recent
study confirms that E2 stimulated tumors become tamoxifen and E2 stimulated after
longterm tamoxifen treatment (Schafer, M.J. et al. 2003). The HER2/neu protein and






Figure 1.20: Proposed model of the integrated mechanism for the target site-specific action of
SERMs. SERMs act as antioestrogens in surface silent cells (i.e. cells that express low levels of
growth factor receptors) resulting in dominant co-repressor activity that retains the antioestrogenic
activity of SERMs. However, when growth factor receptors are expressed at the cell surface resulting
in dominant co-activator activity, the SERM:oestrogen receptor complex becomes transcriptionally
active (source: Schafer, M.J. et al. 2003).
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mRNA as well as the ER and PR protein expression increases. A model for the
integrated mechanism of acquired anlioestrogen resistance has been proposed (see
Fig 1.20). Antioestrogenic action might be linked to breast cancer cells with absent
HER2/neu cell surface signalling where corepressors are recruited by the tamoxifen
bound receptor. In the resistant and tamoxifen stimulated phase, cells might have
been selected for their increased cell surface signalling. Alternative pathways
phosphorylate the ER-tamoxifen complex and coactivators take precedence to
stimulate ER mediated transcription. In this model, both, alternative pathways and
the ER are required for the development of antioestrogen resistance. The ER,
therefore remains to play a pivotal role during acquired antihormone resistance.
However, the molecular mechanism of ER signalling in response to endocrine agents
appears to be a highly adaptable multifactorial network of several pathways.
1.4.3 Model systems
(i) Breast cancer cells
A number of breast cancer cell line and xenograft models have been developed
in recent years attempting to mimic the oestrogen independent phenotype and the
clinical setting of antioestrogen resistance acquisition. Despite the intense interest in
suitable laboratory models, there is only a small core of about 100 breast cancer cell
lines that have been consistently used for research (comprehensive review by
Lacroix, M. and Leclercq, G. 2004). Most common is the use of ER and PR positive
MCF-7 and T-47D. A large panel of breast carcinoma cells designated MDA-MB
was established by Cailleau, R. and collegues (1987). This includes MDA-MB-231
cells, an epithelial adenocarcinoma cell line isolated from a pleural effusion. MDA-
MB-231 cells are ER and PR negative, show invasive
properties in vitro and are able to form tumours in vivo (Garcia, M. et al. 1992;
Thompson, E.W. et al. 1992). Other individual cell lines have been selected for
specific characteristics such as NR status or HER2/neu overexpression as well as
their tumour type to represent a particular clinical phenotype. One example is the
MDA-MB-330 line, which has been isolated from a relatively rare lobular carcinoma
(Cailleau, R. et al. 1978). The differentiated extraction of cells from surrounding
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stroma and their viability long term have made the establishment of cell lines
difficult.
The HCC (Hamon Cancer Centre) series is an example of a series of related
breast cancer cell lines. Related cell lines have either been obtained from the same
patient or in the HCC series case, been isolated in the same laboratory (Gazdar, A.F.
et al. 1998). This series was an attempt to isolate multiple cell lines from tumours
with distinct geno- and phenotypes for comparison between the in vitro and in vivo
material. Breast cancer variant lines are selected from their wild type predecessors
for growth in media containing specific growth factors or antioestrogens. The well-
studied HMT-3522 line was originally established from a fibrocystic lesion as a non-
malignant ER- epithelial line dependent on the presence of growth factor EGF
(Briand, P. and Lykkesfeldt, A.E. 2001). Multiple sublines have been developed
from the wild type cells to establish a model to study breast carcinogenesis.
Malignant HMT-3522/S-2 and HMT-3522/T4-2 cells are EGF inhibited and EGF
unresponsive, respectively. A separate subline, HMT-3522F9, is comprised of EGF
dependent but ER positive cells. Of particular interest are also cell lines containing
particular germline mutations. The ER positive and PR negative HCC 1937 cell line
has shown to carry a BRCA1 mutation (Tomlinson, G.E. et al. 1998).
There has always been debate at to how well cell models represent the tumours
from which they have been derived. Breast cancer tumours are known to be
particularly heterogeneous and progress pathologically and clinically towards a
metastatic phenotype. Although breast cancer cell lines have also shown considerable
heterogeneity, it has been questioned whether pure and clonal populations of breast
cancer cells in vitro characterize changes in the clinical material. Complex DNA
copy number changes have been demonstrated in multiple breast cancer cell lines
and the corresponding primary tumours with genomic hybridisation experiments
(Larramendy, M.L. et al. 2000). Results also reveal that almost all aberration found
in tumours are present in the cell lines although cell lines do show additional
changes. Long term culturing of breast cancer cells may lead to a deceptive selection
of cells based on culturing conditions that do not mirror in vivo settings. Again,
phenotypic or genotypic changes might not develop in cell lines parallel to tumour
material as a result. It has been known that the same cell lines grown in various
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laboratories under differing conditions can give raise to multiple subpopulations.
Variations for separate MCF-7 cell stocks include proliferative response to 17P-
oestradiol and DNA copy number changes (Jones, C. et al. 2000).
(ii) The MCF-7 and MCF-7 resistant cell lines
The model system used in this study originates from MCF-7 cells isolated from
a pleural effusion in a postmenopausal patient with metastatic breast cancer in 1973
(Soule, H.D. et al. 1973). This cell line has since been well established for use in
breast cancer research (reviewed in Levenson, A.S. and Jordan, V.C. 1997). MCF-7
cells have been shown to be multiple receptor positive including glucocorticoid,
progesterone, androgen and oestrogen receptors. Functional ERs have been identified
in the nucleus as well as the cytosol where the majority of ERs reside. MCF-7 cells
have been used to identify potential prognostic markers such as cathepsin D or pS2
(Augerau, P. et al. 1988; Masiakowski, P. et al. 1982). The cells have been of value
to study the mechanisms of crosstalk between E? stimulated growth and TGFa/p or
IGFI/II growth factor pathways. MCF-7 cell proliferation is induced by oestrogen
and TGFa although stimulation is weaker and TGFa alone does not result in E2
independent cell growth (Clarke, R. et al. 1989). Despite their role in MCF-7 cell
growth, growth factors like TGFa and their receptors themselves appear to be
expressed in low levels (Levenson, A.S. and Jordan, V.C. 1997 and references
within). Several antioestrogens inhibit cell growth. This includes tamoxifen which
blocks the Gi phase of the cell cycle (Osborne, C.K. et al. 1983 and others).
A variety of sublines have been developed including the antioestrogen variant
lines MCF-7/MIII, MCF-7/LCC-1, MCF-7/LCC-2 and MCF-7/LCC-9 as illustrated
in figure 1.21. To generate hormone independent but antioestrogen phenotypes
assumed to be present in may postmenopausal women, Mill cells were directly
selected following inoculation of MCF-7 cells into overiectomized NCr nu/nu
athymic nude mice. Generally these cells require the addition of exogenous
oestrogen but a subpopulation of cells grew giving rise to the Mill cell line. This
type of selection assures cell proliferation in an endocrine environment of low
oestrogen serum levels comparable to postmenopausal women (Clarke, R and
Briinner, N. 1995). It gave rise to an oestrogen independent cell line still responsive
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Figure 1.21: Derivation of the MCF-7 variant cell lines Mill, LCC-1, LCC-2 and LCC-9 (source:
Briinner. N. et al. 1997).
of Mill cells resulted in LCC-1 cells, which retain hormone and antihormone
characteristics of its predecessor (Brunner, N. et al. 1993 (a)). LCC-1 cells exhibit a
reduced time to tumour formation in vivo. A stepwise in vitro selection against 4-
OH-tamoxifen and ICI 182,780 from LCC-1 cells established LCC2 and LCC9 cells,
respectively (Brunner, N. et al. 1993 (b) and 1997). Both cell lines show relative
oestrogen resistance. Interestingly, LCC-2 cells are in vitro and in vivo tamoxifen
resistant but remain responsive to steroidal antioestrogens such as ICI 182,780. On
the other hand, LCC-9 cells acquire an in vitro and in vivo resistance to
triphenylethylenes alongside with their resistance to ICI 182,780. Brunner and
collegues report that the three resistant lines express the oestrogen receptor protein
levels similar to the wild type MCF-7 cells. MCF-7, LCC-1 and LCC-2 cells exhibit
E2 inducible PR protein expression. Between the four related cell lines. LCC-9 cells
show the highest level of PR protein but expression is unaffected by oestrogen. This
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sequential cell selection was based on the concept that morphological changes would
mirror a malignant progression in breast cancer. It was hypothesised that this model
could be used to study the clinical progression of hormone independence and
antioestrogen resistance.
LY2 cell were established in a separate branch from MCF-7 cells. As the
name suggests, they were selected by passaging against increasing concentrations of
the antioestrogen LY 117,018 (Bronzert, D.A. et al. 1985)(figure 1.18). LY2 cells are
reported to proliferate rapidly without the presence of E2 but retain a relative E2
responsiveness. In addition to LY 117,018, a benzothiophene, this cell line is also
resistant to triphenylethylenes tamoxifen and 4-OH tamoxifen as well as ICI 164,384
(Bronzert, D.A. et al. 1985; Clarke, R. et al. 1989). LY2 cells were found to not
express PR protein either with or without E2 (Bronzert, D.A. et al. 1985). Levels of
ER protein expression are similar in MCF-7 and LY2 cells although a distinction was
made between cytosolic and nuclear ER expression. Similar to MCF-7 cells,
transcription of E2 target genes CTSD and pS2 was stimulated by the hormone
suggesting ER regulation (Mullick, A. and Chambon, P. 1990). The levels of ER
protein extracted from the nucleus was reported to be much lower. The LY2 cell line
was therefore designed as a model for ER positive breast cancer cross -resistant to
different groups of antieostrogens. Similar to the LCC line, it was hoped this model
could help reveal the molecular mechanism of the development of antieostrogen
resistance. In contrast to MCF-7 cells, LY2 cells are nontumorigenie and
consequently can only be used in in vitro experiments (Clarke, R. et al. 2001).
57
Introduction
1.5 Aims and Objectives
This study aimed to investigate changes in the activation process in MCF-7
variant cell lines with a view to identifying potential mechanisms that may help
explain acquired endocrine resistance by
(i) Confirming the growth phenotypes of the breast cancer cell line MCF-7
and MCF-7 variants for their use as model systems in this study. In
particular, the growth response to oestrogen and the antioestrogen
tamoxifen has been determined.
(ii) Analyse transcription and translation of the ER and PR as well as
coactivators and corepressors in response to endocrine treatment using
quantitative reverse transcription-polymerase chain reaction and western
blot analysis.
(iii) Investigating a series of oestrogen-regulated genes pS2, MYC and
cathepsin D to ascertain which expression pattern changes best reflected
oestrogen-regulated growth.
(iv) Exploring the activation process at the pS2 promoter using ChIP
technology to identify ERa binding, pi60 family protein recruitment and
gene activation as indicated by H4 acetylation.
Hypothesis
Hormone resistant human breast cancer cell lines show differential E2 target gene
expression and ER mediated gene transcription complex assembly. This thesis set out
to explore these possibilities. Changes of this kind may contribute to the




Results: Characterization of cell lines
2.1 Characterization of cell lines as models for endocrine resistance
2.1.1 Introduction
To explore mechanisms of oestrogen and antioestrogen resistance, model systems
were employed. Two groups of cell lines derived from the ER-positive MCF-7 cell
line were selected -the LCC-1/LCC-2/LCC-9 series developed by Clarke, R. and
collaborators (Brtinner, N. et al. 1993 and 1997) and the LY2 cell line developed by
Bronzert, D.A. (1985). The MDA-MB-231 cell line was selected as an example of an
ERa -negative model. This part of the study was designed to validate characteristic
growth patterns exhibited by this panel of breast cancer cells. MCF-7 cells were
plated in phenol red containing media (complete medium) for 24h allowing cells to
attach to the plastic. To remove any oestrogenic stimulation, cells were washed in
PBS and left in phenol red free medium (reduced medium) for 48h. LCC-1, LCC-2,
LCC-9, LY2 and MDA-MB-231 cells were plated immediately in phenol red free
medium and left for 24h. Cells were then maintained in reduced medium and
supplemented with 10"9M E2, 10"6M tamoxifen or 10"9M E2 and 10"6M tamoxifen.
The medium was replaced every two days. Duplicate cell counts were measured
using a Coulter counter on days 0, 2, 4 and 6 where day 0 represents counts on the
day endocrine agents are added to the media (before supplementation). Cells not
treated were used as controls to monitor cellular growth.
Cells were photographed on day 2 to illustrate phenotypic changes supporting the
observed differences between cell lines and different treatement groups. This work
was done as an accompaniment to the detailed characterization experiment using cell
counts.
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2.1.2 Parental MCF-7 cell line
MCF-7 cells demonstrate a distinct morphology of polygonal epithelial cancer
cells (figure 2.1). Cells are spread-out, strongly attached to the plastic and readily
form cell-cell contact. Once well defined colonies are formed, the proliferation rate
increases dramatically. Upon oestrogen addition, the appearance of the cells changes
markedly. Cells become spherical and less adherent. Cells remain in tight colonies
and proliferate at a much higher rate. The morphological effect can be observed to a
lesser extent in cell cultures exposed to E2 and tamoxifen.
Figure 2.1: Morphological comparison of MCF-7 cells in living monolayers. Cells have been plated in
phenol red containing DMEM supplemented with 5%stripped FCS, l%Pen/Strep and 2mM glutamine
for 24h followed by phenol free DMEM for 48h (A) Media was supplemented with 10"9M E2 (B); 10"
6M tarn (C) or 10"9M E2 and 10"6M tarn (D) for 48h. Cells were photographed using an inverted Zeiss
microscope at 200x.
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Day 0 Day 2 Day 4 Day 6
c/e2 C/Tam C/E2+Tam E2/ E2+Tam
Day 0 n.s. n.s. n.s. n.s
Day 2 ** n.s. n.s. **
Day 4 ** n.s. ** **
Day 6 ** n.s. ** **
Figure 2.2: Cell line characterization of MCF-7 cells. Cells were plated in complete media for 24h and
maintained in reduced media for 48h before treatment. Cells were then left untreated (control group),
treated with 10"9M E2; 10"6M tarn; or 10"9M E2and 10"6M tarn. Cells were counted on day 0 (72h after
plating/ day of treatment start) and day 2/4/6 using a coulter counter. Cell counts of triplicate samples
and duplicate counts for each time point in each treatment group are expressed. Error bars=STD.
Representitive experiment is shown of at least two experiments carried out. Table shows significant
variance between treatment groups and control group as well as E2 and E2+Tam determined by one¬
way ANOVA and Tukey-Kramer multiple comparison test: n.s. = not significant, *=p<0.05,
**=p<0.01.
Changes in growth pattern in response to endocrine agents observed under the
microscope were also established with cell counts (Figure 2.2). When MCF-7 cells
are maintained in phenol red free media, proliferation ceases after 24h although most
existing cells remain alive (1.8 fold decrease). Oestrogen markedly stimulated cell
growth with a most dramatic increase in cell number by day 6 (12.1 fold). Counts of
the cell group treated with tamoxifen are very similar to counts of the control group.
The cell number remains largely unchanged throughout day 2 and day 4 and
decreases marginally by day 6 (1.3 fold). In combination, tamoxifen is able to
partially represses the oestrogen stimulated proliferation. When day 6 is reached, the
cell number has increased only 7.7 fold, about half the increase observed in the
oestrogen treated group. These data present MCF-7 cells as a classical oestrogen and
tamoxifen sensitive cell line where oestrogen stimulates and tamoxifen antagonizes
oestrogen-stimulated cell growth.
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2.1.3 MCF-7 variant cell lines
(i) MCF-7/LCC-1 cells
LCC-1 cells are clearly distinguishable from the parental MCF-7 cell line
(Figure 2.3). Cells appear in a more circular shape. Adherence is not as strong
although colony formation is apparent. Proliferation rate appears more rapid than
MCF-7 cells. This was again confirmed using coulter counter analysis (Fig 2.4). In
stark contrast to the parental line, cell numbers in the control group have quadrupled
by 48h. Cells remain in active proliferation throughout the course of the experiment
(17.4 fold by day 6). The growth pattern of cells treated with tamoxifen is
comparable to the control group. Oestrogen steadily increases cell growth but to a
lesser extent than the effect seen in MCF-7 cells. The cell number has increased 22.6
fold by day 6; that is 1.4 fold further than the control group has reached at that point
in the experiment. The addition of tamoxifen did not alter the stimulation of
Figure 2.3: Morphological comparison of LCC-1 cells in living monolayers. Cells have been plated in
phenol red free DMEM supplemented with 5%stripped FCS, l%Pen/Strep and 2mM glutamine for
24h(A). Media was supplemented with 10"9M E2 (B); 10"6M tarn (C) or 10"9M E2 and 10"6M tarn (D)
for 48h. Cells were photographed using an inverted Zeiss microscope at 200x.
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oestrogen in this cell line. The two treatment groups exhibit almost identical growth
phenotypes. These results demonstrate that LCC-1 cells grow rapidly when
maintained in reduced media conditions. However, cells show a markedly reduced
oestrogen and tamoxifen sensitivity as compared to MCF-7 cells.
MCF-7/LCC-1













Day 0 Day 2 Day 4 Day 6
c/e2 C/Tam C/E2+Tam E2/ E2+Tam
Day 0 n.s. n.s. ** n.s.
Day 2 n.s. ** ** **
Day 4 ** n.s. ** n.s.
Day 6 ** * ** n.s.
Figure 2.4: Cell line characterization of MCF-7/LCC-1 cells. Cells were plated in reduced media for
24h before treatment. Cells were then left untreated (control group), treated with lO'^M E2; 10"6M tarn;
or 10"9M E2and 10'6M tarn. Cells were counted on day 0 (24h after plating/ day of treatment start) and
day 2/4/6 using a coulter counter. Cell counts of triplicate samples and duplicate counts for each time
point in each treatment group are expressed. Error bars=STD. Representitive experiment is shown of
at least two experiments carried out. Table shows significant variance between treatment groups and
control group as well as E2 and E2+Tam determined by one-way ANOVA and Tukey-Kramer multiple
comparison test: n.s. = not significant, *=p<0.05, **=p<0.01.
(ii) MCF-7/LCC-2 cells
In a manner similar to LCC-1 cells, the LCC-2 cell line grows as rounded
cells in colonies less tightly fixed to the surface of culture dish compared to the
MCF-7 cells (figure 2.5). Colonies appear to lift off the plastic forming floating
clusters rather than a single layer spreading across the plastic. The number of
individual cells floating in culture media becomes considerable. This is even more
evident when cells are exposed to E2 alone or in combination with tamoxifen. Very
little difference in appearance is observed when cells are treated with tamoxifen
alone. Unlike MCF-7 and LCC-1 cells, all treatment groups of LCC-2 cells show
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very similar growth pattern (Figure 2.6). LCC-2 cell proliferate rapidly in reduced
media with the cell number doubled in less than 48h as seen with LCC-1 cells.
Relative to MCF-7 cells oestrogen and tamoxifen have very small effects on cell
proliferation. At day 6 all groups show a similar increase in cell number (control 14.4
fold, E2 11.6 fold, tarn 13.6 fold, E2 and tam 13.6 fold). These results indicate that
LCC-2 cells are oestrogen and tamoxifen resistant.
Figure 2.5: Morphological comparison of LCC-2 cells in living monolayers. Cells have been plated as
LCC-1 line (see Figure 2.1.2). Media was supplemented with 10"9M E2 (B); 10"6M tam (C) or 10"9M
E2 and 10"6M tam (D) for 48h. Cells were photographed using an inverted Zeiss microscope at 200x.
66
Results: Characterization of cell lines
■Control
MCF-7/LCC-2

















Day 0 Day 2 Day 4 Day 6
c/e2 C/Tam C/E2+Tam E2/ E2+Tam
Day 0 n.s. * n.s. n.s.
Day 2 n.s. n.s. n.s. n.s.
Day 4 n.s. ** ** **
Day 6 ** ** n.s. **
Figure 2.6: Cell line characterization of MCF-7/LCC-2 cells. Cells were plated in reduced media for
24h before treatment. Cells were then left untreated (control group), treated with 10"9M E2; 10"6M tarn;
or 10"9M E2and 10"6M tarn. Cells were counted on day 0 (24h after plating/ day of treatment start) and
day 2/4/6 using a coulter counter. Cell counts of triplicate samples and duplicate counts for each time
point in each treatment group are expressed. Error bars=STD. Representitive experiment is shown of
at least two experiments carried out. Table shows significant variance between treatment groups and
control group as well as E2 and E2+Tam determined by one-way ANOVA and Tukey-Kramer multiple
comparison test: n.s. = not significant, *=p<0.05, **=p<0.01.
(iii) MCF-7/LCC-9 cells
The change in appearance in this series of cell lines is most evident under the
microscope when comparing MCF-7 cells with LCC-9 cells (Figure 2.7). This cell
line gives an appearance of round scattered cells growing in poorly defined colonies.
Cell-cell contact appears less coherent. Upon plating, colony formation does not
appear to be necessary for a rapid proliferation rate as seen in the parental line.
Freely floating cells are present in all groups. Oestrogen treatment seems to promote
detachment of the cells from the culture dish even further.
Growth characteristics for LCC-9 cells are very similar to LCC-2 cells.
LCC-9 cells grow rapidly with a doubling time less than 48h. Proliferation in all
groups is observed within the first 48h of the experiment (control 2.1 fold, E2 2.5
fold, tarn 2.5 fold, E2 and tarn 2.7 fold). Cell growth remains largely unaffected by
treatment with oestrogen as well as tamoxifen indicating a resistance to both agents.
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At day 6, cell numbers in all groups have increased by on average 12.3 fold, an
increase that compares to E2 treated MCF-7 cells (12.1 fold) or to the average of all
groups of LCC-2 cells at this time point (13.3 fold).
Figure 2.7: Morphological comparison of LCC-9 cells in living monolayers. Cells have been plated as
LCC-1 line (see Figure 2.1.2). Media was supplemented with 10"9M E2 (B); 10"6M tarn (C) or 10"9M
E2 and 10"6M tarn (D) for 48h. Cells were photographed using an inverted Zeiss microscope at 200x.
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C/Tam C/E->+Tam E->/ E->+Tam
MCF-7/LCC-9












Figure 2.8: Cell line characterization of MCF-7/LCC-9 cells. Cells were plated in reduced media for
24h before treatment. Cells were then left untreated (control group), treated with lO^M E2; 10"6M tarn;
or 10"9M E2and 10"6M tarn. Cells were counted on day 0 (24h after plating/ day of treatment start) and
day 2/4/6 using a coulter counter. Cell counts of triplicate samples and duplicate counts for each time
point in each treatment group are expressed. Error bars=STD. Representitive experiment is shown of
at least two experiments carried out. Table shows significant variance between treatment groups and
control group as well as E2 and E2+Tam determined by one-way ANOVA and Tukey-Kramer multiple
comparison test: n.s. = not significant, *=p<0.05, **=p<0.01.
Table 2.1 summarizes base line growth rates in reduced media comparing parental
MCF-7 cells with the three variant lines. Numbers illustrate clearly that MCF-7 cells
are unique in that they are oestrogen dependent and therefore unable to grow in Ei
deprived conditions (5% DCC in phenol red free DMEM). In contrast, LCC-1 cells
grow consistently under these conditions with a doubling time of about 36h over the
course of the experiment indicating a reduced need for the hormone. The third
generation of cells derived from MCF-7 cells, LCC-2 and LCC-9 cells, demonstrate
a relative oestrogen independence with similar doubling times of about 36h. MCF-7
cells are also explicitly different under the microscope when compared to the variant
lines (Figure 2.9).
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MCF-7 LCC-1 LCC-2 LCC-9
Day 0 519 204 456 587
Day 2 457 809 1108 1221
Day 4 428 1335 2107 3265
Day 6 282 3548 6537 7530
Table 2.1: Comparison of average basal growth for MCF-7 and LCC-1/2/9 control groups as obtained
in characterization experiments as explained above. Mean numbers from a typical experiment are
shown.
Figure 2.9: Morphological comparison of MCF-7 (A) with LCC-1 (B); LCC-2 (C) LCC-9 (D) Cells
have been kept in reduced medium for 48h and photographed using an inverted Zeiss microscope at
200x.
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(iv) MCF-7/ LY2 cells
This cell line was originally selected for its resistance to the antioestrogen LY
117018 (Bronzert, D.A. et al. 1985) but derived separately from the LCC variant
lines. The growth experiment shows that LY2 cells are profoundly growth resistant
to both tamoxifen and oestrogen (figure 2.10). The hormone fails to induce cell
proliferation. Between day 0 and day 6 all treatment groups show a rapid cell
doubling (control 17.5 fold, E2 16.6 fold, tarn 13.7, E2 plus tarn 16.6 fold). The
doubling time is very similar to that of LCC-1, LCC-2 and LCC-9 cells (about 36h).
MCF-7/LY2
Control Oestrogen (10-9M) ^^"—Tamoxifen (10-6M) E+T (10-9M+10-6M)
c/e2 C/Tam C/E2+Tam E2/ E2+Tam
Day 0 n.s. n.s. n.s. n.s.
Day 2 n.s. n.s. ** n.s.
Day 4 ** n.s. n.s. **
Day 6 ** ** n.s. **
Figure 2.10: Cell line characterization of MCF-7/LY2 cells. Cells were plated in reduced media for
24h before treatment. Cells were then left untreated (control group), treated with 10"9M E2; 10"6M tarn;
or 10"9M E2and 10"6M tarn. Cells were counted on day 0 (24h after plating/ day of treatment start) and
day 2/4/6 using a coulter counter. Cell counts of triplicate samples and duplicate counts for each time
point in each treatment group are expressed. Error bars=STD. Representitive experiment is shown of
at least two experiments carried out. Table shows significant variance between treatment groups and
control group as well as E2 and E2+Tam determined by one-way ANOVA and Tukey-Kramer multiple
comparison test: n.s. = not significant, *=p<0.05, **=p<0.01.
2.1.4 MDA-MB-231 cells
In contrast to the cell lines analyzed so far, MDA-MB-231 cells have not been
derived from MCF-7 cells. This cell line reveals a consistent cell doubling (about
48h) irrespective of oestrogen or tamoxifen addition (figure 2.11). When day 6 is
reached cell numbers have increased by an average of 6.3 fold (control 6.6 fold, E2
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6.5 fold, tam 6.3 fold, E2 plus tam 5.9 fold). MDA-MB-231 cells proved to be a
suitable choice as a control cell line, a cell line that is ERa negative, hormone and
antihormone independent and has been established separately from MCF-7 cells.
■Control
MDA-MB-231
Oestrogen (10-9M) * Tamoxifen (10-6M) • E+T (10-9M+10-6M)
Day 0 Day 2 Day 4 Day 6
c/e2 C/Tam C/E2+Tam E2/ E2+Tam
Day 0 * n.s. n.s. n.s.
Day 2 n.s. ** n.s. n.s.
Day 4 * ** ** **
Day 6 * n.s. n.s. **
Figure 2.11: Cell line characterization of MDA-MB-231 cells. Cells were plated in reduced media for
24h before treatment. Cells were then left untreated (control group), treated with 10"9M E2; 10"6M tam;
or 10"qM E2 and 10"6M tam. Cells were counted on day 0 (24h after plating/ day of treatment start) and
day 2/4/6 using a coulter counter. Cell counts of triplicate samples and duplicate counts for each time
point in each treatment group are expressed. Error bars=STD. Representitive experiment is shown of
at least two experiments carried out. Table shows significant variance between treatment groups and
control group as well as E2 and E2+Tam determined by one-way ANOVA and Tukey-Kramer multiple
comparison test: n.s. = not significant, *=p<0.05, **=p<0.01.
2.1.5 Discussion
Human breast cancer cell lines play a vital part in the discovery of mechanisms
that lie behind the development of the disease. As with all laboratory models, it is of
concern whether cell models represent primary breast cancer tumours. A major
review of randomized trials including 37.000 woman with early breast cancer
showed that about 53% of the ER-positive tumours did show recurrence after 5 years
of treatment (Early Breast Cancer Trialists' Group, 2001). Results therefore indicate
that approximately half of ER+ patients are resistant to this form of treatment
although such observations have to be interpreted with caution as tumours which did
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not recur might also have been tamoxifen resistant but failed to relapse for other
reasons. For the metastatic disease, 67% of ER+ patients respond to tamoxifen
treatment leaving one third resistant (Dowsett, M. and Howell, A. 2002). Both of
these major resistant tumour populations are an example of situations where existing
models, here the MCF-7/LCC-1 and LCC-2 cells, are intended to serve as tools to
investigate mechanisms of endocrine resistance. Identifying antioestrogen- including
tamoxifen- resistant phenotypes is problematic given that adjuvant antioestrogen
treatment is often only precautionary and for some patients the disease has been fully
eradicated by surgery. But by far the biggest issue in establishing appropriate model
systems to accurately reflect clinical situations is the immense heterogeneity of
breast tumors. Based on clinical and laboratory observations, there are at least three
major ER positive phenotypes with respect to Ei and antioestrogen sensitivity as
suggested by Clarke, R. et al. (2001). Firstly, cells may be oestrogen growth
dependent, and antioestrogen as well as aromatase inhibitor responsive. Secondly,
cells responsive to antioestrogen and potentially aromatase inhibitor might be
oestrogen independent but stimulated by the hormone. And lastly, breast cancer cells
growing independently of and unresponsive of oestrogen could show crossresistance
to different antieoestrogens and aromatase inhibitors. The MCF-7 variant cell line
model attempts to cover this range of phenotypes. All lines are ER positive and
while the first phenotype is clearly represented by the parental MCF-7 line, MCF-
7/LCC-l, LCC-2, LCC-9 and LY2 cells each embody the oestrogen growth
independent but differential antioestrogen resistant phenotypes. An example of
clinical evidence directly corresponding with an in vitro model is the MCF-7/LCC-2
cell line. Published in previous studies, oestrogen independent tumours which had
initially been tamoxifen responsive and had subsequently acquired resistance against
the agent, showed a significantly higher response rate to ICI 182,640 than it would
have been expected for the treatment with another similar antioestrogen (Howell, A.
et al. 1995). This corresponds to the oestrogen unresponsive MCF-7/LCC-2
phenotype that exhibits resistance to tamoxifen but not ICI 182,780.
Aside from distinctive endocrine response features, it is significant how cultured
breast cancer cells such as MCF-7 cells compare in their biological properties to the
tumours from which they have been derived. Very few comprehensive studies adress
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this question. As mentioned earlier, longterm cell culturing can have an impact on
hormone sensitivity as a result of which cells have to be tested regularly for their
response. Studies examining human breast and lung cancer cell lines side by side
with their corresponding tumour tissues determined that, generally, cell lines do
retain properties of their original tissues (Wistuba, I.I. et al. 1998 and 1999). In the
case of 18 breast cancer cell lines, morphologic, phenotypic and genetic changes
present in their clinically advanced tumours with poor prognosis correlated amongst
others 100% in morphological features, 75% in TP53 gene mutations and 87% in ER
protein expression. This suggests that changes in gene expression or cell structure
characteristic of advanced metastatic breast cancer are well retained in tissue culture
models. Establishing breast cancer tumour cells long-term for culturing is difficult
and has only been achieved in a small number of cases (Lacroix, M and Leclercq, G.
2004). However, despite obvious concerns, breast cancer models appear to be
representative of their originating clinical specimen.
The MCF-7 mammary tumour cell line has proven to be a particularly useful
model system in breast cancer research since its establishment over 30 years ago.
MCF-7 cells were isolated from a patient with metastatic breast cancer (Soule. H.D.
et al. 1973). MCF-7 cells have been shown to proliferate rapidly and are easily
maintained in vitro and in vivo. Most importantly, cells are highly hormone sensitive
and multiple receptor positive providing a fundamental model for the analysis of
hormone dependent cell growth in breast cancer.
Growth experiments were carried out to confirm basal growth and the effect of
oestradiol and tamoxifen on cell proliferation. MCF-7 cells are routinely maintained
in phenol red containing media supplemented with 10% fetal calf serum. It is widely
acknowledged that phenol red acts as an oestrogen mimic sufficient to stimulate
MCF-7 cell growth (Berthois, Y. et al. 1986). Also, MCF-7 cells have been shown to
adapt to E2 deprived conditions by increasing the sensitivity to the hormone
(Masamura. S. et al. 1995). It was therefore essential to remove phenol red and
utilize charcoal stripped serum to ensure maximum hormone sensitivity in
preparation for all experiments. Results show static MCF-7 cell replication as a result
of successful oestrogen depletion (Figure 2.1; control group). In contrast, growth was
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markedly stimulated by oestrogen under the same conditions. Tamoxifen acted as an
antagonist and partially reversed the stimulatory effect of oestrogen.
A major obstacle in the treatment of breast cancer is that tumors initially
oestrogen dependent commonly progress to a hormone independent and drug
resistant phenotype. The MCF-7 variant cell lines used in this experiment share a
common predecessor and could therefore be used for studies tracing molecular
changes during the acquisition of a more malignant phenotype (Briinner, N et al.
1993). In vivo passaging of MCF-7/MIII cells in overiectomized nude mice resulted
in the in vitro establishment of the MCF-7/LCC-1 cell line. Cell proliferation
experiments showed that LCC-1 cells grow without supplementation of oestrogen.
This allows for the cells to be routinely maintained in media supplemented with
stripped serum and lacking phenol red. Addition of E2 to the media does increase
proliferation indicating that LCC-1 cells do retain some hormone sensitivity. In
contrast, LCC-2 and LCC-9 cells, established by stepwise selection against
antioestrogens 4-OH tamoxifen and ICI182,780, respectively, not only proliferated
without oestrogen but failed to show any response to it. Both cell lines also
demonstrated resistance to tamoxifen. It has previously been shown that while LCC-
2 cells retain sensitivity to ICI182,780, LCC-9 cells are characteristic for their
antioestrogen cross-resistance (Briinner, N. et al. 1993, 1997). LCC-2 cells therefore
imply that breast cancers resistant to tamoxifen do not necessarily acquire cross -
resistance to other anti-hormones simultaneously indicating a situation where one
anti-oestrogen treatment option might fail while the other is still effective. LCC-9
cells then provide a phenotype that is cross resistant to different anti oestrogens a
situation that proves most difficult for effective treatment
In general, findings regarding hormone and antihormone responsiveness in
the MCF-7 and MCF-7 variant lines matched original publications describing their
phenotypes. It has been established many years ago that MCF-7 cells are highly
oestrogen sensitive after phenol red removal (Berthois, Y. et al. 1986). Equally,
tamoxifen has been shown to inhibit E2 stimulated growth (Lippman, M.E. and
Bolan, G. 1975). As suggested in the literature, there is no question that all variant
lines show the ability to proliferate in the absence of endogenous oestrogen.
However, relative hormone sensitivity remains a somewhat elusive issue. For
75
Results: Characterization of cell lines
example, here, LCC-1 cells have shown to be E2 independent but responsive. It has
previously been reported that LCC-1 cells are hormone unresponsive in vitro
although LCC-1 tumours were stimulated by oestrogen (Briinner, N. et al. 1993).
Likewise, E2 has had no mitogenic effect in LCC-2 and LY2 cells in this project but
both cell lines have demonstrated oestrogen stimulation, if to a much lesser degree,
compared to the parental line (Briinner, N. et al. 1997 and Bronzert, D.A. et al.
1985). Small differences in hormone response are most likely due to the absence of
standardized protocols across the research field. Such interlaboratory variability has
been demonstrated for MCE-7 cells (Jones, P.A. et al. 1997 among others).
Differences in the efficiency in oestrogen stripping of serum or hormone
concentrations used in experiments have been shown to have a profound impact on
hormone sensitivity and response. With regards to tamoxifen response, LCC-1 cells
have been reported to be significantly growth inhibited by tamoxifen. In this study,
LCC-1 cells have demonstrated tamoxifen resistance. The published results agree
with the results obtained here that LCC-9 and LY2 cells show clear tamoxifen
resistance. Since LCC-9 and LY2 cells have been isolated as resistant to ICI 182,780
and LY 117018, respectively, it is perhaps not surprising that resistance against the
less potent antioestrogen tamoxifen remains firmly in the phenotype of these cell
lines despite potential sensitivity shifts occuring as a result of long-term culturing.
ICI 182.640 and LY117018 have a higher affinity for the ER than tamoxifen and
may cause more dramatic changes within the ER signalling network (Clarke, R. et al.
2001). It has been demonstrated that LCC-9 cells have first become resistant against
tamoxifen in the selection against ICI 182,640 (Briinner, N. et al. 1997). During
routine cell culture and cell maintenance in the absence of antioestrogens,
insensitivity to tamoxifen might be the less stable characteristic and revert earlier
than the loss of sensitivity to the more potent agent.
The distinct phenotypes with respect to hormone and anti-hormone response
mimicking various human breast cancer phenotypes and their common predecessor is
what makes these cells a particularly appropriate model system to explore further the
mechanistic differences that give rise to these changed growth effects.
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2.2 Oestrogen and tamoxifen regulation of oestrogen and progesterone receptor
expression
2.2.1 Introduction
Oestrogen is thought to mediate gene expression mainly via ERa. Having
established that the MCF-7 variant lines demonstrate different characteristics of
growth resistance, it was important to determine oestrogen receptor expression and
elucidate whether changes in expression between the MCF-7 parental cell line and its
sublines have occurred and might give a first indication of a differential role for the
receptor. Another hormone receptor, the progesterone receptor is known to be a
primary oestrogen target gene. Differential regulation of PR might provide an insight
into ER mediated transcription in these cell lines. First, basal levels of ERa and PR
mRNA were determined under oestrogen-deprived conditions. Then, cells were
subjected to 10"9M E2 for 48h and mRNA expression analysed at various time points.
Finally, the expression pattern of ERa and PR mRNA and protein in response to
10"9M E2, 10~6M tamoxifen or E2 plus tamoxifen were examined at 48h.
The concentrations used for E2 and tamoxifen as well as the time points
chosen for mRNA and protein collection in this experiment have been employed for
the entire project. It has long been known that E2 binding and ER protein turnover
can occur in a matter of minutes (Horwitz, K.B. et al. 1978; Katzenellenbogen, B.S
et al. 1987). The effect of E2 on mRNA and protein expression has been
demonstrated to be apparent within both minutes and over a prolonged period of
time. For example, Mawson, A. and collegues have recently demonstrated that E2
induces c-myc protein within two minutes (Mawson, A. et al. 2005). The effect is
also confirmed at 48h in this study. In addition, the ER has been shown to associate
with the promoter of ER mediated genes such as pS2 and CTSD almost immediately
after hormone addition (Shang, Y. et al. 2000; Metivier, R. et al. 2003). My own
preliminary results showed that pS2 mRNA expression was altered by the addition of
E2 within hours. Based on this observation, together with the numerous publications,
a time course starting as early as lh but covering a period of 48h was chosen for the
experiment.
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The utilized concentration of 10"9M E2 lies well within the range of
physiological serum levels of a premenopausal woman considering that levels of
freely circulating E2 in the serum greatly vary around 10"9M to 10~10M during the
menstrual cycle of a premenopausal woman (Pari, F.F. (b) 2000). The concentration
of 10~6M tamoxifen matches commonly used pharmacological levels in breast cancer
therapy (Jordan, V.C. 1982). To demonstrate hormone responsiveness and resistance
in the different cell models employed in this thesis, E2 and tamoxifen concentrations
causing maximum stimulatory or inhibitory effects were needed. Dose response
curves of E2 have shown that MCF-7 cells respond maximally at concentrations of
10"9M E2 and higher (among others: Masamura, S. et al. 1995). 10"9M E2 and 10"6M
tamoxifen are commonly used concentration in experiments using hormone sensitive
and resistant cell lines observing effects on cell growth but also E2 mediated gene
expression. One example is a study by Chan, C.M.W. et. al. (1999). The study
analyses the regulation of cofactor mRNA and protein expression in parental MCF-
and MCF-7 tamoxifen resistant cell lines comparing expression of cofactors such as
RIP 140 in the absence and presence of 10"9M E2 and 10"6M tamoxifen.
2.2.2 ERa and PR mRNA and protein expression in MCF-7 and resistant cell lines
MCF-7 cells and the MCF-7 sublines (LCC-1. LCC-2, LCC-9 and LY2) cells
studied expressed ERa mRNA (figure 2.1). The four resistant lines all showed a
significantly higher (2-3 fold) level of ERa expression than the parent MCF-7 cells.
MDA-MB-231 cells on the other hand did not show any detectable ERa mRNA.
Quantitative comparison of ERa mRNA between LCC-1. LCC-2, LCC-9 and LY2
revealed only subtle differences with the level gradually slightly decreasing in the
order the cell lines are listed (1.5 fold between LCC-1 and LY2 cells).
PR mRNA presented a different expression profile. MCF-7 and LCC-2 cells
expressed particularly low levels of PR mRNA while MDA-MB-231 did not show
any expression. Although PR mRNA expression in LCC-1 cells was 4-fold higher
than MCF-7, the most markedly different to the parental line was the elevated
expression in LCC-9 and LY2 cells (19.6-fold and 15.6-fold, respectively).
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I ER □ PR
ER alpha and PR mRNA expression
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Cell line
Figure 2.1: ERa and PR mRNA expression in breast cancer cell lines. MCF-7 cells were seeded in
complete medium for 24h and a further 48h in reduced media containing 5% DCC. All other cells
were seeded in reduced media for 24h before RNA collection. Representative experiment is shown of
at least two experiments carried out. Each column presents mean of triplicate PCR analysis for each
sample. Error bars = STD. Significant variance between MCF-7 and other cell lines determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(i) Effect of E2 on ERa mRNA expression over a period of 48h
As described in the previous section, all cell lines tested contained
comparable levels of ERa mRNA with the exception for MDA-MB-231 cells. In
MCF-7 cells, ERa mRNA expression was only marginally affected by the addition of
E2 and showed a slight down-regulation at 24h (1.6 fold) (figure 2.2 A and 2.2 B).
Down-regulation mediated by E2 was also observed in LCC-2, LCC-9 and LY2 cells
where a gradual reduction led to a maximal 3.6 fold, 2.2 fold and 2.2 fold change,
respectively. In contrast, LCC-1 cells revealed an initial up-regulation between Oh
and lh (1.6 fold) before mRNA levels were, again gradually, reduced below baseline
levels (1.7 fold at 3h, 1.9 fold at 24h). Any down-regulation was generally found to
be at its lowest at 6h or 24h for these cell lines.
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Figure 2.2. A: ERa mRNA expression in MCF-7 wild-type and resistant cell lines. Cells were left
untreated (control group) or treated with 10"9M E2. RNA was collected at Oh, lh, 3h. 6h, 24h and
48h. A representative experiment is shown of at least two experiments carried out. Each point
represents mean of triplicate PCR analysis for each sample. Significant variance between time
points and Oh was determined by one-way ANOVA and Dunnets multiple comparison test where
*=p<0.05, **=p<0.01.
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Figure 2.2 B: ERa mRNA expression in LY2 and MDA-MB-231 cells. Cells were left untreated
(control group) or treated with 10"9M E2. RNA was collected at Oh, 6h, 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(ii) Effect of E2 and tamoxifen on ERa mRNA expression at 6h and 48h
Expression studies evaluating ERa mRNA in response to Et and tamoxifen
distinguished MCF-7 cells from the other breast cancer cell lines (figure 2.3). At 6h
as well as 48h, E2 stimulated ER mRNA expression (2.0 fold and 5.1 fold), an
observation that does not match results from the previous E2time course. Tamoxifen
alone did not have an effect on expression at 6h but was able to suppress the
stimulation by E2 when combined with the hormone.
In LCC-1, LCC-2, LCC-9 and LY-2 cells, observations from the oestrogen
time course are confirmed at 6h. E2 mediated a down-regulation of very similar
proportion in all cells (average 2.2 fold). Tamoxifen as well as tamoxifen plus E2
also decreased expression (average of 2.7 fold and 2.6 fold, respectively). The
expression patterns for the MCF-7 variant lines were similar at 48h compared to 6h.
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Figure 2.3: ERa mRNA expression in
MCF-7, LCC-1/2/9 and LY2 cells.
Cells were left untreated (control
group), treated with 10"9M E2; 10"6M
tam; or 10"9M E2and 10"6M tam. RNA
was collected at 6h and 48h. A
representative experiment is shown of
at least two experiments carried out.
Each column presents mean of
triplicate PCR analysis for each
sample demonstrating mRNA
expression relative to actin expression.
Error bars=STD. P-value for variance
between all groups determined by one¬
way ANOVA and multiple
comparison Tukey test. Statistical
significance noted for treatment
groups compared to matched control
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(iii) Effect of E2 and tamoxifen on ERa protein expression at 48h
The expression levels of the ERa protein in the cell lines (figure 2.4)
corresponded well with the expression of ERa mRNA observed in the previous
experiment. ERa protein was present in all MCF-7 variants but not in MDA-MB-231
cells. 1-D band analysis providing approximate OD values confirmed that the basal
levels of ERa protein are strongest in LCC-1 and LCC-2 cells and less strong in
LCC-9 and LY2 cells (table 2.2). MCF-7 cells showed ERa expression levels
comparable to LY2 cells. The expression difference between MCF-7 and LCC-1/
LCC-2 was prominent.
ERa protein expression was significantly decreased by E2 in all ER positive
cell lines. Tamoxifen and the combination of E2 plus tamoxifen had a stimulated ERa
protein expression in MCF-7 and LCC-1 cells. In LCC-2 cells, ERa protein
expression in the presence of tamoxifen was similar to basal levels but this was
markedly reduced by the addition of E2. Remarkably, the presence of E2 and/ or
tamoxifen produced undetectable levels of ERa protein in LCC-9 and LY2 cells.
Taken together, the observations indicate characteristic ERa protein
expression patterns in response to E2 and tamoxifen for MCF-7 cells. Unique protein
expression has been shown for each of the variant lines. Oestrogen decreased ERa
expression in MCF-7 and all variant cell lines. Novel observations have been made
with protein expression in the presence of tamoxifen in variant lines. Unlike in
MCF-7 cells, tamoxifen alone led to no change in LCC-1 cells and reduced
expression in LCC-9 and LY2 cells. In combination with E2, tamoxifen significantly
reduced protein expression in LCC-2, LCC-9 and LY2 cells.
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Figure 2.4: Western blot analysis of ERa (66kDa) in breast cancer cell lines in control, 10"qM E2, 10"
6M tam or 10"9M E2 and 10"6M tam treated groups at 48h. lOOpg protein was loaded per lane and
detected using anti-ERa antibody (Santa Cruz Biotech). Total actin (42kDa) was detected using
anti - (3-actin (CALBIOCHEM®) in all cell lines (one representative cell line shown) as a western blot
loading control.
Sum OD by 1D band analysis
Control Oestrogen Tam E+Tam
MCF-7 382.5 137.8 1677.4 1118.4
LCC1 2553.3 25.5 1565.7 1804.4
LCC2 1617.3 445.0 1893.2 101.72
LCC9 822.83 nd 14.81 nd
LY2 426.62 nd nd nd
MDA nd nd nd nd
Actin
LCC2 1745.50 1668.10 1349.80 1157.70
LCC9 1987.60 1907.60 1425.70 1480.10
Table 2.2: Approximate total OD values of ERa protein (67kDa) obtained from Western blot (Figure
2.4) using LabWorks3.0 and ID band analysis.(nd=not detected).
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2.2.3 PR mRNA and protein expression in MCF-7 and resistant cell lines
(i) Effect of E2 on PR mRNA expression over a period of 48h
MCF-7 and its variant cell lines, LCC-1, LCC-2, LCC-9 and LY2,
demonstrated expression of progesterone receptor mRNA (figure 2.5 A and B).
Oestrogen addition significantly up-regulated the expression, most profoundly in
MCF-7 cells (32.7 fold) and least of all in LCC-9 cells (1.8 fold). The up-
regulation was gradual and continuous up to 48h. However, the effect of E2 was not
immediate. In MCF-7 and LCC-1 lines an increase in PR mRNA was revealed only
after 3h. A further time delay was observed in other cell lines: in LCC-2 cells after




























Figure 2.5 A: PR mRNA expression in MCF-7 and LCC-l cells. Cells were left untreated (control
group) or treated with 10"9M E2. RNA was collected at Oh, lh, 3h, 6h, 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.5 B: PR mRNA expression in MCF-7, LCC-1/2/9 and LY2 cells. Cells were left untreated
(control group) or treated with 10"9M E2. RNA was collected at Oh, lh, 3h, 6h, 24h and 48h (Oh, 6h,
48h only for LY2 and MDA-MB-231 cells). A representative experiment is shown of at least two
experiments carried out. Each point represents mean of triplicate PCR analysis for each sample.
Significant variance between time points and Oh was determined by one-way ANOVA and Dunnets
multiple comparison test where *=p<0.05, **=p<0.01.
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(ii) Effect of E2 and tamoxifen on PR mRNA expression at 6h and 48h
The effects of oestrogen and tamoxifen in these cell lines were next evaluated
at 6h and 48h (figure 2.6). The E2 stimulated up-regulation of the PR mRNA in all
analysed breast cancer cell lines with the exception of MDA-MB-231 cells was again
observed in this experiment. Most marked are the effects when comparing Oh to 48h
reflecting the continuous stimulation of the hormone. In general, tamoxifen and E2
plus tamoxifen only showed significant regulatory effects at 48h.
In MCF-7 cells, E2 stimulated PR mRNA at 6h (50 fold) and most
dramatically at 48h (1017.1 fold). Tamoxifen and the combination of tamoxifen and
E2 cause small increases in mRNA expression at 48h. In LCC-1, LCC-2, LCC-9 and
LY2 cells, E2 induced mRNA expression slightly at 6h but did not reach statistical
significance. At 48h, E2 inducbility is more obvious reflecting the increasing time
delay seen in the previous experiment, the oestrogen time course. Again, a much
smaller stimulation is observed in LCC-9 cells (1.7 fold) compared to LCC-1 cells
(11.3 fold) and LCC-2 cells (8.7 fold). Tamoxifen alone and tamoxifen plus E2
showed stimulatory effects at 48h in LCC-land LCC-9 (tam 8.1 fold and 1.6 fold, E2
plus tam 11.5 fold and 2 fold, respectively) comparable to the effects observed with
E2 in those cells.
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Figure 2.6: PR mRNA expression in
MCF-7, LCC-1/2/9 and LY2 cells.
Cells were left untreated (control
group), treated with 10"9M E^; 10"6M
tam; or 10"9M E2and 10"6M tam. RNA
was collected at 6h and 48h. A
representative experiment is shown of
at least two experiments carried out.
Each column presents mean of
triplicate PCR analysis for each
sample demonstrating mRNA
expression relative to actin expression.
Error bars=STD. P-value for variance
between all groups determined by one¬
way ANOVA and multiple
comparison Tukey test. Statistical
significance noted for treatment
groups compared to matched control
where *=p<0.05, **=p<0.01.
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(iii) Effect of E2 and tamoxifen on PR protein expression at 48h
In MCF-7 cells, progesterone receptor protein could not be detected in the
absence of E2 (figure 2.7). The addition of E2 resulted in the presence of a strong
band with a size of about 116kDa representing protein of isoform hPR-B and about
81kDA for the isoform hPR-A. PR protein was also strongly up-regulated by the
presence of E2 plus tamoxifen. Tamoxifen alone only marginally increased PR
protein expression compared to the untreated control. Protein expression broadly
follows the expression pattern observed at the transcriptional level.
LCC-1 and LCC-2 cells also demonstrated E2 up-regulated PR protein
(approximately 11.1 fold and 24.4 fold, respectively). PR protein expression patterns
with and without oestrogen are comparable between MCF-7 cells and LCC-l/LCC-2
cells. The hormone inducibility has also been demonstrated at PR mRNA expression.
While tamoxifen alone stimulates PR protein expression in LCC-1 cells, it has no
effect in LCC-2 cells where expression was low and comparable to basal levels.
Tamoxifen does not reduce E2 stimulation in either of the cell lines when combined
with the hormone. Interestingly, as observed for mRNA expression, in LCC-9 cells
PR protein expression was constitutively high. The receptor showed marginal
oestrogen inducibility (approximately 1.7 fold). PR protein expression in LY2 was
low and undetectable in MDA-MB-231 cells. This stands in contrast to strong PR
mRNA expression in LY2 cells. Both isoforms of the progesterone receptor were
present in the PR positive cell lines with a predominant expression of hPR-B.
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Figure 2.7: Western blot analysis of PR in breast cancer cell lines in control. 10"9M E;, 10"6M tam or
10"9M E2 and 10"6M tam treatments at 48h. lOOpg protein was loaded per lane and detected using anti-
PR antibody (Neomarker). Total actin was detected using anti - (5-actin (CALBIOCHEM^) in all cell
lines (one representative cell line shown) as a western blot loading control.
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Sum OP by 1D band analysis
PR
Band
Size(kDa) Control Oestrogen Tam E+Tam
MCF-7 116 nd 2914.2 580.7 3252.2
81 nd 1113.5 nd 1177.5
79 nd 66.0 nd 27.7
LCC1 116 190.0 2103.2 1890.9 3061.3
81 nd 234.1 723.2 657.3
79 nd 37.1 nd nd
LCC2 116 64.5 1576.6 354.3 1457.3
81 nd 1397.2 nd 1666.5
79 nd nd nd nd
LCC9 116 3409.6 5866.7 2379.4 4295.9
81 375.4 1420.4 1060.5 967.4
79 421.2 897.9 610.11 501.3
LY2 116 29.6 22.8 nd 122.4
81 nd nd nd nd
79 nd nd nd nd
MDA - nd nd nd nd
Actin
LCC2 42 1316.4 1471 1730.5 1684.4
Table 2.3: Absolute OD values of PR protein obtained from Western blot (Figure 2.7) using Labworks
and 1D band analysis (nd = not detected).
In summary, PR protein was generally E2 inducible in MCF-7 and MCF-7
variant cells. Patterns of expression were comparable in MCF-7, FCC-1 and FCC-2
cells with the exception of tamoxifen treated FCC-1 cells. Consistently highest PR
protein expression was found in FCC-9 cells. Both, FY2 and MDA-MB-231 cell
express insignificant or undetectable amounts of progesterone receptor protein.
Protein expression does not always mirror mRNA expression indicating that rates of
turnover as well as synthesis impact in the levels of expression.
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2.2.4 Discussion
ERa plays a key role in the development of the normal breast and has been
shown to participate in the progression of breast cancer. The receptor serves as a
means for its ligand to mediate most of its known effects and study of the receptor
lies at the core of this project. The ER ligand binding domain not only binds E2 but
directly associates with transcriptional coactivators and corepressors (Enmark, F. and
Gustafsson, J.-A. 1999). Another target of oestrogen is the progesterone receptor. Its
role in breast cancer development remains poorly understood but its functions in
endocrine signalling are thought to be mainly due to its ability to oppose
transcriptional activity of the ERa. The PR isoform hPR-A is known to antagonize
the transcriptional activity of ERa in particular (Giangrande, P.H. and McDonnell.
D.P. 1999). E2 itself increases PR expression (Graham. J.D. and Clarke, C.L. 1997).
This serves as evidence for the complex linking of the receptor pathways particularly
since the progesterone receptor is unable to heterodimerize with the oestrogen
receptor. It is crucial to identify the differential role ER may play in endocrine
resistance by comparing expression pattern as well as response to oestrogen and
antioestrogens in resistant and non-resistant breast cancer cell lines. Insight into the
complex relationship of ER and PR might be beneficial in gaining this knowledge.
It is well documented that MCF-7 cells not only express ERa but that the
expression is influenced by oestrogen and tamoxifen (Horwitz, K.B. and McGuire,
W.L. 1978 (a) and Eckert. R.L. et al. 1984). These observations are confirmed here.
A significant down-regulation of ERa protein was observed after long-term E2
addition (48h) while both tamoxifen and tamoxifen plus oestrogen addition result in
up-regulated ER protein expression. The effect of oestrogen on ERa over the course
of 48h was marginal but contrasted with the second experiment where a slight
increase was observed at 6h and 48h. These conflicting results might partially be due
to shifting baseline expressions at Oh and 48h. Published studies suggest that ERa
mRNA is down regulated by E2 after 6h and up to 48h in MCF-7 cells (Saceda, M. et
al. 1988; Cho, ELS. et al. 1991). Decreased ERa protein expression indicates an
increased ERa use in the presence of its ligand, supported by steady mRNA levels,
coupled with a rapid turnover observed in decreased protein expression long-term.
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Early work on ERa has established that hormone binding takes place within 5min
and a rapid decrease of ERa protein levels occurs after 30min (Horwitz, K.B. and
McGuire, G.L. 1978(a); Katzenellenbogen, B.S. et al. 1987). This processing
continues for 3-5h and remains at a low level for the remainder of the oestrogen
exposure. In fact, ERa half-life has been established to be approximately 3-4h
(Monsma, F.J., Jr. et al. 1984). The short-term unaffected but long-term slightly
increased ERa mRNA expression after tamoxifen treatment matched with increased
protein levels at 48h may confirm the much lower receptor turnover rate with the
antioestrogen (Elorwitz, K.B. and McGuire, W.L. 1978 (a)). If tamoxifen competes
with oestrogen for the binding sites, the tamoxifen-bound receptor is no longer
processed at the rapid rates seen with E2. As the receptor becomes processed at a
much lower rate, protein is allowed to accumulate.
All the MCF-7 variant cell lines studied express ERa mRNA and ERa
protein. Baseline levels of ERa mRNA vary only marginally between the variant
lines but are generally slightly higher than in MCF-7 cells. This may be due to the
resistant cells not being exposed to E2 in passaging in charcoal stripped serum
conditions. The researchers who established the LCC series of cell lines observed
'essentially comparable ER expression levels' in these lines (Briinner, N. et al.
1997). The fact that ERa gene and protein are expressed at comparable or higher
levels in the E2 resistant cell lines obviously eliminates the theory that loss of the
receptor is reponsible for the change in phenotype. In fact, in a tet-inducible ERa
overexpressing MCF-7 system, it has been demonstrated that high concentrations of
the receptor can stimulate gene expression of E2 target genes such as pS2 in a
hormone independent manner (Fowler, A.M. et al. 2004). This clearly indicates that
a mechanism comes into place where the receptor is activated in the absence of E2
and continues to mediate gene transcription in these phenotypes. This is discussed
further in subsequent chapters.
Interestingly, both E2 and tamoxifen treatment lead to reduced ERa mRNA
expression in all resistant lines. The addition of oestrogen revealed a uniform protein
down-regulation leading to non-detectable levels of ERa in LCC-9 and LY2 cells.
Tamoxifen only reverses this effect in MCF-7, LCC-1 and LCC-2 cells. Decreased
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protein levels in response to oestrogen correspond to ERa mRNA expression pattern
in all of the MCF-7 variants while tamoxifen and tamoxifen plus oestrogen effect on
protein varies between protein and mRNA expression. The absence of the ERa in
MDA-MB-231 cells was confirmed (Cailleau, R. et al. 1978). The fact that cells
responding differently to oestrogens and antieostrogens with respect to growth all
retain the ERa is what makes this cell model particularly interesting for the study of
endocrine resistance mechanism. This verifies that loss of the oestrogen receptor is
not the underlying cause of endocrine resistance in these models. In addition, the
observed endocrine independence but responsiveness observed in some cells points
out that the receptor might still be functional although it is likely that receptor
signalling has undergone dramatic changes.
The main focus of research in these cell lines surrounds the functionality of
the receptor. There is no doubt that a selective process comes into place where cells
slowly adapt to grow without hormone supplementation. The identification of several
oestrogen mimicking chemicals in the laboratory environment such as alkyl phenols
released from plastic centrifuge tubes (Soto, A.M. et al. 1991) might suggest that
minimal levels of growth hormone is available for cell growth adapted to such small
concentrations. A stepwise selection to oestrogen independence cells could also
involve various mutations of the oestrogen receptor. Mutations might result in the
receptors altered ability to bind oestrogen and/or antioestrogen. to associate with the
promoter of the target gene or interact with transcription factors. Several mutated
forms of the receptor have been detected. A constitutively active receptor is the result
of the amino acid Tyr537 substitution by Ala, Ser, Asp, or Glu (Weis, K.E. et al.
1997; Zhang, Q.X. et al. 1997; Sommer, S and Fuqua, S. 2001). This mutant has
shown a conformational shift in the LBD and is also able to bind coactivators such as
SRC-1 in the absence of the ligand. An identified shorter ERa isoform hER-a46 is
thought to be involved in cell proliferation in MCF-7 cells (Flouriot, G. et al. 2000).
An increasing number of ERa mRNA splice variants have been identified in vitro
and in vivo. In MCF-7 and endocrine resistant MCF-7 variant lines with resistance to
tamoxifen, similar expression levels of ERa splice variants lacking exon3 to exon 5
and exon 7 were demonstrated but corresponding proteins could not be identified
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(Madsen, M.W. et al. 1997). Other groups have identified distinct expression
patterns of ERa wild type and ERa splice variants in normal and malignant breast
cancer cells including the MCF-7/LCC1/2/9 sublines (Poola, I. et al. 2000 and 2001).
Published results and speculations vary with respect to presence and possible
involvement of mutant receptors in breast cancer. However, it is unlikely that this is
the underlying cause for the development of endocrine resistance. However, the
expression of the receptor across different endocrine resistant phenotypes and the
varying response to endocrine agents despite apparent endocrine independent growth
demonstrates its continued role in oestrogen pathways. It is possible that tumour
specific receptor expression patterns including mutants might contribute to the
adaptability of the tissue to respond to endocrine agents.
It becomes evident that if oestrogen and antioestrogen binding does
differentially mediate ERa expression at the mRNA and protein level, alternative
pathways must be initiated upon ligand binding. Oestrogens as well as tamoxifen
down-regulate ERa mRNA in all MCF-7 variant cell lines. ERa protein is generally
down-regulated in these cell lines and not detectable in the presence of E2 and
tamoxifen in the antioestrogen cross-resistant MCF-7/LCC-9 and LY2 cells. In
MCF-7 cells, ERa protein levels are increased upon the addition of tamoxifen. Much
thought has been given to evidence suggesting use of alternate promoters within the
ERa gene for the transcriptional regulation of the receptor (MacGregor and Jordan,
V.C. et al. 1998). Additionally, several regulatory elements upstream of the
transcription start site have been identified indicating the possibility of differentially
influencing ER transcription regulation. The small ER-EH0 enhancer element has
been shown to be active in ER+ but not ER- breast cancer cells and specific DNA
protein complexes associate with this element (Tang, Z. et al. 1997). Use of alternate
promoters could be used in response to changed environments within the cell such as
the continued presence of an antioestrogen. Ligand binding and interaction of the
receptor with target genes or their transcription complex can also be facilitated by
receptor phosphorylation of specific serine or possibly tyrosine residues (Nilsson, S.
• • 118
et al. 2001). MAP kinase activated phosphorylation of Ser within the N-terminal
region of the oestrogen receptor is thought to enhance ERa AF-1 activity thereby
stimulating protein-protein interactions to increase gene transcription (Kato, S. et al.
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2000). Cross-signalling between the ER and other growth factors is most often linked
to a common mediator, the MAPK cascade. Regulation becomes a complex network
as MAPK activation in turn is influenced by growth factors such as IGF, insulin and
TGF-ot.
Cross-talk between the oestrogen receptor and other signalling pathways also
leaves open the possibility of ligand independent receptor activation. Again, this
corresponds to breast cancer tissue modelled by MCF-7/FCC-1 or FCC-2 cells that
grow independently of oestrogen but are sensitive to oestrogen or an antioestrogen
(Clarke, R. et al. 2001). EGF, TGFa, dopamine or heregulin have all been have
shown to indirectly activate the oestrogen receptor via crosstalk to the respective
signalling pathways (Gruber, C.J. et al. 2002). For example, overexpression of HER-
2 can lead to oestrogen and tamoxifen independent cell growth and HER-2 activation
by its ligand heregulin leads to ER activation via phosphorylation indicating a
potential involvement for this ER ligand independent pathway in the development of
endocrine resistance (Pietras, R.J. et al. 1995).
Ligand independent pathways to alternatively regulate transcription involving
intracellular kinase activity have also been suggested for other nuclear receptors such
as progesterone receptor activation. This may also involve complex cross-signalling
between signalling pathways and provide possible mechanisms to develop
antioestrogen resistance. The protein kinase (PKA) stimulator cyclic AMP (cAMP)
has been shown to activate the progesterone receptor in the absence of its ligand
(Denner, L.A. et al. 1990). Further, PR stimulatory effects observed for oestrogen
have been demonstrated to be similar in magnitude for cAMP or IGF-1 linking
progesterone signalling not only with the oestrogen receptor but with the protein
kinase and insulin receptor pathways, respectively (Aronica, S.M. and
Katzenellenbogen, B.S. 1991). Respective antagonists of the three agents such as the
antieostrogen ICI 164,384 for E2, reversed this stimulation. Effects of E2, IGF and
cAMP were not additive suggesting a complex network with a common element such
as MAPK signalling as a central mediator (Aronica, S.M. and Katzenellenbogen,
B.S. 1991).
MCF-7 cells were shown to express low levels of PR mRNA in the absence
of oestrogen. Protein expression could not be detected under these conditions. This
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might partially be based on the superior sensitivity of RT-PCR relative to Western
blotting although not all mRNA copies are necessarily translated into protein.
Processing of mRNA might prevent protein expression. Most interestingly, oestrogen
strongly increased mRNA expression in a progressive manner over the course of 48h
by which time protein was also strongly expressed. This stimulatory effect was
generally also observed for the expression of PR mRNA and protein in MCF-7
variant lines although inducibility was clearly strongest in MCF-7 cells. Tamoxifen
acted as an agonist inducing mRNA and protein expression long-term across the
panel of cell lines. Overall PR protein expression was comparable between MCF-7
and LCC1/2 cells, slightly higher in LCC-9 but lower in LY2 cells. Small differences
of PR protein expression between MCF-7 and LCC lines had been published
previously confirming a higher PR protein content in LCC-1 and LCC-9 cells, and a
somewhat lower level in LCC-2 cells ( Brtinner, N. et al. 1993 and 1997). Upon
establishment, LY2 cells had been reported as PR negative with and without
oestrogen (Bronzert, D.A. et al. 1985). The presence of oestrogen inducible PR
mRNA and protein in this experiment might indicate the availability of better quality
antibodies now available and the resulting possibility of distinguishing between the
different isoforms of the receptor at the protein level.
The constitutive and long-term stimulation of PR mRNA and protein
expression in the presence of oestrogen is likely to be based on the cross-signalling
between the oestrogen and the progesterone receptor and their role in normal
mammary gland development. Expression of the progesterone receptor changes from
a more uniform to a clustered pattern during distinct phases of female reproductive
system development such as puberty and pregnancy (Mulac-Jericevic and Conneely,
O.M. 2004; Anderson, E. 2002). ERa or PR expressing cells and cells actively
dividing cells have been suggested to be two separate populations since, in normal
breast epithelium, cells containing steroid receptors have shown to be expressed
separately but adjacent to actively proliferating cells (Clarke, R.B. et al. 1997; Russo,
J. et al. 1999). It is therefore assumed that progesterone regulates cell proliferation in
an indirect manner by signalling the release of growth factors only after prolonged
oestrogen exposure. The continuous presence and accumulation of oestrogen in this
experiment resembles this situation and leads to an increased expression of the
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progesterone receptor. During carcinogenesis, a change in growth factor signalling
might also mimic a constitutive hormone presence and lead to uncontrolled cell
proliferation and the development of malignant breast tissue. Interestingly, in breast
tumours, about 65% showed a larger number of proliferative cells expressed ER
supporting altered cell signalling and gene expression (Clarke, R.B. et al. 1997).
Perhaps most intriguing is the question of whether the balance between the
two progesterone isoforms could explain differing endocrine response in breast
cancer tissue. Somewhat conflicting evidence has been collected since the isolation
of the isoforms in the 1980s. In normal mammary tissue, the expression of hPR-A
and hPR-B is thought to be close to even (Mote, P.A. et al. 2002). A predominant
expression of one form or the other has been reported in some publications (Graham,
J.D. et al. 1996 or Mote, P.A. et al. 2002). Here, the predominantly expressed form
was hPR-B in all cell lines. An additional third and smaller band of about 75kDA
was also often found. Other investigators have reported this finding (Graham, J.D. et
al. 1996). The main hPR-A and hPR-B isoforms have been assigned distinct
functionality. While hPR-B acts as a transcriptional activator, h-PR-A might act
predominantly as a repressor and mask the actions of hPR-B where isoforms are co-
expressed (Mulac-Jericevic and Cormeely, O.M. 2004). This might indicate a poor
response to endocrine treatment in cells were hPR-A is predominantly expressed
particularly because this isoform has shown to repress other growth factor pathways
such as the oestrogen receptor. But there is also evidence that isoform hPR-B is
capable of repressing transcriptional activity in line with observations made here in
MCF-7 and MCF-7 variant lines. Oestrogen dependent activation of pS2 was
repressed only in modified MDA-MB-231 cells designed to selectively oeverexpress
hPR-B and ERa (Chalbos, D. and Galtier, F. 1994). This result was also true for
hPR-B overexpressing MCF-7 or HeFa cells and could not be demonstrated for
hPR-A constructs.
The potential functionality difference between isoforms is underlined by the
identification of an additional activation domain in hPR-B (Graham. J.D. and Clarke,
C.F. 2002). The AF-3 region, like the common AF-1 sequence, has been shown to
recruit coactivators. This leaves the possibility that the isoforms not only attract
unique sets of transcriptional cofactors but also show differential binding affinities
98
Results: Regulation of ER and PR
for the same promoters to mediate gene transcription. Isoforms have been
demonstrated to express specific peptide binding affinities (Giangrande, P.H. et al.
2000). Microarray studies have revealed progesterone mediated promoter specific
transcription regulation in T47D breast cancer cells (Richer, J.K. et al. 2002). When
hPR-A or hPR-B were expressed exclusively unique sets of genes mediated by each
isoform were identified with only a small percentage of overlap. Interestingly, when
isoforms were co-expressed in the wild type, regulation was found to be much less
restricted. Similar to the observation where hPR-A is able to reverse transcriptional
activity of hPR-B, hPR-B might be able to mask repressive functions of hPR-A and
utilise its additional region AF-3 to enhance transcriptional activation. The
predominant expression of hPR-A or hPR-B might therefore lead to promoter and
tissue specific PR mediated gene transcription. A change in PR isoform expression
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2.3 Regulation of ER target genes by oestrogen and tamoxifen
2.3.1 Introduction
The oestrogen receptor classically mediates transcription by direct contact
with oestrogen response elements (EREs) or alternative response elements on the
target gene. Cathepsin D (CTSD), pS2 and MYC are three genes whose trancription
is well known to be E2 mediated (Cavailles, V. et al. 1989; Dubik, D. et al. 1987).
All have previously been identified in breast cancer tissues (Rochefort, H. et al.
1987; Masiakowski, P.et al. 1982; Escot, C. et al. 1986) To measure the expression
of pS2, CTSD and MYC mRNA in MCF-7, MCF-7 variant and MDA-MB-231
breast cancer cell lines a similar series of experiments to the ones described in the
previous section were undertaken. RNA was prepared from cultured cells and
amplified using the RT-PCR technique. Results are expressed as actin ratios and
statistically analysed as described previously.
2.3.2 MCF-7 and MCF-7 variant cells show divergent expression of pS2, CTSD
and MYC mRNA
Basal levels of pS2 mRNA were detected in all but the ER negative MDA-
MB-231 cells (Figure 2.8). The parental MCF-7 cell line presents a very low level of
pS2 mRNA under these oestrogen deprived conditions compared to LCC-1, LCC-2
and LCC-9 cells which express elevated almost identical levels (66 fold, 65 fold and
73 fold, respectively relative to MCF-7 cells). In contrast, CTSD as well as MYC
mRNA expression were revealed to be relatively low for all cell lines. Differences in
expression for both genes between cell lines were not as dramatic. One noteworthy
exception is the high expression of CTSD in MDA-MB-231 cells compared to MCF-
7 cells (4.8 fold). Expression of MYC mRNA is generally higher in LCC-1/2/9 and
MDA-MB-231 cells compared to the MCF-7 cell line but only by about 2.0 fold.
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pS2 mRN'A expression
MCF-7 LCC1 LCC2 LCC9 LY2 MDA-MB-231
Cell line
CTSD mRNA expression p< 0 0001 MYC mRNA expression p<Q0001
Cell line
Figure 2.8: Baseline mRNA expression of pS2, CTSD and MYC before treatment (Oh) in breast
cancer cells. MCF-7 cells seeded in complete media for 24h and a further 48h in reduced media
containing 5% DCC. All other cells were seeded in reduced media for 24h before RNA collection. A
representative experiment is shown of at least two experiments carried out. Each column presents the
mean of triplicate PCR analysis for each sample. Error bars =STD. Significant variance between
parental MCF-7 cells and other cell lines was determined by one-way ANOVA and Dunnets multiple
comparison test where *=p<0.05, **=p<0.01.
2.3.3 Modulation of pS2, CTSD and MYC in MCF-7 cells
(i) E2 stimulates pS2, CTSD and MYC mRNA expression in MCF-7 cells
Exposure of MCF-7 cells to E2, resulted in stimulation of pS2, CTSD as well
as MYC mRNA expression (Figure 2.9). pS2 mRNA expression increased after the
first hour and continued to increase markedly up to 48h (120 fold). In contrast, the
level of MYC mRNA remained elevated for 48h following an initial stimulation after
lh (3.7 fold). A continuous increase of mRNA was also detected for CTSD
expression. The magnitude of increase relative to pS2 however was small. Maximum
expression was reached at 48h (2.9 fold).
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24h 48h 48h control
5% sFCS
Figure 2.9: mRNA expression of pS2, CTSD and MYC in MCF-7 cells. Cells were left untreated
(control group) or treated with 10"9M E2. RNA was collected at Oh, lh, 3h, 6h, 24h and 48h. A
representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Error bars =STD. Significant variance between time
points and Oh was determined by one-way ANOVA and Dunnets multiple comparison test where
*=p<0.05, **=p<0.01.
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(ii) Modulation of pS2, CTSD and MYC mRNA by E2 and tamoxifen in
MCF-7 cells at 6h and 48h
Oestrogen inducibility for all three genes was confirmed in this part of the
experiment (figure 2.10). The antioestrogen tamoxifen showed generally little effect
after 6h but acted as a weak agonist in some cases after 48h. pS2 mRNA expression
was strongly induced by E2 after 6h and 48h (90 fold and 666.8 fold, respectively).
Tamoxifen as a single agent increased pS2 mRNA slightly and reached a 2.8 fold
increase after 48h although statistical significance was not reached. Interestingly,
tamoxifen suppressed the E2 induced increase when combined with the E2 at both
time points and expression remained close to basal levels. A similar response to E2
and tamoxifen was detected for the expression of MYC mRNA. E2 treatment
a) MCF-7: pS2 expression
















b) MCF-7: MYC expression
p< 0.0001
c) MCF-7: CTSD expression
p< 0.0001
48h Oh 6h 48h
Figure 2.10: mRNA expression of pS2, CTSD and MYC in MCF-7 cells. Cells were left untreated
(control group), treated with 10"9M E;; 10'6M tam; or 10"QM E;and 10"6M tam. RNA was collected at
6h and 48h. A representative experiment is shown of at least two experiments carried out. Each
column represents mean of triplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple Tukey-Kramer comparison test. Statistical significance noted for
treatment groups compared to matched control where *=p<0.05, **=p<0.01. (**) indicates statistical
significance comparing E+T with matched E2.
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markedly stimulated MYC expression at 6h (7.0 fold) as well as 48h (5.9 fold) while
tamoxifen had slight agonistic effects reaching statistical significance at 48h (3.3
fold). Tamoxifen reduced the E2 stimulated increase to basal levels at 6h and
partially at 48h. As previously observed, E2 increased CTSD expression at 6h but
continued to increase expression with time reaching a 4.8 fold induction by 48h.
Tamoxifen, by itself, had no effect on CTSD expression but reversed oestrogens
stimulatory effect at 6h and 48h.
2.3.4 Oestrogen modulation of pS2, CTSD and MYC in LCC-1 cells
(i) Modulation of E2 on pS2, CTSD and MYC mRNA expression over a
period of 48h
In contrast to MCF-7 cells, a remarkably high constitutive pS2 expression in
LCC-1 was detected from time point Oh (Figure 2.11 A). Both CTSD mRNA and
MYC mRNA were detected at comparably low levels Figure 2.11 B). E2 treatment
produced a small increase in pS2 expression (between 1.5 fold and 1.6 fold) and very
weak oestrogen stimulation over the 48h time span in CTSD and MYC expression.
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Figure 2.11A: mRNA expression of pS2 in LCC-1 cells. Cells were left untreated (control group) or
treated with 10"9M E2. RNA was collected at Oh, lh, 3h, 6h, 24h and 48h. A representative experiment
is shown of at least two experiments carried out. Each point represents mean of triplicate PCR
analysis for each sample. Error bars =STD. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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LCC-1: CTSD expression
Oh 1h 3h 6h 24h 48h 48h control




Figure 2.11: mRNA expression of CTSD and MYC in LCC-1 cells. Cells were left untreated (control
group) or treated with 10"9M E2. RNA was collected at Oh, lh, 3h, 6h. 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Error bars =STD. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(ii) Oestrogen and tamoxifen modulation on pS2, CTSD and MYC mRNA
expression at 6h and 48h
As seen previously. pS2 was particularly strongly expressed in LCC-1 cells
compared to MCF-7 cells and compared to the expression of CTSD and MYC
(Figure 2.12). Interestingly, while E2 led to an attenuated increase in pS2 mRNA
expression (5.0 fold at 48h), tamoxifen alone as well as in combination with E2
reduced expression short-term to below baseline levels (2.0 fold and 2.2 fold,
respectively). This is not the case at 48h although tamoxifen does reduce the
stimulatory effect of E2. A similar observation was made for the transcription of
MYC mRNA. E2 stimulated levels at 6h (1.5 fold) and 48h (2.4 fold) while
tamoxifen decreased mRNA levels strongly at 6h alone (4.8 fold) and in combination
(3.6 fold). Levels remained below baseline in the presence of tamoxifen at 48h.
Neither E2 nor tamoxifen had a marked effect on CTSD expression.
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a) LCC-1: pS2 expression
■ Control C1E2 ■ Tam □E2+Tam
48h
Figure 2.12: mRNA expression of pS2, CTSD and MYC in LCC-1 cells. Cells were left untreated
(control group), treated with 10"9M E2; 10"6M tam; or 10~9M E2and 10"6M tam. RNA was collected at
6h and 48h. A representative experiment is shown of at least two experiments carried out. Each
column represents mean of triplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple Tukey-Kramer comparison test. Statistical significance noted for
treatment groups compared to matched control where *=p<0.05, **=p<0.01. (**) indicates statistical
significance comparing E+T with matched E2.
2.3.5 Oestrogen modulation of pS2, CTSD and MYC in LCC-2 cells
(i) Effect of Es on pS2, CTSD and MYC mRNA expression over a period of
48h
In a manner similar to LCC-1 cells, pS2, CTSD and MYC mRNA expression
were shown to be only marginally oestrogen -inducible in LCC-2 cells when
comparing to MCF-7 cells (figure 2.13). pS2 expression was again markedly high in
LCC-2 cells (Figure 2.3.6). A small cumulative increase in expression was detected
( 2.4 fold at 48h). While CTSD mRNA was expressed at much lower levels than pS2,
it was also weakly oestrogen inducible (2.8 fold at 24h). There was a significant
short-term increase of MYC mRNA at lh (2.2 fold) and a constitutive expression up
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to 48h similar to basal levels. The immediate increase in expression after E2 addition


































24h 48h 48h control
LCC-2: MYC expression
p< 0.0001
Oh 1h 3h 6h 24h 48h 48h control
-24h 10"9M Oestradiol
5% sFCS> *
Figure 2.13: mRNA expression of pS2, CTSD and MYC in LCC-2 cells. Cells were left untreated
(control group) or treated with 10"9M E2. RNA was collected at Oh, lh, 3h, 6h, 24h and 48h. A
representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Error bars =STD. Significant variance between time
points and Oh was determined by one-way ANOVA and Dunnets multiple comparison test where
*=p<0.05, **=p<0.01.
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(ii) Oestrogen and tamoxifen modulation of pS2, CTSD and MYC mRNA
expression at 6h and 48h
When LCC-2 cells were subjected to oestrogen and tamoxifen, pS2 mRNA
expression was found to be slightly stimulated at 6h and more strongly at 48h (1.5
fold and 2.5 fold, respectively) (Figure 2.14). Tamoxifen fully represses the
stimulatory effects of E2 at 48h. MYC and CTSD are expressed at very low levels
compared to pS2. Treatment with E2 only marginally increased the expression of
MYC mRNA at 6h. Treatment with tamoxifen and tamoxifen in combination with E2
reduces MYC mRNA levels below basal levels at 6h (4.0 fold and 3.4 fold,
respectively). However, expression remains at control levels at 48h where neither E2
nor tamoxifen have any effect. On the other hand, tamoxifen exerts an agonistic
effect at 48h to increase CTSD mRNA expression (3.4 fold and 3.4 fold).
a) LCC-2: pS2 expression



















Figure 2.14: mRNA expression of pS2, CTSD and MYC in LCC-2cells. Cells were left untreated
(control group), treated with 10"9M E2; 10"6M tam; or 10"9M E2and 10"6M tam. RNA was collected at
6h and 48h. A representative experiment is shown of at least two experiments carried out. Each
column represents mean of triplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple Tukey-Kramer comparison test. Statistical significance noted for
treatment groups compared to matched control where *=p<0.05, **=p<0.01. (**) indicates statistical
significance comparing E+T with matched E2.
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2.3.6 Modulation of pS2, CTSD and MYC in LCC-9 cells
(i) Oestrogen modulation of pS2, CTSD and MYC mRNA expression over a
period of 48h
Even though pS2, CTSD and MYC mRNA were easily detectable in LCC-9
cells, E2 treatment did not alter gene expression markedly compared to parental
MCF-7 cells (Figure 2.15 A and B). Similar to LCC-1 and LCC-2 cells, pS2
expression was constitutively high and is slightly increased by 24h (1.5 fold) and 48h
(1.7 fold). This expression pattern was also observed for MYC although the overall
expression level was much lower compared to the expression of pS2. CTSD mRNA
































Figure 2.15 A: mRNA expression of pS2 and CTSD in LCC-9 cells. Cells were left untreated (control
group) or treated with 10"9M E2. RNA was collected at Oh, lh, 3h, 6h. 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Error bars =STD. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.15 B: mRNA expression of MYC in LCC-9 cells. Cells were left untreated (control group) or
treated with 10"9M E2. RNA was collected at Oh, lh, 3h, 6h, 24h and 48h. A representative experiment
is shown of at least two experiments carried out. Each point represents mean of triplicate PCR
analysis for each sample. Error bars =STD. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(ii) Oestrogen and tamoxifen modulation of pS2, CTSD and MYC mRNA
expression at 6h and 48h
The expression pattern for pS2, MYC and CTSD mRNA was found to be
similar in LCC-9 cells to LCC-2 cells (Figure 2.16 A and B). A late stimulatory
effect on the expression of pS2 and CTSD was detected as seen previously at 48h
(3.6 fold and 1.5 fold, respectively). Tamoxifen alone slightly reduced expression
levels at 6h for pS2 and 6h as well as 48h for MYC (although not statistically
a) LCC-9: pS2 expression






Figure 2.16 A: mRNA expression of pS2 in LCC-9cells. Cells were left untreated (control group),
treated with 10"9M E2; 10"''M tarn; or 10"9M E2 and 10"6M tarn. RNA was collected at 6h and 48h. A
representative experiment is shown of at least two experiments carried out. Each column presents
mean of triplicate PCR analysis for each sample demonstrating mRNA expression relative to actin
expression. Error bars=STD. P-value for variance between all groups determined by one-way
ANOVA and multiple Tukey-Kramer comparison test. Statistical significance noted for treatment
groups compared to matched control where *=p<0.05, **=p<0.01. (**) indicates statistical
significance comparing E+T with matched E2.
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b) LCC-9: MYC expression p< 0.0001 c) LCC-9: CTSD expression
Figure 2.16 B: mRNA expression of CTSD and MYC in LCC-9cells. Cells were left untreated
(control group), treated with 10"9M E2; 10"6M tarn: or 10"9M E2and 10"6M tam. RNA was collected at
6h and 48h. A representative experiment is shown of at least two experiments carried out. Each
column presents mean of triplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple Tukey-Kramer comparison test. Statistical significance noted for
treatment groups compared to matched control where *=p<0.05, **=p<0.01. (**) indicates statistical
significance comparing E+T with matched E2.
significant). Tamoxifen reduced the E2 induced expression increase of pS2
significantly at 48h. The expression of CTSD was increased by E2 at 6h as well as
48h (1.4 fold and 1.5 fold, respectively). Again, as seen in LCC-2 cells tamoxifen
alone and in combination with E2 revealed a late stimulation in LCC-9 cells. The
expression was increased 2.7 fold and 3.0 fold, respectively.
2.3.7 Modulation of pS2, CTSD and MYC in LY-2 cells
(i) Modulation of pS2, CTSD and MYC mRNA expression over a period of
48h
The expression of pS2, CTSD and MYC was detected to be constitutively
high in LY2 cells (Figure 2.17). A small increase in expression was observed for pS2
at 48h (2.4 fold). The decrease in expression for CTSD was observed at 6h and 48h
(1.1 fold and 1.5 fold) and a small increase at 6h for MYC (1.3 fold). The expression
of MYC mRNA returned back to baseline at 48h. More detailed analysis will have to
be carried out to draw definite conclusions on the short and long-term effect of E2
treatment.
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Figure 2.17: mRNA expression of pS2, CTSD and MYC in LY2 cells. Cells were left untreated
(control group) or treated with 10"9M E2. RNA was collected at Oh, 6h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Error bars =STD. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(ii) Oestrogen and tamoxifen modulation of pS2, CTSD and MYC mRNA
expression at 6h and 48h
Uniquely, tamoxifen treatment showed a significant decrease in expression
for MYC and to a lesser extent for CTSD (figure 2.18). At 6h, MYC mRNA
expression was reduced by tamoxifen alone and tamoxifen plus Ei (5.5 fold and 4.1
fold). mRNA levels recovered by 48h. CTSD expression was reduced slightly at 6h
(1.8 fold and 1.5 fold). However, this effect was reversed by 48h and tamoxifen
increased expression in the presence of tamoxifen alone and in combination with E2
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Figure 2.18: mRNA expression of pS2, CTSD and MYC in LY2 cells. Cells were left untreated
(control group), treated with 10"9M E2; 10"6M tam; or 10"9M E2and 10"6M tam. RNA was collected at
6h and 48h. A representative experiment is shown of at least two experiments carried out. Each
column represents mean of triplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple Tukey-Kramer comparison test. Statistical significance noted for
treatment groups compared to matched control where *=p<0.05, **=p<0.01. (**) indicates statistical
significance comparing E+T with matched E2.
(1.3 fold and 2.0 fold, respectively). Ej stimulated pS2 mRNA levels at 48h as seen
in the previous experiment (figure 2.17). This effect was partially reversed by the
addition of tamoxifen.
2.3.8 Modulation of pS2. CTSD and MYC in MDA-MB-231 cells
(i) Oestrogen modulation of pS2, CTSD and MYC mRNA expression over a
period of 48h
To compare the expression of pS2, CTSD and MYC to an ERa negative cell
line, MDA-MB-231 cells were subjected to mRNA analysis (figure 2.19). As
previously reported. pS2 mRNA could not be detected in these cells. E2 exposure did
not trigger transcription and had no effects on the expression of CTSD or MYC
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Figure 2.19: mRNA expression of pS2, CTSD and MYC in MDA-MB-231 cells. Cells were left
untreated (control group) or treated with 10"9M E2. RNA was collected at Oh, 6h and 48h.
Representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Error bars =STD. Significant variance between time
points and Oh was determined by one-way ANOVA and Dunnets multiple comparison test where
*=p<0.05, **=p<0.01.
although constitutively high levels were observed for both genes. The level of CTSD
mRNA was relatively high compared to MCF-7 and MCF-7 variant cell lines.
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mcf-7 x +++ + + x + + + x +
lcc-1 xxx + x + xx + + +
lcc-2 xxx + x + + x - + +
lcc-9 xxx + - - x + + xx +
ly2 xxx + x + + x - + +
Table 2.4: Summary of E2 and tamoxifen modulation on mRNA expression in MCF-7 and MCF-7
variant cell lines at 48h. Baseline 48h mRNA expression analysis (C): Actin ratio is shown where x:
<2; xx: 2-10; xxx: >10. Fold changes in response to E2, tarn and E2+tam are indicated in comparison
to matched basal levels. +++ = >50 fold; ++ = > 10 fold; + = >2 fold; - = <2 fold; n.d. = not detected.
2.3.8 Discussion
Expression analysis at the transcriptional level has been carried out to
examine the regulation of three oestrogen responsive genes: pS2, CTSD and MYC.
The effects of oestrogen and tamoxifen have been studied to evaluate their role in
endocrine response and also to identify a gene profile that best reflects observations
in the cells' phenotypes. A summary of results is shown in table 2.4. Basal
transcription of the three genes between cell lines varied to a great extent particularly
for pS2. Here, mRNA expression was exceptionally high and comparable in LCC-1,
LCC-2, LCC-9 and LY2 cells while MCF-7 cells showed a significantly lower
expression. Differential expression of pS2 suggests a unique role for the gene in each
of the cell lines. This role might be linked to altered endocrine phenotypes as all
oestrogen resistant cell lines share high pS2 expression. MDA-MB-231 cells were
pS2 negative implying that pS2 expression is linked to ERa signalling. This is not
true for MYC mRNA expression in MDA-MB-231 cells where it was particularly
strong compared to MCF-7 and LCC-1 cells as well as LCC-9 and LY2 cells. In
MCF-7 and MCF-7 variant cell lines, only small baseline expression differences
were detected for CTSD and MYC. Cathepsin D was generally expressed at lower
levels comparable to MYC. Most dramatic was the stimulatory effect of oestrogen
seen in MCF-7 cells although some stimulation for this gene was seen in all other
cell lines. Analysis of baseline expression and E2 modulation indicates a clear
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oestrogen driven pS2 expression in MCF-7 cells but also suggests high pS2
expression in the MCF-7 variant lines is largely driven in an E2 independent manner.
It might also imply that any remaining stimulation of pS2 expression bypasses ERa
and oestrogen regulates the expression through an indirect signalling pathway.
Oestrogen induced transcription of MYC and CTSD mRNA significantly on
relatively few occasions, most notably the expression of MYC in MCF-7 and LCC-1
cells. Interestingly, tamoxifen has a late stimulatory effect for CTSD expression
particularly in LCC-2, LCC-9 and LY2 cells. The antioestrogen generally also
reversed the stimulation of oestrogen in all but MDA-MB-231 cells whenever an
induction was observed such as in pS2 expression, or MYC expression in LCC-1
cells. Additionally, Ei induced MYC expression was not only reversed by tamoxifen
but reduced below baseline levels. This is clearly an indication that oestrogen and
tamoxifen have cell line and promoter specific effects on gene transcription. Both,
oesrteogen as well as tamoxifen can show agonistic and antagonistic effects on
mRNA expression and tamoxifen is clearly not always able to reverse the effects of
oestrogen.
Studies investigating the clinical relevance of pS2/TFFl have established a
positive correlation between pS2 and oestrogen receptor expression. This clearly
suggested that the expression of pS2 in breast carcinomas is oestrogen dependent
(reviewed in Ribieras, S. et al. 1998). Multiple in vitro studies have produced
evidence that pS2 gene transcription is oestrogen inducible at the mRNA as well as
protein level in MCF-7 cells producing accumulating high levels of pS2 mRNA and
protein in the presence of the hormone (Masiakowski, P. et al. 1982, Jakowlew, S.B.
et al. 1984 and Nunez, A.M. et al. 1987). Structural analysis has shown that the
clover-like organization of the pS2 protein is compact and stable as it is resistant to
proteases and thiol agents (reviewed in May, F.E.B. et al. 1997). Little or no pS2
expression has been observed in the hormone free environment. A more recent study
also confirms the immediate and continuous inducibility of pS2 mRNA as a
significant increase in expression is reported after just lh and up to 24h (Kim, J. et
al. 2000). In more detail, in vivo DNase I footprinting studies gave insight into the
involvement of the ERE of pS2 located within the promoter. Both ERE half sites, the
consensus as well as the imperfect sites, and adjacent nucleotide sequences appeared
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to be protein protected indicating extensive protein binding and gene interaction.
Importantly, the oestrogen receptor proved to be part of this protein complex. In
contrast, only the consensus site was shown to be protected in the absence of the
hormone. Tamoxifen has been shown to be weakly agonistic influencing the
expression of pS2 mRNA but effective in reversing oestrogen induced expression
levels (Weaver, C.A. et al. 1988, Osborne, C.K. et al. 1995). This is supported by the
observation that minimal ERE protein binding takes place in MCF-7 cells treated
with tamoxifen (Kim, J. et al. 2000). On the other hand, the pure antioestrogen
ICI182,780 (not studied in this experiment) demonstrated intensive and distinct ERE
protection. Taken together, these observations suggest that the pS2 gene is not only
clearly, oestrogen regulated but distinct use of ERE half sites in the form of protein
recruitment enables differential response to oestrogen and antioestrogens, and pS2
transcription.
pS2/TFFl is expressed in ER positive but not ER negative breast cancer cell
lines (May, F.E.B. and Westley, B.R. 1986 and 1988). This was confirmed in the
experiment comparing ER positive MCF-7 variant cell lines with ER negative MDA-
MB-231 cells. Additionally, expression differences of pS2 protein have been
demonstrated between ER positive MCF-7, T47D and ZR75 cells (Prest, S.J. et al.
2002). Here, expression of the gene was particularly strong in LCC-1/2/9 and LY2
cells compared to MCF-7 cells. These results might indicate a link between strong
pS2 expression and a more advanced breast cancer phenotype as seen in the MCF-7
variant lines. Trefoil factor proteins are thought to be involved in homeostasis and
repair of damaged tissue through motogene functions (reviewed in Ribieras, S. et al.
1998). Observations were first made in the gastrointestinal tract. TFFs stimulate the
mobilization of epithelial cells surrounding damaged area to resurface the epithelium.
This concept was also applied for investigations in breast cancer cells. Evidence
suggests that TFFl/pS2 concentrations detected in the cell medium but also TFF2
stimulate MCF-7 cell movement perhaps through interaction of pS2 with to date
unknown cell surface receptor (Prest. S.J. et al. 2002 and May, F.E.B. et al. 2004).
The two molecular forms of the protein are expressed equally but the homodimer
appeared to stimulate at lower pS2 concentrations than the monomer. The presence
of two different pS2 forms and the concentration providing sensitive cell motility
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may hint at an explanation for the role of different expression levels of pS2 in breast
cancer cell lines. If pS2 encompasses motogenic functions, then cells expressing this
factor are able to spread more easily and potentially exhibit increased invasiveness
compared to normal tissue. In oestrogen sensitive breast cancer cells, exposure to the
hormone might consequently lead to enhanced cancer progression through pS2
mediated cell movement.
However, oestrogen exposure is not the mediator in oestrogen insensitive
breast cancer such as LCC-9 and LY2 cells. Transcription of pS2 could partially be
mediated by cross-talk to growth factor or protein kinase pathways as suggested for
the signalling networks of ERa or CTSD (Gruber, C.J. et al. 2002; Laurent-Matha,
V. et al. 2005). Also, recombinant pS2 stimulated cell movement was demonstrated
in MDA-MB-231 cells despite their lack of pS2 expression (Prest, S.J. et al. 2002).
Migration was stimulated at higher pS2 concentration than the pS2 expressing tissue
suggesting a lower sensitivity to pS2 in this cell line. This implies a process by which
a breast cancer cell deficient of pS2 can reach a cancerous state characterized by
enhanced metastatic properties.
The absence of detectable levels of pS2 mRNA in MDA-MB-231 could also
point to a loss of pS2 function in growth factor signalling in some malignant breast
tissue. pS2 inactivated mouse models have revealed that lack of the protein leads to
abnormal cell proliferation and differentiation in gastric tissue (Lefebvre, O. et al.
1996). The gene has therefore been suggested to acts as a tumor suppressor in this
form of cancer. Supportive of this proposition, it has been determined multiple times
that progression of normal gastric epithelial cells to a malignant phenotype can
include the loss of pS2 expression (reviewed in Ribieras, S. et al. 1998). In addition,
normal surrounding epithelium can remain pS2 positive while expression is absent in
malignant tissue. Molecular mechanisms for such observations remain elusive and
similar detailed investigations in breast cancer are rare. In the breast it is known that
pS2 is expressed in many mammary carcinomas but not in normal tissue (Rio, M.C.
et al. 1987 and Jakowlew, S.B et al. 1984).
Overexpression of cathepsin D in breast cancer has long been associated with
an increased risk of clinical metastasis and shorter survival (reviewed in Rocherfort,
H. et al. 2000). Many investigations have since focused on the molecular
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mechanisms leading to the overexpression and its role in cancer development. RT-
PCR analysis has demonstrated that MCF-7 cells and all MCF-7 variant lines express
CTSD mRNA at similar levels. Interestingly, the ER negative MDA-MB-231 cell
line not only expressed CTSD but also showed levels higher than the other cell lines.
Oestrogen had slight long-term stimulatory effects in MCF-7 cells and LCC-9 cells.
The antioestrogen tamoxifen had differing effects on CTSD transcription. In MCF-7
cells, oestrogen induced expression was reversed. In contrast, tamoxifen acted as
agonist and revealed an approximately 2-3 fold increase in mRNA expression in
LCC-2, LCC-9 and LY2 cells.
There is extensive evidence that CTSD mRNA and protein are expressed not
only in ER positive but also ER negative breast cancer cell lines (Cavailles, V. et al.
1988 and 1989. Westley, B. and Rochefort, H. 1980 and others). Furthermore,
oestrogen has been shown to induce mRNA and protein expression in ER positive
breast cancer cells at E2 concentration levels sufficient to fully occupy the receptor,
implying an ER mediated event in these cells (Westley, B.R. and May, F.E.B. 1987).
The oestrogen regulation has been shown to be due to binding of the ER dimer to an
oestrogen response element identified in the promoter of the CTSD gene (Augerau,
P. et al. 1994). Oestrogen induced CTSD mRNA transcription after longterm
exposure in MCF-7 cells in this experiment. Flowever, in the ER positive but
oestrogen unresponsive LCC-2, LCC-9 and LY2 cells, the same principle as in ER
negative cells such as the MDA-MB-231 may apply. Previous studies have shown
that CTSD is expressed in ER negative breast tumour cell lines BT 20 and MDA-
MB-231 but not regulated by oestrogen (Westley, B.R. and May, F.E.B. 1987). That
gives reason to believe that the ER is either activated in a ligand independent manner
or bypassed and cross-talk with other pathways takes place. Other factors such as
EGF and insulin have been shown to play a role in CTSD activation (Cavailles, V. et
al. 1988). Alternative pathways circumventing the ER will be in place in oestrogen
unresponsive as well as oestrogen receptor negative cells. Antioestrogen exposure
has previously shown to have no effect on CTSD expression in MCF-7 cells,
although, it did reverse oestrogen stimulated expression (Westley, B. and Rochefort,
H. 1980). As seen with other oestrogen-regulated genes, tamoxifen exerts its partial
agonistic properties when inducing CTSD expression in oestrogen responsive tissues.
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This had been reported in LY2 cells (Cavailles, V. et al. 1988). Reasons for the
induction are unknown.
Despite the consistent expression of CTSD across the breast cancer cell panel,
the relatively small effects of oestrogen and tamoxifen might at first glance make this
a less interesting gene for breast cancer research. However, recent studies present
strong arguments for its role in breast cancer tumor progression. Mitogenic
characteristics of CTSD were first established in MCF-7 cells (Vignon, F. et al.
1986). Two forms of CTSD, the catalytically active mature protein cath-D and an
inactive precursor pro-cath-D have been reported to be expressed in vitro and in vivo
and to be involved in cell proliferation and angiogenesis (Berchem, G. et al. 2002
and references within). In addition, CTSD overexpressed in epithelial cancer cells
might signal to neighbouring stromal fibroblasts stimulating cell growth, survival,
motility and invasion (Laurent-Matha, V. et al. 2005). This fibroblast activation
could be an essential step for tissue surrounding the primary tumour site to become
more invasive and proliferative. Mechanistically, the involvement of a cell surface
receptor responding to the release of CTSD seems plausible. The only known
receptors to interact with CTSD are two types of Man-6-P/IGF2 receptors
(Rochefort, H. et al. 2000). However, conflicting evidence of their mediation has
lead to suggestions of the involvement of an unidentified receptor and cross-
activation through the complex MAPK pathway (Glondu, M. et al. 2001; Berchem,
G. et al. 2002; Laurent-Matha, V. et al. 2005). Taken together, this evidence suggests
a role for CTSD in the development of breast cancer. More research is essential to
uncover its potential as a therapeutic target.
MYC plays a vital role in cell proliferation and growth by affecting many
aspects of cell cycle regulation, apoptosis, metabolism, differentiation and cell
adhesion (Dang, C.V. et al. 1999). The involvement in breast cancer has been
demonstrated extensively (Escot, C. et al. 1986; Berns, E.M. et al. 1992, 1996; and
others). In malignant tissue, over-expression of MYC is thought to be due to a loss of
down-regulation leading to constitutive gene expression (reviewed in Grandori, C. et
al. 2000 and Pelengaris, S. et al. 2002). Growth factor independence has been
reported as a result of MYC over-expression. Oestrogen has been shown to stimulate
MYC mRNA and protein expression in ER positive breast cancer cells including
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MCF-7 cells (Dubik, D. et al. 1987 and Watson, P.H. e al. 1991). Malignant and
non-malignant ER negative cells have been shown to express MYC to varying levels
but remain unaffected by oestrogen and some antioestrogens including tamoxifen. In
this experiment MYC mRNA expression in ER positive and ER negative breast
cancer cell lines was also observed. Lower baseline levels were detected in ER
positive MCF-7 and LY2 cells compared to ER positive LCC-1/2/9 and ER negative
MDA-MB-231 cells. Strong oestrogen inducibility was confirmed in MCF-7 cells
and to a lesser degree in LCC-1 cells. Interestingly, tamoxifen reduced mRNA
expression in LCC-1 cells on its own and reduced the oestrogen stimulation when
combined with the hormone. The antieostrogen had a slight delayed stimulatory
effect in MCF-7 cells. Generally, constitutively high expression of MYC mRNA was
observed in LCC-2 and LCC-9 cells unaffected by oestrogen or tamoxifen exposure.
Antisense oligonucleotide experiments have been shown to inhibit E2
stimulated cell growth in MCF-7 cells giving MYC a central role in breast cancer
cell growth (Watson, P.H. et al. 1991). Further experiments utilising RNAi directed
against MYC indicate a decreased cell growth rate and colony formation as well as
an increased sensitivity to apoptosis in vitro (Wang, Y. et al. 2005). MYC RNAi led
to tumour inhibition longterm in vivo and in vitro after short RNAi exposure despite
complete recovery of MYC protein levels. This indicated that a sustained loss of
malignant characteristics could be caused by brief c-myc inhibition. However, there
is also evidence that suggests that a continuous overexpression of MYC is necessary
for tumour maintenance (Pelengaris, S. et al. 1999 and others). Whether the effects
of MYC are reversible or not, the immediate change in malignant phenotype does
indicate alternate pathways come into place immediately for MYC to exert its
effects. One such pathway coming into effect in response to deregulated expression
of MYC might involve the activation of the ras pathway. RAS had been suggested to
inhibit MYC protein degradation resulting in accumulation of MYC activity (Sears,
R. et al. 1999). About half the tumours of another study showed KRAS2 mutations, a
member of the ras proto-oncogene family (D'Cruz, C. et al. 2001). This group was
unable to show tumour regression after reinduction of MYC expression whereas
tumours lacking the KRAS2 mutation did regress after MYC reinduction. Also, a
fraction of mutation lacking group did recur after weeks or month hinting at a
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selection process of cells through the heterogeneity of the tissue. Pathways such as
the Ras/Raf/MAP Kinase or P13K pathway have been linked to MYC function on
several occasions (for example: Mawson, A. et al. 2005). Taken together, the tumors
are able to switch to preferred secondary oncogenic pathways, MYC independent
growth mechanisms, leading to more malignant hormone and other external signal
independent phenotypes as seen in LCC-2 and LCC-9 cells. The large range of
mitogens such as IGF1, TGF-P and E2 have shown to influence MYC expression and
the increasing number of factors associating with MYC such as AP-2 or BRCA1
supports this theory (Dang, C. et al. 1999; Pelengaris, S. et al. 2002).
The malfunction of MYC is thought to be a result of failure of down-
regulation of the myc gene as opposed to altered function the MYC protein.
Relatively rare genomic alterations such as retroviral transductions, amplifications or
chromosomal translocations have been identified (reviewed in Grandori, C. et al.
2000). Such alterations are thought to cause myc over-expression by increasing
MYC mRNA levels by enhanced transcription initiation, decreased transcription
attentuation and mRNA stability. In normal tissue, MYC expression levels are low
and protein has a short half-live. Studies have suggested that MYC mutations might
lead to altered protein stability (Salghetti, S.E. et al. 1999). It is a suggested that an
ubiquitin-mediated proteolysis mechanism comes into place and MYC protein
accumulates stimulating malignant cell proliferation. Despite the identification of
such mutations, it remains questionable if they directly lead to altered cell
proliferation, differentiation or apoptosis. Another possibility is that high levels of
MYC expression are required for malignant development in cooperation with
secondary mutations in MYC target genes. MYC amplification may induce genomic
instability in such genes. This has been reported for the cyclin D2 gene (Mai, S. et al.
1999). Human and mouse B-lymphocytic tumour cells exhibiting amplified levels of
MYC demonstrated an instability of the cell cycle regulating protein suggesting that
elevated levels of cyclin D2 might be involved in tumour development. Genomic
instabilities caused by MYC over-expression have been identified for other genes,
for example the ribonucleotide reductase R2 gene (Kuschak, T.I. et al. 1999). The
cooperation with other oncogenes as a result of constitutive MYC expression might
enable the cell to fully avoid normal myc regulated cell proliferation. Again, a
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rapidly dividing more malignant phenotype is the result. The complexity of MYC
regulated cell growth makes it unlikely that targeting the MYC pathway only will
have any potential benefit for breast cancer treatment.
There is no doubt that all three genes investigated in this part of the study are
involved in malignant development of breast cancer and are therefore of potential
value as therapeutic targets for breast cancer treatment. They have demonstrated
unique expression patterns in response to oestrogen and tamoxifen. Results also
suggest that these genes are expressed and regulated in a cell line and promoter
specific manner. It also suggests that regulation does not simply take place through
direct ER-ERE interaction within the target promoter but alternative elements such as
the E-box as the interaction site within MYC or the receptors alternative activation
site AF- 1. In addition, several other transcriptional cofactors might serve as links
between the receptor and the promoter. The cooperativity between the ER signaling
pathway to other growth factors pathways takes a vital role in differential gene
regulation as discussed in subsequent chapters.
All three candidate genes show at least some reflection of the phenotype with
respect to cell growth in the different cell lines. Because the changes in mRNA
expression observed in response to oestrogen and tamoxifen were most consistent
and dramatic for pS2, the gene was chosen for more detailed studies in this project.
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2.4 Regulation of coactivators and corepressors by oestrogen and tamoxifen
2.4.1 Introduction
Oestrogen receptor activity has been associated with cofactors that can
mediate either transcriptional activation or suppression. To determine a potential role
for cofactors in ERa transcription, mRNA expression of coactivators of the pi60
family, p300 and RIP 140 as well as corepressors NCoR and SMRT were analysed in
MCF-7 cells treated with 10~9M E2 at multiple time points up to 48h. Furthermore,
the cells were subjected to 10~9M E2, 10~6M tamoxifen and the combination of E2 and
tamoxifen for two periods of exposure, 6h and 48h and mRNA expression was
investigated. Protein expression of the SRC-1/2/3, RIP 140 and REA was investigated
at 48h. Results were compared to the analysis of LCC-1, LCC-2, LCC-9, LY2 and
MDA-MB-231 cells to establish possible characteristic expression patterns and
detect whether a balance of these cofactors could reflect the cell line specific
endocrine responses. Analysis of NCoR and SMRT protein could not be carried out.
Testing of several commercially available antibodies did not identify one that
detected bands representing the proteins clearly distinguishable from other proteins
on a Western blot. NCoR with a size of about 270kDa and SMRT with a size of
about 270, 180 and 80kDa are large proteins which makes separation on ordinary
Western blots difficult.
Figure 2.20 compares cofactor expression in MCF-7, MCF-7 variant and
MDA-MB-231 cells in the absence of oestrogen and tamoxifen. Coactivators and
corepressors are expressed at comparable levels in MCF-7 cells. Differential
expression of cofactor mRNAs have been detected for variant lines. Within the pi 60
family, SRC-3 showed reduced levels of expression in all variant cell lines and in
MDA-MB-231 compared to the parental line. In MDA-MB-231 cells, SRC-1 and
SRC-2 expression was also relatively low. LCC-1, LCC-2 and LCC-9 cells showed a
paticularly high RIP 140. These results could suggest a role for cofactors such as
SRC-3 or RIP 140 in the development of hormone resistant phenotypes.
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Figure 2.20: Cofactor mRNA expression in MCF-7 and MCF-7 variant cells. Cells were seeded in
complete media for 24h and a further 48h in reduced media; all other cells were plated in reduced
media for 24h before RNA collection. Each column represents the mean of triplicate PCR analysis.
Error bars =STD: n.d.=not detectable; n.e.= not examined.
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2.4.2 Modulation of coactivators and corepressors in MCF-7 cells
(i) Effect of E2 on cofactor mRNA expression in MCF-7 cells
MCF-7 cells showed very similar levels of all analysed cofactors (Figure 2.21 A-C).
Overall, the addition of oestrogen did not markedly regulate mRNA expression
although minor changes were detected. Most notable was a common if subtle down-
regulation at 24h and subsequent recovery by 48h. Highest expression was found for
p300 mRNA. Expression was constitutive but an expression reduction (1.5 fold) was
observed at 24h compared to Oh. This reduction was found to be similar for members
of the pi60 family but strongest in SRC-1 (2.5 fold). An oestrogen stimulated
increase in any pi60 factor mRNA was not observed. One of the corepressors,
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Figure 2.21 A: mRNA expression of SRC-1 and SRC-2 in MCF-7 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M
E2. RNA was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h. A
representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.21 B: mRNA expression of SRC-3, p300. NCoR and SMRT in MCF-7 cells. Cells were
seeded in complete media for 24h and placed in reduced media conditions for 48h before treatment
with 10"qM E2. RNA was collected at Oh (72h after plating before treatment), Ih, 3h, 6h, 24h and 48h.
A representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.21 C: mRNA expression of actin as a control in MCF-7 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M E?, RNA
was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(ii) Effect of E2 and tamoxifen on cofactor mRNA and protein expression in
MCF-7 cells
As seen in the previous experiment, MCF-7 cells showed similar expression
levels for all cofactors (figure 2.22 A and B). Oestrogen showed small stimulatory
effects on SRC-1 (3.1 fold), SRC-2 (2.3 fold), SRC-3 (2.4 fold, not statistically
significant) and p300 (1.9 fold) expression at 48h when compared to the control of
each time group. Not all of these changes were apparent in the previous experiment
and some may be due to differences in basal levels for the control groups. Tamoxifen
was able to reduce expression levels significantly in SRC-1 and SRC-2 at 6h (1.8
fold and 1.7 fold, respectively). This down-regulation for SRC-1 and SRC-2 was also
observed when E2 is combined with tamoxifen (1.7 fold and 1.5 fold, respectively).
A small induction by E2 was found present at 6h in NCoR as seen before in the E2
time course.
Unique patterns of expression were seen for mRNA expression of RIP 140 and
NCoR. Treatment with E2 produced an induction of RIP140 and NCoR at 6h (4.6
fold and 1.4 fold respectively) and 48h (13.3 fold and 3.8 fold, respectively).
Tamoxifen by itself had no effect at 6h and led to a small increase by 48h (2.5 fold
and 2.4 fold). For both, RIP140 and NCoR, tamoxifen reversed the effect of E2 fully
at 6h and partially at 48h when both agents were combined.
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Figure 2.22 A: SRC-1/2/3 and p300 mRNA expression in MCF-7 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment of 10"9M E2, 10"6M
tam or 10"9M E2 and 10"bM tam. The control group was left untreated. RNA was collected at Oh (72h
after plating and before treatment), 6h and 48h. Representative experiment is shown of at least two
experiments carried out. Each column represents mean of quadruplicate PCR analysis for each sample
demonstrating mRNA expression relative to actin expression. Error bars=STD. P-value for variance
between all groups determined by one-way ANOVA and multiple comparison Tukey test. Statistical
significance noted for treatment groups compared to matched control where *=p<0.05, **=p<0.01.
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Figure 2.22 B: RIP140, NCoR and SMRT mRNA expression in MCF-7 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment of 10"9M E2,
10"6M tam or 10"9M E2 and 10"6M tam. The control group was left untreated. RNA was collected at Oh
(72h after plating and before treatment), 6h and 48h. Representative experiment is shown of at least
two experiments carried out. Each column represents mean of quadruplicate PCR analysis for each
sample demonstrating mRNA expression relative to actin expression. Error bars=STD. P-value for
variance between all groups determined by one-way ANOVA and multiple comparison Tukey test.
Statistical significance noted for treatment groups compared to matched control where *=p<0.05,
**=p<0.01.
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When protein levels were analysed, bands corresponding to SRC-2/3. RIP 140
and REA were detected in the control groups (figure 2.23). Neither oestrogen nor
tamoxifen has any effect on protein expression for any of these cofactors although it
has to be noted that RIP 140 expression did reveal differences in band numbers for
each treatment group. While the control lane showed two or possibly three bands
spaced apart, samples treated with E2 and E2 +tamoxifen produced uniform double
bands. Tamoxifen treatment by itself led to a multiple band cluster representing
protein of about 140kDa. SRC-1 protein expression was not detected in control or E2
treatment but did show faint products in both tamoxifen groups. Aside from SRC-1,
the protein expression broadly corresponds to mRNA expression detected in the
previous experiment. The amplified protein expression observed in SRC-3 (and
SRC-2) compared to SRC-1 confirms published results (Azorsa, D.O. et al. 2001
among others).






Actin for RIP 140 (42kDa)
Figure 2.23: Western blot analysis of several cofactors in MCF-7 cells were seeded in complete media
for 24h and placed in reduced media conditions for 48h before treatment with 10"9M E2, 10"SM
tamoxifen or 10"'M E2 and 10"6M tamoxifen. The control group was left untreated. Protein was
collected at 48h of treatment. lOOpg protein was loaded per lane and detected using anti- SRC-1
(Upstate), SRC-2 (BD Biosciences), SRC-3 (Affinity Bioreagents), RIP 140 (Affinity Bioreagents) and
REA (Upstate). Total actin was detected using anti - P-actin (CALBIOCHEM®) in all cell lines (one
representative cell line shown)as a western blot loading control.
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2.4.3 Modulation of coactivators and corepressors in LCC-1 cells
(i) Effect of E2 on cofactor mRNA expression in LCC-1
Cofactor mRNA expression in LCC-1 cells revealed cell line specific expression
patterns (figure 2.24 A -C). Most remarkable was an initial E2 stimulation at lh of
varying degree for the studied coactivators and corepressors. Increases were about 2-
3 fold compared to Oh (highest increase: NCoR 6.3 fold; lowest increase: SRC-3 1.4
fold, although statistically insignificant). Expression generally returned to basal
levels by 6h. Basal expression levels do not greatly differ between cofactors. The
lowest mRNA expression was observed for SRC-3, the cofactor that also showed the
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Figure 2.24 A: mRNA expression of SRC-1 and SRC-2 in LCC-1 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M E2. RNA
was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.24 B: mRNA expression of SRC-3, p300, NCoR amd SMRT in LCC-1 cells. Cells were
seeded in complete media for 24h and placed in reduced media conditions for 48h before treatment
with 10"9M E2. RNA was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h.
A representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.24 C: mRNA expression of actin as control in LCC-l cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M E2. RNA
was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(ii) Effect of E2 and tamoxifen on cofactor mRNA and protein expression
Comparison between mRNA expression treated with E2 and tamoxifen
revealed only minor differences in LCC-l cells at 6h and 48h (figure 2.25 A and B).
There was no stimulatory effect of E2 at 48h reflecting observation of the oestrogen
time course in the previous section where expression had returned to basal levels by
that time. Not observed before was a significant decrease in expression of SRC-3 by
E2 at 6h (7.7 fold) suggesting oestrogen is effectively capable of blocking SRC-3
expression. This E2 induced decrease was completely overturned by the addition of
tamoxifen and expression appeared at basal levels. The oestrogenic effect was lost at
48h. Tamoxifen by itself had no effect at either 6h or 48h.
As observed in MCF-7 cells, RIP140 mRNA expression revealed interesting
differences with respect to E2 and tamoxifen treatment. A comparably high basal
expression was observed. At 6h, tamoxifen slightly reduced expression (1.2 fold).
The addition of E2 lead to a further reduction (now 1.7 fold compared to control). In
contrast, at 48h tamoxifen dramatically increased mRNA expression (4.3 fold) and
the addition of E2 reduced this effect slightly (3.7 fold compared to control).
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Figure 2.25 A: Coactivator mRNA expression in LCC-1 cells. Cells were seeded in complete media
for 24h and placed in reduced media conditions for 48h before treatment with 10"9M E2, 10"6M tam or
10"9M E2 and 10"6M tam. The control group was left untreated. RNA was collected at 6h and 48h.
Representitive experiment is shown of at least two experiments carried out. Each column represents
mean of quadruplet PCR analysis for each sample demonstrating mRNA expression relative to actin
expression. Error bars=STD. P-value for variance between all groups determined by one-way
ANOVA and multiple comparison Tukey test. Statistical significance noted for treatment groups
compared to matched control where *=p<0.05, **=p<0.01.
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LCC-1: RIP140 expression
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Figure 2.25 B: RIP140 and corepressor mRNA expression in LCC-1 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M
E2, 10"6M tam or 10~9M E2 and 10"6M tam. The control group was left untreated. RNA was collected at
6h and 48h. Representitive experiment is shown of at least two experiments carried out. Each column
represents mean of quadruplet PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple comparison Tukey test. Statistical significance noted for treatment
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Analysis of protein expression in LCC-1 cells with the same parameters
detected a small increase in expression of SRC-1 in the presence of E2 and tamoxifen
(figure 2.26). Roughly even double bands of about 160kDa were observed. This
effect had not been seen at the mRNA level. Protein expression appeared at basal
level when E2 and tamoxifen are combined. An increase in expression was also
observed for RIP 140 in the presence of E2. Here, particularly the smaller protein of
the double band observed appeared stronger with E2. SRC-2, SRC-3 and REA were
readily detected but did not show any obvious expression differences with respect to
the different treatment groups.






Actin for SRC-3 (42kDa)
Figure 2.26: Western blot analysis of several cofactors in LCC-1 cells were seeded in reduced media
conditions for 24h before treatment with 10"9M E2, 10"6M tam or 10"9M E2 and 10"6M tam. The control
group was left untreated. Protein was collected at 48h of treatment. lOOpg protein was loaded per lane
and detected using anti- SRC-1 (Upstate), SRC-2 (BD Biosciences), SRC-3 (Affinity Bioreagents),
RIP 140 (Affinity Bioreagents) and REA (Upstate) Total actin was detected using anti - |3-actin
(CALBIOCHEM") in all cell lines (one representative cell line shown)as a western blot loading
control.
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2.4.4 Modulation of coactivators and corepressors in LCC-2 cells
(i) Effect of E? on cofactor mRNA expression
The most apparent expression characteristic in LCC-2 cells was a common down-
regulation at 3h of all cofactors with the exception of SMRT (figure 2.27 A- C).
Down-regulation was gradual and ranged from 2.4 fold in p300 to 4 fold in SRC-3.
Expression increased steadily again after 3h and reached basal levels by 48h. SMRT
mRNA expression differed from the other cofactors to such effect that E2

































Figure 2.27 A: mRNA expression of SRC-1 and SRC-2 in LCC-2 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10"''M E2. RNA
was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.27 B: mRNA expression of SRC-3, p300, NCoR and SMRT in LCC-2 cells. Cells were
seeded in complete media for 24h and placed in reduced media conditions for 48h before treatment
with 10"9M E2. RNA was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h.
A representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.27 C: mRNA expression of actin in LCC-2 cells. Cells were seeded in complete media for
24h and placed in reduced media conditions for 48h before treatment with 10"9M E2. RNA was
collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(ii) Effect of E2 and tamoxifen on cofactor mRNA and protein expression
The oestrogenic modulation observed in the previous experiment were confirmed
in this part of the analysis looking at the effects of E2 and tamoxifen (figure 2.28 A
and B). Reduced expression levels were still apparent at 6h for SRC-1, SRC-2 and
SRC-3 (1.8 fold, 3-fold, 3.1 fold, respectively). At 48h, mRNA levels were largely
unaffected by E2 or tamoxifen. The most significant changes were again identified
for RIP 140 and here particularly at 48h. E2 had a stimulatory effect on mRNA
expression (2.8 fold). Tamoxifen as well as tamoxifen plus E2 also increased RIP 140
expression but even more strongly than E2 (3.5 fold and 4.3 fold, respectively). This
observation had also been made in LCC-1 cells (figure 2.25). The expression of both
corepressors mRNA, NCoR and SMRT, was largely unaffected by the addition of
oestrogen or tamoxifen.
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Figure 2.28 A: pi60 and p300 mRNA expression in LCC-2 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M E2, 10"6M
tam or 10"qM E2 and 10"6M tam. The control group was left untreated. RNA was collected at 6h and
48h. Representative experiment is shown of at least two experiments carried out. Each column
represents mean of quadruplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple comparison Tukey test. Statistical significance noted for treatment
groups compared to matched control where *=p<0.05, **=p<0.01.
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Figure 2.28 B: RIP140 and corepressor mRNA expression in LCC-2 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M
E2, 10"6M tam or 10"9M E2 and 10"6M tam. The control group was left untreated. RNA was collected at
6h and 48h. Representative experiment is shown of at least two experiments carried out. Each column
represents mean of quadruplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple comparison Tukey test. Statistical significance noted for treatment
groups compared to matched control where *=p<0.05, **=p<0.0l.
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Protein expression was readily detected for all investigated cofactors in LCC-
2 cells (figure 2.29). E2 had opposing effects within expression of the pi60 family
proteins in this cell line. While the hormone increased expression of SRC-1 and
SRC-3, a clear decrease was observed in SRC-2 expression. Remarkable differences
were observed in band numbers in SRC-1 and RIP 140 protein expression. Both
factors were detected as strong single bands in the control group and in the presence
of tamoxifen as opposed to strong double bands in the presence of E2 and E2 plus
tamoxifen. This trend had been observed in LCC-1 cells (figure 2.26).






Actin for SRC-3 (42kDa)
Figure 2.29: Western blot analysis of several cofactors in LCC-2 cells placed in reduced media
conditions for 48h before treatment with 10"9M E2. 10"6M tam or 10"9M E2 and 10"6M tam. The control
group was left untreated. Protein was collected at 48h of treatment. lOOpg protein was loaded per lane
and detected using anti- SRC-1 (Upstate), SRC-2 (BD Biosciences), SRC-3 (Affinity Bioreagents),
RIP140 (Affinity Bioreagents) and REA (Upstate). Total actin was detected using anti - (3-actin
(CALBIOCHEM®) in all cell lines (one representative cell line shown)as a western blot loading
control.
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2.4.5 Modulation of coactivators and corepressors in LCC-9 cells
(i) Effect of Ei on cofactor mRNA expression
In LCC-9 cells, oestrogen reduced most of the investigated cofactors similar to
the observations in LCC-2 cells (figure 2.30 A- C). Between Oh and 6h, the SRC
family, p300 and NCoR mRNA were down-regulated to varying degrees. Most
strongly reduced was NCoR gene expression at 6h (3.4 fold) but also p300 (2.1 fold)
and SRC-2 (2.9 fold). The expression levels recovered to basal levels between 24h
and 48h. The exception was once again found to be SMRT mRNA which remained
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Figure 2.30 A: mRNA expression of SRC-1 and SRC-2 in LCC-9 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M E2. RNA
was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.30 B: mRNA expression of RIP140 and corepressors in LCC-9 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M
E2. RNA was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h. A
representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Significant variance between time points and Oh was
determined by one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.30 C: mRNA expression of actin in LCC-9 cells. Cells were seeded in complete media for
24h before treatment with 10"9M E2, 10"6M tarn or 10"9M E2 and 10"6M tarn. The control group was left
untreated. RNA was collected at Oh (72h after plating before treatment), lh, 3h, 6h, 24h and 48h.
Representative experiment is shown of at least two experiments carried out. Each point represents
mean of triplicate PCR analysis for each sample. Error bars =STD. Significant variance between time
points and Oh was determined by one-way ANOVA and Dunnet's multiple comparison test where
*=p<0.05, **=p<0.01.
(ii) Effect of E2 on cofactor mRNA and protein expression
In general, expression changes in response to oestrogen and tamoxifen were
subtle at both time points in LCC-9 cells (figure 2.31 A and B). As mentioned in the
previous section, oestrogen only shows small inhibitory effects on gene expression
although some trends could not be detected to the same degree again. This is
particularly apparent for NCoR where oestrogen does not show a significant
reduction as seen in the time course. These differences may be due to cells collected
during different functional states in their cell cycle. Small changes in expression
were detected in the presence of tamoxifen namely for p300 and NCoR. p300 mRNA
and NCoR mRNA were decreased by tamoxifen at the earlier time point (1.8 fold
and 2.3 fold, respectively) and by tamoxifen plus E2 (1.3 fold and 2.1 fold,
respectively).
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Figure 2.31 A: pi60 and p300 mRNA expression in LCC-9 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10"QM E2, 10"6M
tam or 10"9M E2 and 10"6M tam. The control group was left untreated. RNA was collected at 6h and
48h. Representative experiment is shown of at least two experiments carried out. Each column
represents mean of quadruplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple comparison Tukey test. Statistical significance noted for treatment
groups compared to matched control where *=p<0.05, **=p<0.01.
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Figure 2.31 B: RIP140 and corepressor mRNA expression in LCC-9 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M
E2, 10"6M tam or 10"9M E2 and 10"6M tam. The control group was left untreated. RNA was collected at
6h and 48h. Representative experiment is shown of at least two experiments carried out. Each column
represents mean of quadruplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple comparison Tukey test. Statistical significance noted for treatment
groups compared to matched control where *=p<0.05, **=p<0.01.
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The protein expression for coactivators and corepressors was consistent with
mRNA findings with respect to oestrogen and tamoxifen regulation (figure 2.32).
Neither agent showed any marked influence on expression. Within the pi60 family,
SRC-2 protein was particularly strongly present while SRC-1 and SRC-3 were
almost undetectable. This observation does not correspond to mRNA findings. Also
strongly expressed were REA and RIP 140. The latter exhibited multiple bands
representing the about 140kDA protein with one distinctly darker band revealed for
all treatment groups.






Actin for RIP 140 (42kDa)
Figure 2.32: Western blot analysis of several cofactors in LCC-9 cells placed in reduced media
conditions for 48h before treatment with 10"9M E2, 10"6M tarn or 10"9M E2 and 10"5M tarn. The control
group was left untreated. Protein was collected at 48h of treatment. lOOpg protein was loaded per lane
and detected using anti- SRC-1 (Upstate), SRC-2 (BD Biosciences) and SRC-3 (Affinity
Bioreagents), RIP140 (Affinity Bioreagents) and REA (Upstate). Total actin was detected using anti -
P-actin (CALBIOCHEM®) in all cell lines (one representative cell line shown)as a western blot
loading control.
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2.4.6 Modulation of coactivators and corepressors in LY2 cells
(i) Effect of E2 on cofactor mRNA expression in LY2 cells
Analogous to the effect seen in LCC-9 cells, oestrogen only slightly down-
regulated the expression of cofactor mRNA by 6h in LY2 cells. Changes varied
between 1.8 fold for NCoR and 1.5 fold for p300. Expression generally tended to
recover by 48h. SRC-3 exhibited a particularly low expression. The expression
profile for SMRT was again slightly different than the other cofactors. SMRT
demonstrated a small down-regulation at 48h (1.6 fold). A limited time course of 6h
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Figure 2.33 A: mRNA expression of p 160 cofactors and p300 in LY2 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M
E2. RNA was collected at Oh (72h after plating before treatment), 6h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.33 B: mRNA expression of corepressors and actin in LY2 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment with 10"QM
E2. RNA was collected at Oh (72h after plating before treatment), 6h and 48h. A representative
experiment is shown of at least two experiments carried out. Each point represents mean of triplicate
PCR analysis for each sample. Significant variance between time points and Oh was determined by
one-way ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
(ii) Effect of E2 and tamoxifen on cofactor mRNA and protein expression in
LY2 cells
mRNA expression for the pi60 family members revealed several changes in
response to tamoxifen (figure 2.34 A and B). Noteworthy are significant changes in
RIP 140, NCoR and SMRT. At 6h. E2 slightly increased expression for RIP 140 (1.3
fold). Tamoxifen reduced the expression (2.1 fold) and not only actively reversed the
effect of E2 but reduced expression below basal levels (1.6 fold). Interestingly, at
48h, E2 showed a stronger stimulatory effect (2.0 fold) and tamoxifen no longer
inhibited but also stimulated gene expression (1.7 fold). The combination of E2 and
tamoxifen led to a 1.99 fold expression increase compared to the matched control. In
the structurally similar NCoR and SMRT, E2 had a small inhibitory effect on mRNA
expression at 6h (1.9 fold and 1.3 fold). The same could be observed for tamoxifen
(2.4 fold and 1.8 fold, respectively) and E2 plus tamoxifen (2.6 fold and 1.6 fold). At
48h, all three treatment versions revealed an up-regulatory trend for both NCoR (not
152
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Figure 2.34 A: pi60 mRNA expression in LY2 cells. Cells were seeded in complete media for 24h
and placed in reduced media conditions for 48h before treatment with 10"9M E2, 10"6M tam or 10"9M
E2 and 10"6M tam. The control group was left untreated. RNA was collected at 6h and 48h.
Representative experiment is shown of at least two experiments carried out. Each column represents
mean of quadruplicate PCR analysis for each sample demonstrating mRNA expression relative to
actin expression. Error bars=STD. P-value for variance between all groups determined by one-way
ANOVA and multiple comparison Tukey test. Statistical significance noted for treatment groups
compared to matched control where *=p<0.05, **=p<0.01
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Figure 2.34 B: p300, RIPI40. NCoR and SMRT mRNA expression in LY2 cells. Cells were seeded in
complete media for 24h and placed in reduced media conditions for 48h before treatment with I(OM
E2, 10"6M tam or 10~9M E; and 10~6M tam. The control group was left untreated. RNA was collected at
6h and 48h. Representative experiment is shown of at least two experiments carried out. Each column
represents mean of quadruplicate PCR analysis for each sample demonstrating mRNA expression
relative to actin expression. Error bars=STD. P-value for variance between all groups determined by
one-way ANOVA and multiple comparison Tukey test. Statistical significance noted for treatment
groups compared to matched control where *=p<0.05, **=p<0.01.
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In contrast to the parental MCF-7 cell line and the sublines mentioned so far,
protein expression for cofactors was not easily detected in LY2 cells with the
exception of SRC-2 (figure 2.35). SRC-2 protein was revealed to be present in all
treatment groups and was represented by a sharp band of about 160 kDa. A small
down-regulation may be observed with tamoxifen treatment. This was also observed
for SRC-1. All other cofactors were detected in the form of faint bands although both
RIP 140 and SRC-2 revealed characteristic multiple bands as observed previously.






Actin for SRC-1 (42kDa)
Figure 2.35: Western blot analysis of several cofactors in LY2 cells placed in reduced media
conditions for 48h before treatment with 10"9M E2, 10"6M tam or 10"9M E2 and 10"6M tam. The control
group was left untreated. Protein was collected at 48h of treatment. lOOpg protein was loaded per lane
and detected using anti- SRC-1 (Upstate), SRC-2 (BD Biosciences), SRC-3 (Affinity Bioreagents),
RIP140 (Affinity Bioreagents), REA (Upstate). Total actin was detected using anti - P-actin
(CALBIOCHEM-) in all cell lines (one representative cell line shown)as a western blot loading
control.
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2.4.7 Modulation of coactivators and corepressors in MDA-MB-231 cells
(i) Effect of E2 on cofactor mRNA expression in MDA-MB-231 cells
MDA-MB-231 cells were used as a comparison of an ERa negative cell line to
the receptor expressing MCF-7, LCC-1/2/9 and LY2 cells. All studied cofactors were
present as detected by mRNA. Most remarkable was the particularly low constitutive
expression of SRC-3 (figure 2.36 A And B). This observation is well described
(Anzick, S.L. et al. 1997 and Thenot, S. et al. 1999). Nothing atypical could be
identified for the expression of other cofactors. Unusually, as observed in LCC-9 and
LY2 cells, the presence of oestrogen produced a small down-regulation between Oh
and 6h for some cofactors despite the fact that MDA-MB-231 cells do not express
ERa though they do express ERp. Significant reductions were observed in NCoR
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Figure 2.35 A: mRNA expression of pi60 in MDA-MB-231 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10""M E2. RNA
was collected at Oh (72h after plating before treatment) 6h and 48h. A representative experiment is
shown of at least two experiments carried out. Each point represents mean of triplicate PCR analysis
for each sample. Significant variance between time points and Oh was determined by one-way
ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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Figure 2.35 B: mRNA expression of cofactors in MDA-MB-231 cells. Cells were seeded in complete
media for 24h and placed in reduced media conditions for 48h before treatment with 10"9M E2. RNA
was collected at Oh (72h after plating before treatment) 6h and 48h. A representative experiment is
shown of at least two experiments carried out. Each point represents mean of triplicate PCR analysis
for each sample. Significant variance between time points and Oh was determined by one-way
ANOVA and Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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(ii) Effect of E2 and tamoxifen on cofactor protein expression
The low mRNA expression of SRC-3 in MDA-MB-231 cells was reflected in
low protein levels. SRC-3 protein was almost undetectable (figure 2.37). In contrast,
SRC-2 bands representing the 160 kDa product were detected in a uniform fashion
across all treatment groups. The same could be revealed about SRC-1. Unlike
observations in LCC-2 cells where the protein product revealed variations within the
double bands, a consistently strong upper band and an equally consistent faint lower
band was observed. This uniform band expression for multiple band products was
also detected in RIP 140. Overall, in MDA-MB-231 cells, cofactors protein levels
were not modulated at 48h by the addition of E2 or tamoxifen.






Actin for SRC-1 (42kDa)
Figure 2.37: Western blot analysis of several cofactors in MDA-MB-231 cells placed in reduced
media conditions for 48h before treatment of 10"qM E2, 10"6M tam or 10"QM E2 and 10"6M tam. The
control group was left untreated. Protein was collected at 48h of treatment. lOOpg protein was loaded
per lane and detected using anti- SRC-1 (Upstate), SRC-2 (BD Biosciences), SRC-3 (Affinity
Bioreagents). R1P140 (Affinity Bioreagents) and REA (Upstate). Total actin was detected using anti -
P-actin (CALBIOCHEM"') in all cell lines (one representative cell line shown) as a western blot
loading control.
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MCF-7 LCC-1 LCC-9
SRC-1 XXX xxx xxx
SRC-2 XX XX XX
SRC-3 xxx xxx XX
p300 XX xxx XX
RIP140 XX xxxx xxxx
NCoR xxx xxxx xxx
SMRT xxx xxx XX
Table 2.5 A: Summary of coregulator baseline mRNA expression levels in MCF-7, LCC-1 and LCC-9
cells. Actin ratio is shown where x: <0.1; xx: 0.1-1; xxx: 1-2; xxxx: >2.
MCF-7 LCC-1 LCC-9
e2 T ET e2 T ET e2 T ET
SRC-1 —> — —
SRC-2 if- a- a- -*• -*
SRC-3 -+ -> -> -► ->• ->
p300 -> -»/t — — -*
RIP140 t -> -»/ t -/t ->/t — —■ —•
NCoR t -/1 -/ r —*• 4/- l/ —
SMRT —> —>• —*■ —1* —> —>
Table 2.5 B: Changes of cofactor mRNA expression in response to E2, tamoxifen (T) or E2 plus
tamoxifen (ET); control (C): no change (—>), significant decrease (J.), significant increase (f). Two
symbols separated by are only depicted where 6h results vary from 48h results.
2.4.6 Discussion
The function of ERa is modulated by interaction with a growing number of
coregulatory proteins. Coactivators enhance gene transcription, corepressors inhibit
gene transcription. Two regions, AF-1 and AF-2 within the A/B and E domain of the
ERa, respectively, have been identified as docking sites for coregulators (Klinge,
C.M. 2000). Numerous studies have produced evidence that coregulators interact
directly with the ERa and are part of a large multi-component complex (Rosenfeld,
M.G. and Glass, C.K. 2001, Glass, C.K and Rosenfeld, M.G. 2000). This allows
coregulators to modulate chromatin organisation and recruit basal transcription
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factors initiating or repressing transcription and has led to speculation as to whether
changes in cofactors expression and functionality could be involved in the
development of breast cancer and/or the development of antioestrogen resistance.
The pi 60 family of coactivators is a group of three homologous coactivators
which serve as an ideal case to study potential distinct functionality and involvement
in malignant development. Involvement in breast cancer has primarily been
demonstrated for SRC-3. SRC-3 gene expression has been reported in normal and
malignant breast tissue and amplification in breast cancer relative to normal tissue
has been detected of varying magnitude (reviewed in Klinge, C.M. 2000). Amplified
SRC-3 expression has been correlated with tumour size and grade (Bouras. T. et al.
2001) as well as ER positivity in vitro and in vivo (Bautista, S. et al. 1998; Azorsa,
D.O. et al. 2001), although other researchers suggest an inverse correlation between
SRC-3 and ER amplification (Bouras, T. et al. 2001). In MCF-7 cells, SRC-3 mRNA
and protein are highly expressed (List, H.J. et al. 2001 and Thenot, S. et al. 1999).
Expression has been shown to be unaffected by E2 or tamoxifen in these cells
(Cremoux, P. et al. 2003). The same study analysed expression in LCC-1, LCC-2
and LCC-9 cells and found comparable levels of SRC-3 mRNA. Low levels of SRC-
3 mRNA have been reported for ER-negative MDA-MB-231 cells and protein
expression of pi60 proteins was determined to be weaker in MDA-MB-231 than in
MCF-7 cells (Thenot, S. et al. 1999).
mRNA transcription of all SRC family members in MCF-7 cells was
confirmed in this study. It was established that the resistant cell lines LCC-1. LCC-2
and LCC-9 and LY2 express comparable levels of SRC-1 and SRC-2 (see
comparison table 2.5 A). SRC-3 was considerably lower in the resistant lines as well
as in MDA-MB-231 cells without E2 and tamoxifen. Interestingly, E2 caused a short-
lasting down-regulation of mRNA expression after 3h and up to 6h in LCC-2, LCC-9
and to some extent in LY-2 cells in most cases of the three SRC mRNA. This
contrasts with expression in MCF-7 cells where E2 had no effect and LCC-1 cells
where E2 exposure led to a small increase after lh with a return to baseline after 6h.
Baseline protein expression differences for all three SRC members were detected
between parental and resistant cell lines. While SRC-1 protein was absent or was
detected only weakly in MCF-7, LCC-9 and LY2 cells, it appeared more strongly in
160
Regulation of coactivators and corepressors
LCC-2 and in LCC-1 cells. SRC-2 expression was particularly high in LCC-2, LCC-
9 and LY-2 cells while SRC-3 was expressed consistently in all cell lines except
MDA-MB-231 where expression was low. In general, neither E2 nor tamoxifen seem
to impact on SRC protein expression with notable exceptions. For example, SRC-1
was strongly induced by both ligands in LCC-1 cells. Ei acted as a weak antagonist
for both SRC-2 and SRC-3 mRNA expression and SRC-2 protein expression in
LCC-2 cells.
While there is no doubt that pi60 proteins are involved in ER transcription, it
remains unclear whether transcription is dependent upon the presence and
functionality of individual members or whether members are able to compensate for
one another (Xu, J. and Li, Q. 2003 (b)). Distinct functionality has primarily been
shown within in vitro experiments. For example, in T47D reporter transfection
studies, progesterone and glucocorticoid receptors showed selective recruitment of
SRC-1 and SRC-2, respectively, leading to differential recruitment of downstream
coregulatory factors and differential histone modification (Li, X. et al. 2003). A
detailed study analysing direct target genes of SRC-3 identified 18 strong and 11
weak distinct genomic binding sites all involving the binding of ERa (Labhart, P. et
al. 2005). SRC-3 responsive sites were located upstream, within or even downstream
of the target genes. ERa-SRC-3 binding was promoted by oestrogen on several but
not all sites. This is evidence for a target gene, receptor and ligand specific role of
coactivator SRC-3. In vivo, SRC-3 has shown tissue specific expression and
suppression of the cofactor has resulted in disrupted aspects of female reproductive
development including delayed puberty and attenuated mammary development in
mice (Xu, J. et al. 2000). Loss of SRC-3 expression has been associated with reduced
tumour incidence and delayed latency in oncogene v-Ha-ras expressing transgenic
mice independent of ovarian hormones (Kuang, S.-Q. et al. 2004). On the other hand,
SRC knockout mice experiments have demonstrated that SRC members do exhibit
specific functions but are nevertheless able to compensate for each other. Structural
homology between SRC family members would support partial compensatory
behaviour. SRC-1 deficient mice are viable and fertile although they exhibit
decreased growth in several reproductive organs (Xu, J. et al. 1998). Interestingly,
SRC-1 null mutants express elevated levels of SRC-2 in several regions of the brain
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and other tissues compared to normal animals. Another study supports this finding.
In the rat brain, oestrogen dependent progesterone receptor synthesis is inhibited by
antisense to SRC-1 and SCR-2 resulting in blocked reproductive behaviour
(Apostolakis, E.M. et al. 2002). Normal reproductive behaviour was displayed by
SRC-1 knock-out mice suggesting that up-regulated SRC-2 might compensate for the
SRC-1 deficiency. Cofactor expression profiles and oestrogen and antioestrogen
modulation has been established to be specific for each of the resistant and sensitive
phenotypes. This could demonstrate distinct roles for SRC coactivators in these
tissues. At the same time, altered oestrogen signalling might eliminate the expression
and/or function of one SRC coactivator while another SRC member with its
particular functions may take its place. Over expression of this cofactor would be
apparent. Antisense experiments selectively inhibiting individual members would
help to confirm the latter hypothesis.
Altered SRC mRNA expression does not always correlate with changes in
protein expression at 48h. This observation can in general also be found in the
literature. High SRC-3 mRNA expression does not necessarily translate into elevated
protein levels in breast cancer tissue (List, H.J. et al. 2001). This indicates that ER
signalling changes that manifest in resistant phenotypes may not influence mRNA
expression but could determine SRC cofactor levels in a post-translational manner.
Differential SRC involvement in ER regulated transcription might take place through
altered protein production, turnover and breakdown. Protein expression studies are
also not sufficient to detect changes in protein activity. It is known that oestrogen
receptor activation can be accomplished by complex signalling between growth
factor pathways. For example, activation of one of the ErbB receptors by EGF can in
turn activate ERa via SER118 phosphorylation by MAPK (through ERK1/2) is just
one example that has been described (Kato, S. et al. 1995, reviewed by Driggers,
P.H. and Segars, J.H. 2002). However, it is not just the ERa itself that is prone to
direct cross-activation by other signalling pathways such as the ERK1/2 mitogen-
activated protein kinase pathway (MAPK). It has been demonstrated that the AD2
region within SRC-3 is responsive and can be directly activated by MAPK/ERK
phosphorylation in MCF-7 cells (Font de Mora J. and Brown, M. 2000). This
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Figure 2.38: Alternate activation of SRC-3/A1B1 by MAPK phosphorylation to modulate gene
transcription (Font de Mora, J. and Brown, M. 2000).
implicates a much more complex cross talk where cofactors such as SRC-3 can be
activated not directly by E2 but by other growth factor stimulated pathways which in
turn then modulate gene transcription via feedback to the ERa (see figure 2.38). To
produce further evidence for this mechanism, it was shown that MAPK/ERK
phosphorylated SRC-3 demonstrates increased recruitment of p300/CBP, another
coactivator able to modulate H3/H4 acetyltransferase activity. This study also failed
to detect significant levels of SRC-3 phosphorylation in SRC-3 expressing BT-474
cells, strengthening the argument that cofactor expression levels alone do not
necessarily correspond to heightened cofactor activity and relative levels are not an
indicator of active involvement in gene transcription.
If SRC-3 is activated by the MAPK pathway in a manner similar to ER
activation to stimulate gene transcription, it could also be actively involved in
antioestrogen resistance. This possibility seems even more plausible since SRC-3
amplification in breast cancer has been linked to overexpression of HER2/neu (or
ErbB2), a member of epidermal growth factor (EGF) receptor family able to activate
the MAPK/ERK signalling cascade (Bouras, T. et al. 2001). An earlier study
suggested that HER2/neu overexpression correlates with a low level of tamoxifen
resistance in MCF-7 sublines (Benz, C.C. et al. 1993). This HER2/neu
overexpressing cells subline, MCF-7/HER2-18, demonstrates rapid tumour growth
insensitive to tamoxifen in overiectomized athymic nude mice in the presence of
oestrogen. In contrast, in a separate study by different investigators, MCF-7 variant
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cells resistant to antioestrogens tamoxifen, ICI 164,384 and ICI 182,780, failed to
express altered levels of ErbB-family receptors including HER2/neu, and oestrogen
as well as antioestrogens regulated HER2/neu in a similar pattern than the parental
cells (Larsen, S.S. et al. 1999). Further, inhibition of Her-2/neu receptor signalling
with Herceptin, an antibody to this receptor, did not modulate cell growth indicating
that activation of the HER2/neu signalling pathway alone does not lead to
antieostrogen resistance. Interestingly, in transfected HER2/neu overexpressing
MCF-7 cells, activation of the HER2/neu pathway by addition of the ligand heregulin
1-betal diminished growth inhibitory effects of ICI 182,780 demonstrating that both,
overexpression of HER2/neu and ligand actived receptor signalling are necessary to
alter antioestrogenic effects of ICI 182,780. In tamoxifen resistant -also HER2/neu
overexpressing MCF-7 cells, it has been shown that after inhibition of FIER2/neu and
MAPK signalling, tamoxifen can regain antagonistic characteristics and override
resistance (Kurokawa, H. et al. 2000).
A recent clinical study assessing SRC-3 protein expression with relation to
tumour characteristics and patient outcome concluded that only tumours with high
expression of SRC-3 in combination with high expression of HER2/neu show a
relative resistance to tamoxifen (Osborne, C.K. et al. 2003). High HER2/neu
expression alone did not result in reduced tamoxifen treatment benefits compared
with low Her2/neu expressing tumours. This would indicate, that only where
HER2/'neu activated MAPK signalling also activates SRC-3 via phosphorylation
instigating feedback to the ER pathway might the effectiveness of tamoxifen as an
antioestrogen be modified. Furthermore, in experiments comparing parental E2 and
tamoxifen sensitive MCF-7 cells with E2 sensitive and tamoxifen resistant MCF-
7/HER2-18 neu cells, increased crosstalk between the oestrogen and HER2/neu
receptor has been proposed as a mechanism for acquired tamoxifen resistance (Shou,
J. et al. 2004). Oestrogen and tamoxifen act as agonists in the HER2/neu
overexpressing cells stimulating tumour growth in xenograft models. Enhancing
signalling between EGFR/HER2 and E2 receptor pathways is accomplished by cross-
phosphorylation of both receptors but also MAPK/ERK mediators ERK1/2 and Akt
as well as SRC-3. Tamoxifen and E2 bound ER recruit SRC-3 in resistant MCF-
7/HER2-18 cells whereas in parental MCF-7 cells, tamoxifen recruits corepressors
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NCoR and HDAC giving SRC-3 a pivotal role in the development of tamoxifen
resistance.
Our understanding of the intricate oestrogen and tyrosine kinase receptor
signalling network is growing as research progresses. Communication takes place via
an increasing number of other pathways including ligands EGF or heregulin, signal
transducers Ras and Raf and the ERK1 and ERK2 activated MAPK pathway in the
case of the ErbB network (Driggers, P.H. and Segars, J.H. 2002). Traditional
activation of the ER by its ligand E2 has long been shown to be only one way of
transcriptional regulation. As functional consequences of this crosstalk are being
discovered, new strategies will become available to combat this acquired hormone
and antihormone resistance. In addition, it becomes apparent that monotherapy
targeting single growth factor pathways is unlikely to be optimal treatment (Shou, J.
et al. 2004).
The discovery of corepressors, transcriptional coregulators repressing
oestrogen receptor mediated transcription, led to the obvious suggestion that the
functional absence of these coregulators might allow amplified transcriptional
enhancement by coactivators thereby promoting breast cancer cell growth.
Corepressors such as NCoR and SMRT are generally thought to impose their
regulatory function by association with the ER and recruiting other coregulators and
transcription factors to form a repressive transcription complex but have also been
shown to act through other mechanisms such as actively blocking ER helix 12, a
coactivator binding site, to prevent transcriptional activation (reviewed in
Dobrzycka, K.M. et al. 2003). Tamoxifen mediated ER transcription has therefore
been suggested to involve the predominant recruitment of corepressors and the
expression of such coregulators might be predictive of tamoxifen response in breast
cancer. Corepressor association with the ER has been firmly established in the
presence of an antagonist. NCoR and SMRT have been shown to interact with
helices H3/H4 within the LBD of ERa in the presence of trans-hydrotamoxifen
(TOT), a tamoxifen metabolite (Yamamoto, Y. et al. 2001). Reduced corepressor
interaction was observed in a helix H3 ERa mutant where TOT acts as an agonist.
NCoR is reported to immunoprecipitate strongly only in the presence of TOT in
parental MCF-7 cells (Lavinsky, R.M. et al. 1998). ERa has also been shown to
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actively recruit NCoR and SMRT into large transcription complexes at E2 responsive
genes cathepsin D and pS2 where tamoxifen is present as an antagonist (Shang, Y. et
al. 2000). However, unaltered ER transcriptional activity was demonstrated in MCF-
7D cells, an ER positive but NCoR negative MCF-7 clone (Morrison, A.J. et al.
2003). Based on the before -mentioned findings, treatment with tamoxifen might be
expected to increase E2 responsive gene transcription and cell proliferation in the
absence of NCoR. This might imply a shift in coregulators complex assembly and
the use of alternative corepressors such as the structurally similar SMRT in such
mutant cells to control cell growth.
Most proposed corepressor mediated ER transcription mechanisms are based
on in vitro studies. In vivo investigations are infrequent and provide more conflicting
findings. In a mouse model, consistent exposure to tamoxifen not only leads to
tamoxifen resistance but significantly reduced NCoR expression suggesting that
reduced NCoR expression or blocked NCoR binding enables the antioestrogen to
increase cell proliferation (Lavinsky, R.M. et al. 1998). Low NCoR mRNA
expression also correlated with significantly shorter relapse -free survival in ER
positive breast cancer patients suggesting a possible predictive role for NCoR with
respect to endocrine treatment benefit (Girault, I. et al. 2003). Other in vivo studies
have so far failed to demonstrate specific tamoxifen resistant corepressor expression
patterns for SMRT. A small investigation of 19 tamoxifen resistant breast tumour
samples failed to detect mRNA expression differences of corepressor levels
including SMRT compared to 21 control tumours (Chan, C.M.W. et al. 1999). Short
term tamoxifen treated tumours did not reveal different SMRT mRNA levels. The
same publication had first mentioned no differences in SMRT mRNA expression in
vitro for MCF-7 cells and an MCF-7 tamoxifen resistant variant line. If relative
expression levels of corepressors are responsible for tamoxifen resistance, lower
levels of SMRT might have been present in the resistant tissue samples.
In agreement with Chan, C.M.W. and colleagues (1999), SMRT as well as
NCoR mRNA was detected in similar levels in parental MCF-7 and all MCF-7
variant cells irrespective of their oestrogen or antioestrogen sensitivities (see
comparison table 2.5 A). Both coregulators were also observed in ER negative
MDA-MB-231 cells. Protein expression using Western blotting for both corepressors
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was attempted but unsuccessful. Protein expression in these cell lines was too low for
accurate analysis. As described for pi60 coactivators, a small short-term oestrogen
mediated increase in LCC-1 cells and decrease in NCoR mRNA level was noticed in
LCC-2, LCC-9 and LY2 cells. Interestingly, tamoxifen had generally no or small
effects on either SMRT or NCoR expression in these cell lines (see comparison table
2.5 B). These results oppose the theory that acquired tamoxifen resistance is due a
lack of corepressor expression. If these corepressors played a role in tamoxifen
resistant growth, lower levels of NCoR and/or SMRT would have been expected in
resistant models and tamoxifen treatment in antieostrogen sensitive MCF-7 cells
might also have resulted in lower corepressor expression. However, this does not rule
out corepressors as part of tamoxifen acquisition. Firstly, NCoR and SMRT are two
of a constantly increasing number of identified corepressors. If the function of
coregulators determines the cells response to an antioestrogen, it might not be SMRT
or NCoR that are important in these cell lines. And secondly, both corepressors were
discovered only ten years ago (Chen, J.D. and Evans, R.M. 1995; Horlein, A.J. et al.
1995). Since then ongoing research has provided a large amount of information about
their role in ER mediated gene transcription but knowledge is still limited. Functional
studies analysing corepressor activation might help to elucidate the role of NCoR and
SMRT in antioestrogen mediated signalling in MCF-7 cells and the LCC models. For
example, similar to findings within the SRC coactivator family, binding was shown
to be involved in cross-signalling between ER and ErbB receptors in tamoxifen
resistant HER2/neu overexpressing MCF-7 cells (Kurokawa, H. et al. 2000). In this
study, levels of NCoR were unchanged in the MCF-7 variants but increased NCoR
binding was observed when both, HER2/neu and MAPK signalling were inhibited
suggesting perhaps not corepressor availability but altered binding capacity
determines corepressor participation in tamoxifen resistance.
The coregulator RIP 140 illustrates the additional dimension each and every
one of the coregulators can add to nuclear receptor function. RIP 140 had been
identified as a coactivator based on its ability to interact with the LBD of nuclear
receptors and specifically with the ER in an oestrogen dependent manner (Cavailles,
V. et al. 1995). Inconsistent evidence was published in several in vitro models
questioning whether interaction with the ER did or did not occur in the presence of
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antieostrogens such as 4-OHT or ICI182,780 and ICI164,384 (reviewed in Klinge,
C.M. 2000). It soon became evident that RIP 140 can also modulate transcriptional
repression. The direction of transcriptional modulation might be based on several
findings. Reporter gene activation by RIP 140 was observed in the presence of low
concentrations of E2 but gene repression in the presence of high concentrations of E2
(Cavailles, V. et al. 1995). In addition to the N-terminal coactivator common
LXXLL motif, a further ER interacting site within the C-terminal of RIP 140 was
identified (L'Horset, F. et al. 1996). Different ERa binding sites were shown to
associate with the coregulator and receptor specific binding affinities were
demonstrated (Peters, G.A. and Khan, S.A.I999; Kumar, M.B. et al. 1999). Most
significantly, a study indicated that the function of RIP 140 is sensitive to histone
deacetylase inhibitors (Wei, L.N. et al. 2000). It is reported that RIP 140 is able to
directly recruit HDAC1 and HDAC3 to its N-terminal interacting site leaving no
doubt that this protein can modulate in a bidirectional manner either repressing or
activating gene transcription. Coregulators such as RIP 140 are often called negative
coregulators or corepressors because they directly antagonize coactivators and
compete for association with AF-2, the traditional coactivator binding site (Nilsson.
S. et al. 2001).
Based on these diverse functions of RIP 140, it is perhaps not surprising that
evidence for this protein as a marker of tamoxifen resistance is rare and conflicting.
It appears that the function of this coregulator is particularly tissue and promoter
specific and dependent on the availability of ligands or other coregulatory proteins.
Several studies state subtle or no variations of RIP 140 mRNA and protein expression
between cells of different diseases as well as in-between different breast cancer
tissues. The coregulator has been reported to be expressed in EleLa, ZR75-1 and
MCF-7 breast cancer cells (Cavailles, V. et al. 1994). A comparison between breast
cancer and endometrial cancer cells revealed uniform expression of RIP140 mRNA
and protein across the panel of seven cell lines including the ERa negative MDA-
MB-231 cells (Thenot, S. et al. 1999). In this study, expression of RIP 140 is
stimulated 2-3 fold by oestrogen and reduced by 4-OHT and ICI 164,384 in MCF-7
cells. This modulation is reported to be rapid and persisting over a period of 24h and
is suggested to be independent of de novo protein synthesis. However, a separate
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study comparing parental MCF-7 cells and a tamoxifen resistant variant does not
observe this oestrogen stimulation in the parent line (Chan, C.M.W. et al. 1999).
Basal levels of RIP140 mRNA are lower in the resistant MCF-7 cells and oestrogen
stimulation is of small magnitude. This result was confirmed for RIP 140 mRNA
levels in a panel of untreated and short term tamoxifen treated as well as tamoxifen
resistant breast tumours.
In this study, RIP 140 mRNA expression was generally slightly higher in
tamoxifen resistant LCC-1, LCC-2 and LCC-9 cells compared to the MCF-7 parent
line (see comparison table 2.5 A). This contrasts with previously mentioned
publications where either no differences were reported or lower expression was
associated with tamoxifen resistance. It needs to be considered that in this
experiment RIP 140 mRNA expression was compared between MCF-7 and several
tamoxifen resistant lines. MCF-7 cells only represent one tamoxifen sensitive breast
cancer phenotype and conclusions with respect to coregulators as a marker of
antioestrogen resistance without analysis of other antioestrogen models would be
premature. Oestrogen clearly stimulated the expression of RIP140 in MCF-7 cells
short term at 6h as well as long term at 48h but remained unaffected by the
antioestrogen tamoxifen. The fact that some laboratories do not find any or only
small oestrogen stimulation might partially be due to the initially small induction.
The magnitude of the response did not become apparent until 48h of treatment was
applied. Some oestrogen stimulation was observed in all MCF-7 variant lines
including LY2 cells but not LCC-9 cells (see comparison table 2.5 B). Unlike MCF-7
cells, this stimulation was found to be a late effect and was not observed until 48h. A
delayed increase in RIP140 mRNA was also observed when tamoxifen was added.
RIP 140 protein was detectable in similar levels in all cell lines. This might imply that
changes in expression at the translational level are generally not responsible for the
acquisition of tamoxifen resistance. Neither oestrogen nor tamoxifen had an effect on
expression with the exception of LCC-2 cells where oestrogen as well as oestrogen in
combination with tamoxifen increased protein expression. Results corresponded to
observations at the mRNA level. Detection of varying multiple bands for RIP 140
could suggest an additional element of RIP 140 where the expression of different
isoforms and splice variants might determine the functionality of the protein in a
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particular tissue type and its response to endocrine agents. It could also be the results
of posttranslational modifications such as phosphorylation.
These results suggest that expression of individual coactivators or
corepressors determine the phenotype of breast cancer tissue with respect to
endocrine response. In most cases variations in basal expression are subtle and
response to oestrogen or tamoxifen cannot always be linked to the tissues
proliferative behaviour. There is no doubt that each one of the coregulators plays a
significant role in normal and malignant development. Rather then the absence or
misfunction of corepressors in the case of malignant development, it has been
suggested that a balance of coactivators and corepressors might define the response
to oestrogen and antioestrogens. In this case, analysis of individual cofactors might
provide limited information. The specificity of transcriptional regulation for each
cofactor is dependent the promoter-receptor complex in its cellular environment. The
availability of large numbers of coregulatory proteins and the complex receptor
cross-talk makes the mechanism of oestrogen dependent gene transcription extremely
versatile.
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2.5 Identification and recruitment of oestrogen regulated transcription
complexes at the pS2 promoter
2.5.1 Introduction
Chromatin immunoprecipitation (ChIP) was used to investigate the activation
process at the pS2 promoter. The pS2 gene had previously been identified to reflect
the oestrogen-regulated growth pattern observed in the MCF-7 wild-type and variant
breast cancer cell lines. This experiment examined gene activation as indicated by
H4 acetylation and sought to identify ERa binding as well as cofactor SRC-1 and
SRC-3 recruitment in response to oestrogen. Based on recent reports suggesting a
dynamic recruitment assembly at oestrogen responsive promoters such as pS2
(Shang, Y. et al. 2000; Metivier, R. et al. 2003), a 90 min time course was carried
out to gain insight into the recruitment kinetics of transcription components in the
resistant cell lines. The experiment used the oestrogen sensitive MCF-7 and the
related oestrogen independent LCC-1 and LCC-9 cell lines.
MCF-7 cells were seeded in complete medium, washed in PBS and incubated
in reduced media for 48h to ensure an oestrogen-deprived environment. LCC-1 and
LCC-9 cells were plated directly into reduced media and incubated for 24h. Cells
were treated with 10"7M E2 for a maximum of 90min. DNA-binding proteins were
cross-linked to the DNA with the addition of formaldehyde every lOmin and the
DNA was sonicated into fragments of 500-1 OOObp. Fragments were examined using
specific antibodies to immunoprecipitate acetylated histone H4, ERa and cofactors
SRC-1 and SRC-3. Eleat was applied to reverse crosslinks and DNA purified from
the samples. Quantitative PCR with pS2 specific primers was used to analyze pS2
promoter fragments with binding of the proteins of interest. A graphic representation
of the technique is shown in figure 2.39. For more details of the methodology see
section 4.2.4.
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Figure 2.39: Schematic diagram of ChIP technique. Ac = acetylated histones. See text for details.
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2.5.2 Optimization of ChIP assay
(i) Optimisation of DNA fragmentation
The protocol for this assay is largely based on guidelines published by the cell
signalling company Upstate®. Optimization for use with MCF-7 and MCF-7 variant
cell lines was necessary. DNA fragmentation resulting in the majority of sequences
containing 500-1000 base pairs was essential. Longer fragments would have
increased the background and decreased the solubilization of the chromatin from
ruptured cells. Furthermore, it would have made it difficult to distinguish a DNA
sequence where a particular protein is bound from a nearby promoter sequence
(Aparicio, O. et al., 2004). Shearing of DNA was carried out using different
sonication intensities as well as pulse length for cells of all cell lines. After
sonication and centrifugation, the DNA was precipitated during phenol-chloroform
extraction and the size of DNA fragments was estimated on an agarose gel (for more
details see Materials and Methods (4.2.4 b.)). The desired fragment length could be
achieved with 3 sets of 10 second pulses and the sonicator set to 4Ap as documented
for MCF-7 cells in figure 2.40.
1018bp
507bp
Figure 2.40 : Optimization of DNA fragmentation. Two separate MCF-7 samples, treated with 10 0 M
E2 for 40min, were sonicated SxlOsec at 4pA and phenol-chloroform extracted. Similar experiments
were carried out for other cell lines used in this project.
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(ii) Selection of antibodies for immunoprecipitation
To determine the binding efficiency and concentration of antibodies to be
used for immunoprecipitations was also of fundamental importance. In cross-linked
chromatin, antibody binding may be less efficient because epitopes are less
accessible as binding sites (Orlando, V. 2000). In addition, chromatin
immunoprecipitation is used to precipitate several transcription factors associated
with the chromatin packed promoter. Association of such bound proteins to the DNA
can mask epitopes and produce misleading results where antibodies couple with
freely available proteins while bound proteins remain obscured (Aparicio, O. et al.,
2004). It was therefore essential to identify antibodies that could be used for binding
to components in the chromatin bound complex. For that reason polyclonal
antibodies were the preferred option as such antibodies often recognize multiple
determinants within a protein.
For detection of histone modifications it was important to use antibodies able
to bind to a range of residues as opposed to a specific single residue binding to
increase the probability of identifying the modification. The antibody was required to
identify acetylated isoforms as opposed to methylated or phosphorylated forms.
Modification by acetylation exposes the DNA to restriction enzymes and
transcriptional cofactors and is therefore an indicator of transcriptional activation
(reviewed in Li, Y.-J. et al. 2004). Several antibodies were tested in MCF-7 cells.
Anti-acetylated 114 06-866 was chosen for its binding efficiency and ability to detect
a span of 19 aa, between the amino acids 2-19 (figure 2.41 and 2.42). Similar
experiments were carried out for cofactor antibodies. Optimization for SRC-3 (AIB-
1/RAC3) as an example is shown in figure 2.43. The most efficient binding antibody
identified for anti- SRC-3 was the polyclonal anti-SRC-3 antibody designated RAC-
3 C-20 (figure 2.43 (A)). In addition, concentration curves were constructed to
ensure an excess of antibody in each reaction for optimal binding and precipitation
efficiency. An example is given in Figure 2.43 (B) where the optimal concentration
for each reaction with the SRC-3 antibody was established to be lpg/ml.
Two control samples are included during each immunoprecipitation. The first
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interaction with the protein of interest. The second sample is a parallel
immunoprecipitation with lysates of the parental MCF-7 cell line. The anti-acetylated
H4 antibody was used to ensure successful immunoprecipitation when examining
other cell lines and using other antibodies. This is particularly important for
comparison with precipitation of non-histone proteins where apparent
immunoprecipitation efficiency is much lower.
H4 acetylation at pS2 promoter
H4 06-946 Penta H4 07-323 Lys12 H4 06-866 aa2-19 H4 07-367 Lys20
Figure 2.42: ChIP using 45min 10"7 M E2 treated MCF-7 samples and a variety of Histone H4
antibodies at 5pi/ reaction.
(A) (B)
SRC-3 recruitment to pS2 promoter SRC-3 (RAC3 C-20) recruitment to pS2
promoter
RAC3 C-20 AIB 05-490 AIBMA1-84 0.6ug/ml 0.8ug/ml 1ug/ml 1.2ug/ml 1.4ug/ml
Figure 2.43: A. ChIP using MCF-7 samples treated with 10"7 M E2 for 45min immunoprecipitating
with various anti-SRC-3 antibodies at lpg/ml and B. ChIP using different SRC-3 (RAC3 C-20)
antibody concentrations.
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(ii) Primer design
The pS2 gene is approximately 4.5kb long (reviewed in Ribieras, S. et al.
1998). Its promoter stretches over 980 nucleotides and starts 26 bases away from the
gene start codon (see figure 2.45 (A)). The TATA box and an ERE element are
located at nucleotide positions -26 and -392, respectively, from the gene start. The
primers used in this experiment amplify a region of 352bp within this promoter
starting 93 nucleotides away from the gene start (primers designed and published by
Shang, Y. et al. 2000) (see figure 2.45 (B)). A second set of primers was designed
amplifying a region of 185bp approximately 3kb (nucleotide positions -3446 to -
3946 relative to the gene start) upstream from the gene start to ensure specific
recruitment of the complex to the ERE of the promoter of interest not to more
random regions. This also verifies that the majority of sequences fragmented by
sonication had a length of on average lOOObp. As discussed in 2.5.1 (i), larger DNA
fragments decrease the resolution between the region where a protein of interest is
bound and a region nearby (Aparicio, O. et al. 2004). The expression of this region
was constitutive and largely independent of E2. Some H4 acetylation was detected
although the acetylation state of the region was much lower. This is due to the less
specific binding properties of the histone antibody and the availability of binding
sites on the entire genome (Aparicio, O. et al. 2004). Binding of ERa or any
coactivators could not be detected at this distant site. A representative example of the
analysis of pS2 distant region is shown in figure 2.44.
LCC-9: ERalpha recruitment to region 3kb upstream
of pS2 promoter
.1 20 -
0 10 min 20 min 30 min 40 min 50 min 60 min 70 min 80 min 90min
Figure 2.44: ERa recruitment to a region ~3kb upstream form the pS2 promoter. LCC-9 cells were
plated in reduced medium (5%DCC in DMEM lacking phenol red) for 24h and treated with 10"7M E2.
Chromatin fraction were collected every ten minutes. Each bar represents the mean of at least
triplicate PCR analysis for each sample. Error bars = STD
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(A)





-998 gctccgagca ggggagggga gtgaggcatg gtacaggaga gcaggaggct
-948 gtcctctaaa atacaggagt ccaggggacc aactgggaag gtgtgggagg
-898 gggagggagg gagccccata gacacagggg agtgaaccac gttcactttg
-848 tcagtttttg atggcagctc gtatatacta tttttttctc cctcctgccc
-898 ccagcccctc ccagaaggag acttaatctg tcgctcaggc tggagtgcag
-748 tagggtgatc tcgactcact gcaacctccg cctcccaggt tcaagtgatt
-698 ctcctgactt aacctccaga gtagctagga ttacaggcac ccgccaccat
-649 gcctggctaa tttttgtatt tttttttttt gtagagacgg ggtttcgcca
-598 tgttggccag gctagtctca aactcctgac tttaagtgat ccgcctgctt
-548 tggcctccca aagtgttggg attacaggcg tgagccactg cgccaggcct
-498 acaatttcat tattaaaaca attccactgt aaaagaatta gcttaggcct
forward primer: -407
-448 aqacqqaatq qqcttcatqa qctccttccc ttccccctgc aaggtcacgg
-392
-398 tggccacccc gtgagccact gttgtcacgg ccaagccttt ttccggccat
-348 ctctcactat gaatcacttc tgcagtgagt acagtattta ccctggcggg
-298 agggcctctc agatatgagt aggacctgga ttaaggtcag gttggaggag
-248 actcccatgg gaaagaggga ctttctgaat ctcagatccc tcagccaaga
-198 tgacctcacc acatgtcgtc tctgtctatc agcaaatcct tccatgtagc
reverse primer: atcacc tctaataaca
-148 ttgaccatgt ctaggaaaca cctttgataa aaatcaqtqq aqattattqt
gagtc -94
-98 ctcaqaqqat ccccgggcct ccttaggcaa atgttatcta acgctcttta
-26 +1
-48 agcaaacaga gcctgcccta.taaaatccgg ggctcgggcg gcctctc a(tg)
Gene start
Figure 2.45: A. pS2 gene organisation and regulatory elements. Promoter and distal primer binding
sites are indicated relative to the gene start (+1). B. Nucleotide sequence of the human pS2 promoter.
The ERE is shown in bold. TATA box is underlined. The binding sites for forward and reverse
primers used for ChIP experiments are also underlined (figure source: Lu, D. et al. 2001).
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(iv) Data analysis
After formaldehyde treatment and sonication but before immunoprecipitation
a small fraction of each sample is set aside. These fractions were used as 'input-
controls' and serve as comparison for the immunoprecipitated samples. These
samples should contain not just DNA fragments selected by antibodies against
proteins of interest but the total genomic content. Levels of expression should be
unaffected by the addition of E2 and therefore constant across the sample pool.
Formaldehyde crosslinking was reversed and input samples analysed by RT-PCR
parallel to experimental samples. Examples of input control RT-PCR results are
shown in figure 2.46. Results were then used to normalize experimental samples and
account for variations during material collection.
A common standard curve was used for RT-PCR quantification of
experimental samples in all ChIP experiments to enable quantitative comparison
between cell lines. This curve was constructed using a random MCF-7 input.
Employing the same pS2 primers as used in ChIP analysis, the pS2 fragment was
amplified, identified and excised from a 1% agarose gel. The isolated pS2 fragments
were quantified during a second electrophoretic run with a DNA fragment sizing
ladder. The resulting molecular weight of this PCR fragment was used to generate a
sample containing lxlO10 molecules/pl from which a series of dilutions was establish
for a standard curve.
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Figure 2.46: pS2 DNA expression of two representative sets of input samples. MCF-7 cells were
plated in complete medium (10%FCS in containing phenol red DMEM) for 24h followed by 48h
reduced medium (5%DCC in DMEM lacking phenol red) before treatment with 10"7M E2. LCC-1
cells were plated in reduced medium (5%DCC in DMEM lacking phenol red) for 24h and treated with
10"7M E2. Chromatin fraction were collected every ten minutes. Each bar represents the mean of at
least triplicate PCR analysis for each sample. Error bars = STD.
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2.5.3 Oestrogen modulates dynamic cyclic transcription complex assembly in
MCF-7 cells
In MCF-7 cells without E2 treatment (Omin), low level H4 acetylation was
detected indicating active transcription at the pS2 promoter was detectable (at Omin)
(Figure 2.47). H4 acetylation increased upon E2 treatment after lOmin. Two peaks of
acetylation were observed, at 30min and 80 min, suggesting two acetylation cycles
with a frequency of about 45min within the 90min experiment. Interestingly, during
the initial cycle, the level of acetylation was slightly reduced compared to the
following cycle and the level of pS2 promoter bound to acetylated H4 appeared to
increase in a cumulative manner. Further, during a more detailed time course, the
dramatic increase in H4 acetylation in response to E2 was demonstrated after just 5
min (Figure 2.48). Analysis of samples every 5 min revealed a less efficient subcycle
of H4 acetylation reaching a peak at 10 min and, as observed in the 90min time
course, subsequently at 30 min.
Active pS2 gene transcription paralleled recruitment of ERa and also
coactivators SRC-1 and SRC-3. Addition of E2 stimulated the recruitment of all three
transcriptional components immediately. Within 90min, two cycles of recruitment
were detected for ERa, SRC-1 and SRC-3 although peaks did not always coincide
with H4 acetylation high points. While ERa recruitment peaks roughly corresponded
with H4 acetylation, SRC-1 and SRC-3 promoter occupancy reached a first
maximum slightly earlier at about lOmin for SRC-1 and at about 20min for SRC-3.
The level of recruitment was higher for ERa than the coactivators. Also for ERa,
oestrogen produced the greatest fold-increase: immediately after lOmin (12.5 fold)
and reaching the first peak at 30min (24.2fold). This was due to almost undetectable
levels of ERa recruitment in the absence of the ligand.
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MCF-7: SRC-1 recruitment
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MCF-7: SRC-3 recruitment
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Figure 2.47: H4 acetylation and ERa/SRC-l/SRC-3 recruitment to pS2 promoter in MCF-7 cells.
Cells were plated in complete medium (10%FCS in phenol red containing DMEM) for 24h followed
by 48h reduced medium (5% DCC in DMEM lacking phenol red) before treatment with 10"7M E2.
Chromatin fraction were prepared every lOmin. Data shown are the result of a single collection. Each
bar represents the mean of at least triplicate PCR analysis for each sample. Error bars = STD.
Significant variance between Oh (no treatment) and time points determined by one-way ANOVA and
Dunnets multiple comparison test where *=p<0.05, **=p<0.01. Note: Statistical significance for the
recruitment of SRC-1 is only reached comparing data of all time points with 30min, not the control
group.
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Figure 2.48: H4 acetylation and SRC-1 recruitment to pS2 promoter in MCF-7 cells. Cells were plated
in complete serum (10%FCS in phenol red DMEM) for 24h followed by 48h reduced serum
(5%ssFBC DMEM lacking phenol red) before treatment with 10"7M E2. Chromatin fraction were
prepared every 5min. Data shown are the result of a single collection. Each bar represents the mean of
at least triplicate PCR analysis for each sample. Error bars = STD. Significant variance between Oh
(no treatment) and time points determined by one-way ANOVA and Dunnets multiple comparison test
where *=p<0.05, **=p<0.01.
2.5.4 Oestrogen differentially modulates dynamic transcription complex assembly
in LCC-1 cells
Activation of the pS2 promoter was also revealed to be responsive to
oestrogen in LCC-1 cells (Figure 2.49). H4 acetylation reached at least two peaks, at
30min and at 70 min throughout the time course of 90 min. However, cycles of
transcriptional activation were not as clearly defined as in MCF-7 cells. Oestrogen
mediation on H4 acetylation was less evident reaching first statistical significance at
20min (1.8 fold fold). ERa was recruited to the promoter and association increased
immediately after E2 stimulation (2 fold). Stimulation was weaker than that seen in
the parental MCF-7 cell line (compare tol2.5 fold, see figure 2.47). ERa recruitment
gradually increased to reach a peak at 50 min and decrease up to the 90 min time
point.
In addition to ERa, coactivators SRC-1 and SRC-3 associated with the pS2
promoter upon E2 addition. Compared to MCF-7 cells, higher levels of SRC-1 were
found to occupy the promoter. Elevated levels of SRC-1 protein were present at the
gene at 0 min and E2 promoted further recruitment. Promoter occupancy of SRC-3
was increased upon hormone addition similar to the pattern observed in MCF-7 cells.
Levels of recruitment were slightly higher than in MCF-7 cells.
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Figure 2.49: H4 acetylation and ERa/ SRC-1 recruitment to pS2 promoter in LCC-1 cells. Cells were
plated in reduced serum (5%DCC in DMEM lacking phenol red) for 24h and treated with 10"7M E2.
Chromatin fractions were prepared every ten minutes. Data shown are the result of a single collection.
Each bar represents the mean of at least triplicate PCR analysis for each sample. Error bars = STD.
Significant variance between Oh (no treatment) and time points determined by one-way ANOVA and
Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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2.5.5 Oestrogen modulates dynamic transcription complex assembly in LCC-9
cells with increased pi60 recruitment
In contrast to MCF-7 cells, oestrogen appeared to downregulate H4
acetylation at the pS2 promoter immediately after oestrogen treatment in LCC-9 cells
(figure 2.50). High levels of H4 acetylation were detected initially in the absence of
the hormone. The first nadir in acetylation was reached at 20min (9 fold) followed by
an increase. This acetylation pattern resembles the reverse of gene activation
observed in MCF-7 cells where a high point in transcription was reached at about 30
min.
The active promoter was simultaneously occupied by coactivators SRC-1 and
SRC-3. Both proteins appeared to be present in the absence of oestrogen. Hormone
treatment lead to an immediate dissociation of SRC-1 (3 fold decrease) and SRC-3
(10 fold decrease). After the initial dissociation, a cyclic pattern of recruitment was
revealed. Recruitment peaks for SRC-1 as well as SRC-3 roughly coincided with
peaks of H4 acetylation. Compared to the parental MCF-7 cells, SRC-1 and SRC-3
recruitment levels were decidedly higher. Unlike the coactivator association, the
recruitment pattern of ERa strongly resembled MCF-7 cells where low levels of the
receptor were detected in the absence of the ligand and addition of E2 lead to a
marked increase in receptor binding. ERa recruitment peaks appear to coincide with
the inactive state of the pS2 promoter as well as with low-level recruitment of SRC-1
and SRC-3.
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LCC-9: H4 acetylation
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Figure 2.50: H4 acetylation and ERa/ SRC-1 recruitment to pS2 promoter in LCC-9 cells. Cells were
plated in reduced serum (5%FCS in DMEM lacking phenol red) for 24h and treated with 10"7M E2.
Chromatin fractions were prepared every ten minutes. Data shown are the result of a single collection.
Each bar represents the mean of at least triplicate PCR analysis for each sample. Error bars = STD.
Significant variance between Oh (no treatment) and time points determined by one-way ANOVA and
Dunnets multiple comparison test where *=p<0.05, **=p<0.01.
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2.5.6 ChIP using breast and ovarian tumour samples
To test the feasibility of ChIP analysis in clinical samples, H4 acetylation and
coactivators SRC-3 recruitment were examined in a small selection of ER expressing
human ovarian tumours (figure 2.51). Results revealed remarkable differences in
acetylation as well as SRC-3 recruitment. Highest H4 acetylation in the sample
designated HOV58 was comparable to levels detected in MCF-7 cells. ER protein
content inversely correlated with tumour H4 acetylation. SRC-3 recruitment varied
between non detectable levels and very strong expression in the sample designated
AM.
H4 acetylation and SRC-3 recruitment to pS2 promoter
■ H4 ■ SRC-3
50 -r






HOV 58 36 9
HOV 19 116 4
Figure 2.51: H4 acetylation SRC-3 recruitment to pS2 promoter in human ovarian tumours and
controls (MCF-7 cells treated with 10"7M E2 for 40min). Data representative of two separate PCR
runs. ER and PR status noted in table underneath (fmol/mg protein).
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Summary of fold changes in cofactor recruitment to pS2 promoter
SRC-1 SRC-3
lOmin 20min 40min 80min lOmin 20min 40min 80min
MCF-7 + - - + + ++ + ++
LCC-1 + + + + ++ +++ ++ +++
LCC-9 - - + +
Table 2.6: Summary of SRC-1 and SRC-3 recruitment to pS2 promoter in response to E2 in MCF-7,
LCC-1 and LCC-9 cells. Fold changes are indicated in comparison to time point Oh (no treatment).
+++ = >50 fold increase; ++ = >5 fold increase; + = >1 fold increase; - = >0.5 fold decrease; -- = < 0.1
fold decrease.
2.5.7 Discussion
Studying chromatin regulation and the site of transcription is currently the
centre of much research. This is based on the recognition that chromatin is not just a
way of tightly packaging DNA but a site where complex signals are integrated to
regulate gene transcription. Histone modification by acetylation facilitates DNA
access to restriction enzymes and transcription factors and has been linked to
transcriptionally active chromatin fractions (Li, Y-J. et al. 2004). Proteins such as the
members of the pi 60 family with histone acetylation or deacetylation functions thus
play a vital role in determining transcriptional output.
The technique of chromatin immunoprecipitation enables the detection and
identification of factors involved in gene transcription in vivo. This method allows
for a 'snap shot approach', and a detailed analysis of transcription sites. Activation of
an oestrogen responsive gene pS2 via histone H4 acetylation was examined in
oestrogen dependent MCF-7 cells and compared with oestrogen independent but
responsive LCC-1 and resistant LCC-9 cells. Of particular interest was the
involvement of ERa, the hormone's mediator, and recruitment of cofactors SRC-1
and SRC-3 known to be influenced by oestrogen and known to play a role in breast
cancer. Using a detailed time course, transcriptional kinetics were examined in each
of the cell lines. Differences in transcription factor participation and transcription
complex assembly might help to elucidate ER-mediated gene transactivation in these
tissues.
Much of the current knowledge of transcriptional activation of oestrogen
responsive genes is based on in vitro work with MCF-7 breast cancer cells. It was
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therefore essential to confirm these findings in MCF-7 cells. ChIP analysis
demonstrated a cyclic pattern of H4 acetylation with coordinated recruitment of ERa
as well as coactivators SRC-1 and SRC-3. The ER and both cofactors are recruited
immediatly after hormone addition (see table 2.6). These results suggest the dynamic
assembly of a transcription complex at the pS2 promoter involving the ligand-bound
oestrogen receptor consistent with previously described models (Metivier, R. et al.
2003 and others). Transcriptional activation was less intense in the first of the two
45min cycles. Transcriptional activity was highly regulated by oestrogen. These
results are supported by previous mRNA analysis where not only oestrogen
inducibility was clearly demonstrated but also an accumulation of pS2 mRNA
became apparent in the continued presence of the hormone.
Several researchers have reported immediate acetylation of H4 in response to
oestrogen. An earlier study describes a 5-8-fold increase in acetylation within
minutes for the pS2 as well as MYC and CTSD genes (Chen, H. et al. 1999). An
acetylation peak reached at lh was followed by a reduction. For pS2, promoter
association with SRC-3 as well as ERa was reported. Acetylation of pi 60 proteins by
p300/CBP was suggested to lead to cofactor dissociation. This suggested to lead to
























Figure 2.52: Dynamic model of ER mediated gene transcription (Shang, Y. et al. 2000).
cofactor dissociation. This gave the first indication against constitutive gene
activation but in favour of a dynamic association and dissociation process to regulate
gene transcription. A study comparing ER -positive MCF-7/T5 variant cells with ER
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-negative MDA-MB-231 cells shows an increase in H3 and H4 acetylation in
response to E2 in MCF-7/T5 cells only highlighting the fact that this gene activation
is ER dependent (Sun, J.M. et al. 2001). Others have presented results for oestrogen
responsive genes showing weak ER binding in the absence of the ligand in contrast
with strong enhancement once E2 is added (Shang, Y. et al. 2000; Planas-Silva, M.D.
et al. 2001; Zhang, H. et al. 2004). Studies have since revealed detailed kinetics of
transcriptional activation in MCF-7 cells. Based on ChIP experiments over the
course of 2h and detailed observations of sequential recruitment of transcriptional
factors, a cyclic model of ER transcription was suggested for CTSD (Shang, Y. et al.
2000). In agreement with results in this experiment, acetylation does not return to
baseline after an initial cycle. Two 45min cycles of transcription were proposed (see
figure 2.52). Upon oestrogen addition, the ER binds to the promoter and actively
recruits a histone acetylate transferase (HAT) containing pl60-p300 and a PBP
containing transcription complexes. Following histone acetylation, RNA polymerase
II is recruited and subsequently phosphorylated. Transcription is now active. p300 is
then replaced by CBP, also a histone acetylase, and p300/CBP associated factor
pCAF brought in. Association of CBP leads to the release of pi60 proteins via
acetylation and dissemblance of the transcription complex including CBP and pCAF.
All factors are now available for the following transcription cycle.
When examining such detailed dynamics of transcripiton, it is of concern that
cells are harvested in different functional states particularly since large numbers of
cells are needed for each precipitation. In this project, exact dynamics were not
considered as important as the identification of transcription factors and hormonal
regulation of their recruitment comparing different hormone responsive phenotypes.
However, others have provided further insight into the kinetics of the transcription
process utilizing a-amanitin cell cycle synchronized MCF-7 cells (Metivier, R. et al.
2003). Again, the role of the oestrogen receptor for pS2 transcription initiation in
MCF-7 cells was explored and its involvement verified. A large array of additional
transcription factors involved in active transcription were identified. These included
histone methyltransferases such as CARM1, mediators such as TRAP 150 and
multiple additional general transcription factors such as TBP. An additional initial
cycle was suggested to be transcriptionally silent. This cycle lasted 20min and
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acetylating and dimethylating histones H3 and H4 were at a constitutive level. The
recruitment of distinct HAT and histone methylation transferase (HMT) containing
cofactors in the following two cycles leads to increased histone acetylation and gene
activation. The authors not only confirm the sequential assembly of a transcription
complex but also identify several different complexes. This would suggest that the
rate of transcription is regulated by adaptation of individual cycles of a continuous
gene transcription in response to a changing cell environment and emphasizes not
only sequential but also combinatorial mechanisms of gene transcription. Depending
on transcription factors present and recruitment to the promoter, accessibility of the
gene as well as activation and repression or duration of transcription could be altered
in a short space of time.
Such a mechanism is substantiated by the fact that most transcription factors
were reported to be already present at the promoter in the absence of E2 and were
only further recruitment stimulated by its addition (Metivier, R. et al. 2003). This
was also the case in the current experiment where H4 acetylation and recruitment of
coactivators was detected at low levels in the absence of E2. Other transcription
factors have been shown to associate with the pS2 promoter without E2. Low levels
of acetylated H3 and H4 are maintained without E2 alongside active binding of Spl
family members Spl and Sp3 whose binding sites are found close to ERE sequences,
in MCF-7 cells (Sun, J.-M. et al. 2005). Addition of oestrogen increases acetylation
levels and reduces Spl but not Sp3 binding. In a previous study, the ER is suggested
to alter the balance of HATs and HDACs such as SRC-1 or CBP (Sun, J.-M. et al.
2001). After ER localization to nuclear matrix on ligand binding, the receptor
reorganizes already available transcriptional coactivators to increase the
deacetylation rate. Together this underlines the theory of a dynamic transcription
process where the promoter is in a 'state of readiness' as suggested by the authors.
The sequential and combinatorial transcription model provides the
opportunity to apply the same mechanism as a general model to other gene promoters
as well as tissue types. Each cycle can be continuously adapted to changing
conditions such as binding sequences and spatial organisation within promoters and
can involve different transcription factors. Dynamic recruitment of an ERa
transcription complex has been demonstrated in ECC-1 and Ishikawa endometrial
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carcinoma cells as well as the hepatocarcinoma cell line HepG2 (Shang, Y. et al.
2000 and 2002 (a); Barkhem, T. et al. 2002(a)). The corepressor SMRT potentiates
transcriptional repression in a large transcriptional complex at the thyroid receptor
(Guenther, M.G. et al. 2000). ChIP studies revealed a coordinated recruitment of
SRC-2 and RNA polymerase II in parallel with histone acetylation for androgen
receptor (AR) mediated PSA transcription, a gene coding for the prostate-specific
antigen (Shang, Y. et al. 2002 (b)). Different transcriptional cofactors are recruited to
the promoter of the PSA gene in response to agonist or antagonist bound AR
association. The dynamics of transcription complex assembly are again found to be
similar to ER mediated transcription though with different timing.
Much less knowledge has been accumulated about ER mediated transcription
in hormone independent breast tissue. The results obtained here demonstrated that
the pS2 gene is actively transcribed in a constitutive manner in LCC-1 and LCC-9
cells. Levels of transcription were much higher in oestrogen independent but
responsive and tamoxifen independent LCC-1 cells as well as oestrogen and
tamoxifen unresponsive LCC-9 cells. Oestrogen stimulation of pS2 transcription was
small. This indicated a pS2 transcriptional mechanism different to MCL-7 cells
where the ER is alternatively activated. ChIP analysis of H4 acetylation revealed a
remarkably similar transcription pattern between MCL-7 and LCC-1 cells. Addition
of E2 led to cyclic stimulation of gene transcription. Interestingly, H4 acetylation in
LCC-9 cells was also altered by the presence of E2 although in a pattern opposite to
that seen in MCF-7 or LCC-1 cells. An initial downregulation suggests an
antagonistic effect on oestrogen. Next, involvement of the oestrogen receptor was
examined and also revealed no obvious differences between hormone dependent and
independent cell lines with clear oestrogen stimulation in ER recruitment remaining.
Together, these results demonstrate active pS2 transcription involving ER binding
regulated by E2.
Whether the ER is activated directly by ligand binding, or indirectly through
cross-talk to other growth factor pathways remains a subject of debate. Recruitment
of the ER in oestrogen and tamoxifen sensitive MCF-7 cells but also oestrogen
sensitive and tamoxifen resistant MCF-7/HER2-18 cells has been reported in vitro
and in vivo (Shou, J. et al. 2004). In both models, ER activation took place via
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phosphorylation of Ser-118 but only in the HER2 overexpressing MCF-7 variant
MCF-7/HER2-18 did oestrogen and tamoxifen also induce phosphorylation of
EGFR, HER2, Akt and ERK1/2 MAP kinases. This suggests an indirect path of ER
activation where E2 and tamoxifen activate alternative growth factor pathways,
which then in turn activate the ER via phosphorylation. This could explain the
remaining regulatory effect of E2 on ER mediated gene transcription observed in
hormone independent LCC-1 and LCC-9 models. Such cross talk leading to indirect
118
ER activation has extensively been demonstrated for example by Ser
phosphorylation through the EGFR or HER activated MAPK pathway as previously
discussed ( Kato, S. et al. 1995; Font de Mora, J. et al. 2000). With alternative
receptor activation in place, ER function might not be ER -ligand -binding
dependent. Elevated levels of pS2 expression in the absence of the hormone have
been reported in ERaHA cells, a tet-inducible ERa overexpressing MCF-7 cell line
(Fowler, A.M. et al. 2004). Moreover, pS2 expression levels in these cells were
comparable to expression levels in uninduced control cells in the presence of E2.
Traditionally, ER activation has been linked to transactivation domains AF-1 and
AF-2, the former in a ligand -dependent manner, the latter constitutive. In this
model, pS2 transcription is AF-2 independent but AF-1 dependent and ERa is found
to be strongly bound to the pS2 promoter despite the absence of the hormone. This
transcriptional activation could not be linked to cross-talk to ERK/MAPK pathway
given that MAPK signalling factors Erk and Elkl were not activated. Most
interestingly, ERaHA cells proliferate in the absence of oestrogen which compares
with a static level of proliferation in MCF-7 cells. Together, results indicate that an
increase in cell growth in hormone independent phenotypes might in part be due to
increased unliganded ERa gene expression. This observation correlates with LCC-1
and LCC-9 models where cell growth is similar in the presence and the absence of E2
and ERa mRNA and protein expression is elevated compared to hormone sensitive
MCF-7 cells.
To explain increased ERa AF-1 function, it is speculated that receptor
abundance might stabilize an active receptor confirmation and increase recruitment
and association with various transcriptional cofactors such as the pi60 proteins
(Fowler, A.M. et al. 2004). This would assign such coactivators a critical role in
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ligand independent gene transcription. ChIP analysis presented here does provide
evidence for this suggestion. Coactivators SRC-1 and SRC-3 are recruited to pS2
promoter in both, LCC-1 and LCC-9 cells. The addition of oestrogen leads to an
initial increase in SRC-1 and SRC-3 promoter association although only in LCC-1.
SRC-1 and SRC-3 recruitment in LCC-9 cells is initially decreased upon hormone
treatment as to suggest that both coactivators are strongly associated with the
promoter but easily detached once E2 is present (see comparison in table 2.6). These
coactivators might be associated with other cofactors during the transcriptionally
inactive gene and the absence of E2. Recruitment of ERa in response to E2 arrival
may trigger their release to initiate the assembly of transcription complexes
activating gene transcription. The levels of promoter occupancy for SRC-3 in LCC-1
and both pl60 proteins in LCC-1 and LCC-9 cells were significantly higher than
levels observed in parental MCF-7 cells. Previously, protein analysis showed that
SRC-1 was undetectable in MCF-7 cells but present in LCC-1 and LCC-9 cells
(chapter 2.4). To support this key role for pl60 coactivators, SRC-1 and other
cofactors have been shown to enhance ligand-independent ER mediated gene
transcription (Kalkhoven, E. et al. 1998; Lavinsky, R.M. et al. 1998). More
specifically, SRC-1 and CBP enhance AF-1 activity of the unliganded ERa to
potentiate pS2 gene transcription (Duterte, M. and Smith, C.L. 2003). Coactivator
action is due to interaction with phosphorylation sites in the receptor A/B domain as
well as classical recruitment through the LBD in the E section suggesting a possible
cofactor enhanced synergism between the two receptor domains to mediate ER
transactivation (Onata, S.A. et al. 1998; Benecke, A. et al. 2000).
Several studies propose models where cofactors serve as links not only
between the receptor and other transcription factor but also between different regions
within the promoter or surrounding the promoter. The androgen receptor is recruited
to the promoter of the PSA gene as well as an enhancer region located 4kB upstream
from the starting site (Shang, Y. et al. 2002 (b)). Coactivators such as SRC-2 and
CBP and RNA pol II are also recruited to both regions. Cofactor recruitment and
histone acetylation dynamics were found identical between the two sequences and
PSA mRNA expression detected to correlate with this timing. In addition, SRC-2
mutation studies have shown that the coactivator bound to both, the A/B domain and
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the LBD can also directly enhance AR activity by bridging the two receptor domains
(Shen, H.C. et al. 2005). ER mediated activation of the pS2 gene in HepG2
carcinoma cells is dependent on cooperation between ERE and AP-1 regions within
the promoter (Barkhem, T. et al. 2002(b)). Underlined by the finding that HAT
containing cofactors such as CBP/p300 do not directly interact with the receptor, it
seems plausible to assume that transcription complexes formed at different regions of
the gene are physically brought together to share coactivator proteins to stabilize and
facilitate transcription through a large coactivator complex. Transcriptional response
and pi60 cofactor potentiation might be dependent on the ERE sequence itself
resulting in distinct receptor confirmations and differential cofactor recruitment, but
also the relative position of cooperating elements of the gene. For example,
decreasing the distance between the pS2 ERE and AP-1 site has been reported to
increase transcription (Barkhem, T. et al. 2002 (a)). In the same study, SRC-1 and
SRC-2 mRNA expression was found to be similar. However, distinct functionality
was revealed for the two proteins. This could help to explain observations in this
project where increased pS2 pi60 protein recruitment was observed but not reflected
in mRNA expression. While both, SRC-1 and SRC-2, potentiate pS2 transcription
via ERE and AF-1 motifs, AF-1 deletion resulted in differentially potent gene
activation by SRC-1 and SRC-2. SRC-2 functionality appears less dependent on AF-
1. As discussed during earlier chapters, extensive evidence does suggest pi60
proteins exhibit distinct functionality such as differences in ERa binding affinity
between SRC-1 and SRC-2 (Hall, J.M. et al. 2002).
The concept of chromatin dynamics and the large number of identified factors
involved in ER mediated gene transcription provides insight into the complexity of
transcription. ChIP analysis in this study supports a transcriptional mechanism with
great potential for adaptation according to the gene and its environment. This
posttranslational gene regulation might explain the differential hormone response in
breast cancer tissue, but it is also likely that general features apply to most hormone
responsive genes in eukaryotic cells.
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Conclusion and future studies
3.1 Summary
Oestrogen plays a vital role in the growth and development of the normal
breast but can also mediate proliferation into malignant phenotypes. A major
problem in breast cancer development concerns the changes in phenotype from
hormone dependent to independent growth. Understanding the precise mechanism of
Et action is the basis for advances in endocrine therapies. To help elucidate the
mechanism of hormone resistance this study examined the regulation of E2 mediated
target genes comparing breast cancer cell lines with differential phenotypes
regarding hormone responsiveness. One such gene was selected to investigate
transcriptional activation in response to Et.
A breast cancer cell line model was chosen where classically E2 and
tamoxifen sensitive MCF-7 cells serve as a common parent line for three MCF-7
variant cell lines with distinct phenotypes; LCC-1 cells demonstrated a modest E2
sensitivity and tamoxifen resistance while LCC-1, LCC-9 and LY2 cells showed Ei
and tamoxifen resistance (figure 3.1). This model therefore represents diverse human
breast cancer phenotypes and was appropriate to explore differences in hormone
regulated gene transcription.
The parental MCF-7 cell line clearly differs from all the variant cell lines
examined by its oestrogen and tamoxifen sensitivity with respect to cell growth. The
analysis of ERa and PR expression as well as a series of oestrogen target genes
E2 sensitive
Tam sensitive E2 independent




Figure 3.1 Summary of results: Growth characteristics of MCF-7 and MCF-7 variant cells.
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showed that E2 has profound effects on mRNA and protein expression of these
genes. In the absence of E2, ERa and PR mRNA were expressed at relatively low
levels. E2 greatly reduced ERa and increased PR protein expression. The expression
of pS2, CTSD and MYC mRNA were increased by E2 although the most dramatic
stimulation was observed for pS2 after 48h of hormone exposure (663 fold).
Coactivator and corepressor mRNA were found to be expressed at comparable levels
with relatively small effects being modulated by E2 and tamoxifen with few
exceptions, for example, a strong stimulation of RIP 140 by E2. However, protein
expression revealed marked variations. While coactivator SRC-1 protein could not be
detected, the other pi60 family members, SRC-2 and SRC-3, were expressed
strongly and unaffected by the presence of E2 or tamoxifen. Variations in multiple
protein band expression of RIP 140 in different treatment groups suggested
posttranslational changes. A detailed analysis by ChIP showed cyclic H4 acetylation,
indicative of active pS2 gene transcription, as well as cyclic recruitment of
coactivators SRC-1 and SRC-3 and the recruitment of ERa to the promoter of pS2 in
response E2 as previously reported (Shang, Y. et al. 2000; Metivier. R. et al. 2003).
In the absence of E2, the level of H4 acetylation and the level of ERa and cofactor
recruitment is low.
All variant LCC as well as LY2 cell lines share a characteristic complete E2
independence with respect to cell proliferation. Uniquely, the LCC-1 cell line was
shown to be E2 independent but responsive to the hormone. A small increase in
proliferation was observed in the presence of E2. In common with the other variant
lines, ERa and PR mRNA were expressed at significantly higher levels in LCC-1
cells. Compared to MCF-7 cells, ERa protein expression was much higher but like
the parent line, was reduced to almost undetectable levels in the presence of E2. The
expression of PR protein was high in the presence of E2; tamoxifen also increased
expression of PR protein in LCC-1 cells. This tamoxifen induced expression was not
detected in MCF-7 cells. Most strikingly, pS2 mRNA expression was considerably
higher in the absence of E2 in LCC-1 cells and a comparably small stimulation was
observed once E2 was added. The expression of cofactors RIP140 and NCoR mRNA
were particularly strong in LCC-1 cells. A short term increase in mRNA expression
was observed for all cofactors but SRC-3. A strong induction by E2 was also
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observed for SRC-1 and RIP 140 protein expression. ChIP analysis revealed varying
acetylation and recruitment patterns to the pS2 promoter. H4 acetylation was found
to be in a 'ready state' in the absence of the hormone. Acetylation, ERa and cofactor
recruitment were induced in response to Ei. While the recruitment pattern for both
coactivators was comparable, the level of recruitment was markedly higher,
particularly for SRC-1, compared to MCF-7 cells.
LCC-2 and LCC-9 cells showed many similarities in addition to their
common resistance to E2 and tamoxifen. As with LCC-1 cells, pS2 and MYC mRNA
were expressed at high levels compared to MCF-7 cells in LCC-2 and LCC-9 cells.
E2 mildly increased whereas tamoxifen had no effect on pS2 mRNA expression in
both cell lines resulting in constitutive expression of the gene. Comparable levels of
cofactor mRNA were generally decreased by E2 exposure between 3h and 6h.
Differential expression of cofactor protein was detected also in response to E2 and
tamoxifen. E2 increased the expression of SRC-1 and SRC-3 protein but reduced the
strong baseline expression of SRC-2 in LCC-2 cells. SRC-1 and SRC-3 were
generally expressed at very low levels in LCC-9 cells. LCC-2 and LCC-9 cells could
be clearly distinguished by their ERa but also PR mRNA and protein expression.
Basal expression of ERa mRNA was high compared to MCF-7 cells in both variant
lines and reduced by E2. However, the basal level of ERa protein detected in LCC-2
cells was considerably stronger than in LCC-9 cells. While E2 reduced protein levels
in both cell lines, tamoxifen, which has no effect on protein expression in LCC-2
cells, also reduced ERa protein in LCC-9 cells. PR mRNA was particularly strong in
LCC-9 cells compared to MCF-7 but also LCC-2 cells. The most remarkable
variations occurred on the PR protein level where a uniformly strong band was
revealed across all treatment groups in LCC-9 cells, whereas PR protein in LCC-2
cells could only be detected in the presence of E2. ChIP analysis of the pS2 promoter
in LCC-9 cells showed a distinct pattern of H4 acetylation. Initially high levels of
acetylation were decreased after E2 exposure before recovery into an acetylation
pattern different to MCF-7 cells. Also in contrast to MCF-7 cells, coactivators SRC-1
and SRC-3 were found to occupy the promoter in the absence of E2 and recruited
following E2 exposure in much higher levels. ERa recruitment followed a pattern
similar to MCF-7 cells.
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Unlike LCC-2 and LCC-9, LY2 cells are direct descendants from MCF-7
cells and were derived as a separate branch from all LCC lines (see figure 3.1.1).
Nevertheless, growth phenotype, ERa and PR as well as E2 target gene and cofactor
expression are most similar to LCC-9 cells. Like LCC-9 cells, LY2 cells expressed
higher ERa mRNA than MCF-7 and strong PR mRNA. E2 as well as tamoxifen
reduced ERa protein to non -detectable levels. PR protein expression in LY2 cell was
low irrespective of E2 or tamoxifen presence which stands in contrast to the strong
expression of the receptor protein in LCC-9 cells giving LY2 cells a unique
characteristic. pS2, CTSD and MYC expression levels were most similar to LCC-9
but also LCC-2 cells with generally small effects produced by E2 and tamoxifen,
pi60 coactivator mRNA was expressed at differing levels. SRC-3 expression was
particularly low. Similar to LCC-9 cells, SRC-1 and SRC-3 protein was found to be
scarcely expressed whereas SRC-2 protein expression was particularly strong.
3.2 Conclusions
The key results of this project are summarized in figure 3.2. The
analysed cell lines exhibit distinctively different phenotypes. Where MCF-7 cell
growth was shown to be highly dependent on the presence of E2, LCC-1 cells
exhibited E2 independence but cell proliferation remained sensitive to the hormone
whereas LCC-2, LCC-9 and LY2 cells were E2 independent and were completely
insensitive to E2. (figure 3.2 (C)). The comparison of ERa transcription and
translation between MCF-7 and variant cell lines did not produce any indications that
loss of expression or function of the receptor determines the phenotype of these cells.
However, it is obvious that the expression and the modulation of E2 and tamoxifen
on ERa, PR and several ERa target genes differs between phenotypes (figure 3.2
(B)). Most markedly, expression for all analysed E2 target genes was strongly E2
inducible in MCF-7 cells. In contrast, E2 (and tamoxifen) showed no effect or
relatively small increasing or decreasing effects in all MCF-7 variant cell lines. This
implies profound mechanistic changes in E2 modulated gene expression between
hormone sensitive and hormone insensitive breast cancer cells.
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(A) Transcription complex assembly at pS2 promoter
Coactivator complexes'
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Figure 3.2.: Summary of key results comparing MCF7 with MCF-7 variant cell lines: (A) Transcription complex assembly as
observed by ChlP. H4 acetylation and SRC-1/3, ERa recruitment to pS2 promoter. RE=response element. other cofactors.
See text for details. (B) mRNA expression of E2 target genes at 48h with ( ) and without (—) E2. Scale corresponds to gene/actin
ratio as observed by RT-PCR. (C) Cell proliferation with ( ) and without (0) E2 at day 6. • represents >1000 (xlO4) cells.
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ChIP analysis suggested cell-type specific dynamics of H4 acetylation and
involvement of ERa and pi60 coactivator in transcription complex assembly
irrespective of the cells growth characteristics with respect to hormone sensitivity
(figure 3.2 (A)). Acetylation of histone H4, indicative of active pS2 gene
transcription, in response to E2 was observed in all three cell lines and confirmed to
be of a specific cyclical pattern in MCF7 cells (Shang, Y. et al. 2000). However, in
LCC-1 and LCC-9 cells H4 acetylation appears at a 'steady state' in the absence of
E2 before further recruitment in a distinct albeit unpredictable pattern after hormone
addition. In LCC-1 and LCC-9 cells, higher levels of coactivators recruitment
(indicated by proportionally larger symbols for SRC-1 and SRC-3) were detected,
hormone sensitive and hormone insensitive breast cancer cells or changes in basal
(non-oestrogen stimulated) conditions. Further, levels of cofactor recruitment
particularly SRC-1 did not change between LCC-1 and LCC-9 cells, yet the
dynamics of recruitment were altered. E2 appears to facilitate further recruitment as
the promoter-bound coactivator is initially removed from the site and re-recruited to
high levels by E2.
In all cell lines, transcription is likely to take place by assembly of several
transcription complexes involving a multitude of transcriptional cofactors as
suggested by Metivier. R. et al. 2004 and others. Sequential and combinatorial
recruitment of HATs, HMTs and other mediator proteins into complexes, mediates
posttranslational histone modification and factors of the basal transcription
machinery including RNA pol II initiate active gene transcription. The differential
phenotypes appear to be based on an altered mechanism of ERa mediated gene
transcription. These findings are consistent with evidence of changed dynamics of
histone acetylation and transcription complex assembly.
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3.3 Future directions
Considerable progress has been made in understanding oestrogen mediated
gene transcription. However, the precise mechanism remains elusive particularly
with respect to changes that occur during the acquisition of hormone resistance.
The results described here are based on detailed analysis of a single gene. It
will be important to determine which other genes play an important role in
orchestrating cell proliferation in response to E2. Detailed analysis of MYC or CTSD
using the ChIP technique might confirm the cell-type specific transcription complex
assembly established for the pS2 promoter and help to determine potential promoter
specificity. High levels of cofactor expression has previously been suggested to be
indicative of tamoxifen resistance (Osborne, C.K. et al. 2003). Cofactor knockout
experiments using RNAi would lead to further insight into the differential role of
individual cofactors in transcription complex assembly and reveal functional
significance determining the cells' growth response to E2 and tamoxifen. Knockout
of multiple transcriptional cofactors could indicate potential functional
interdependence or redundancy characteristic for specific phenotypes. Such
experiments also apply to involvement and functionality of ERa. The correlation of
cofactor expression to oestrogen and/or tamoxifen resistance might provide the
opportunity for SRC-1 or SRC-3 to serve as diagnostic markers. This could identify a
subgroup of ER positive patients who fail to respond to endocrine therapy or present
with an acquired tamoxifen resistance during treatment.
The discovery of enzyme families that modify chromatin structure to
facilitate gene transcription created new therapeutic approaches (Spotswood, H.T.
and Turner, B.M 2002). The selective inhibition of HAT and HDAC activity carrying
enzymes might prevent abnormal cell proliferation. Analysis of the effect of HAT
and HDAC inhibitors on pS2 transcription would provide additional information on
the mechanism of histone acetylation and deacetylation to regulate gene
transcription.
ChIP analysis of cells treated with antioestrogens such as tamoxifen would
explore the potential absence of coactivators such as the pi60 family at the pS2
promoter in E2 dependent MCF-7 cells as suggested in previous publications (Shang,
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Y. et al. 2000). Promoter occupancy in the presence of tamoxifen in breast cancer
cells with an acquired hormone independence is currently being studied in our
laboratory.
Finally, preliminary results have shown that ChIP can be applied to examine
breast cancer tumour material. Analysis of pS2 promoter occupancy in response to E2
in a panel of tumour material might offer confirmation of the differential role of
coactivators in E2 in insensitive cells and help identify other factors involved in the
acquisition of hormone independence.
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Materials are listed by technique. All chemicals are from Sigma unless
otherwise stated. All laboratory plastics are from Nuncleon, Life Technologies unless
otherwise stated. Primers and antibodies are listed in the relevant RT-PCR, ChIP and
Western blot method sections.
4.1.1 Cell culture
(i) Cell lines
All cell lines were kindly provided by Dr.Robert Clarke, V.T.Lombardi Cancer
Research Center, Georgetown University Medical School, Washington, D.C., USA.
The MCF-7 cell line was originally established by Dr. Herbert Soule who obtained
the cells from a pleural effusion taken from a patient with a breast carcinoma (Soule,
H.D. et al, 1973). LCC-1, LCC-2, LCC-9 and LY2 cells are sublines of MCF-7 cells
selected in vivo and in vitro for their different oestrogen and antiestrogen
responsiveness (Brtinner, N. et al. 1993a, 1993b, 1997; Bronzert, D.A. et al. 1985).
MDA-MB-231 cells were obtained from the American Type Culture Collection.
(ii) Tissue culture reagents
Cryovials
Tissue culture flasks
Petri dishes and well trays
Waterbath
Trypsin
Phosphate Buffered Saline (PBS)
Foetal calf serum (FCS)
Penicillin/Streptomycin
DMEM growth media +/- phenol red
E2
TAM





Grant Instruments Cambridge Ltd.
Gibco BRL, Life Technologies
Gibco BRL, Technologies
PAA limited
Gibco BRL, Life Technologies
Gibco BRL, Life Technologies
Sigma, Poole, Dorset, UK
Sigma, Poole, Dorset, UK











Chemiluminescence Western Blotting kit
Signal West Femto Maximum
Sensitivity Substrate
Photographic paper: Hyperfilm










Protein G agarose beads
DNA purification kit






Sigma, Poole, Dorset, UK
Qiagen Ltd., Crawley, UK
Qiagen Ltd., Crawley, UK
Rotorgene RG-3000 Corbett Research
















Qiagen Ltd., Crawley, UK










(i) Routine Culture of cell lines
MCF-7 cells were grown in phenol red containing DMEM supplemented with
10% foetal calf serum (FCS) and 1% penicillin/ streptomycin (complete medium).
LCC-1, LCC-2, LCC-9 and LY2 cells were routinely kept in phenol free DMEM
supplemented with 5% dextran activated charcoal stripped FCS (DCC), 1%
penicillin/ streptomycin and 2mM Glutamine (reduced medium). All cells were
grown at 37°C in 5% C02 in a humidified incubator. Media was changed every 2-3
days.
(ii) Cell harvesting
Cells were grown in monolayers to 80% confluence in 75 or 175cm2 flasks.
Confluent flasks were washed in PBS pH 7.3 to remove traces of serum and detached
by incubation at 37° in l-3ml trypsin for 5-10min. Trypsin was inactivated by the
addition of serum- containing media, and cells were pipetted up and down to produce
a single cell suspension.
(iii) Cell storage and recovery from liquid nitrogen
Cells to be stored in liquid nitrogen were trypsinized as above and pelleted for
8min at 1800rpm. Supernatant was removed and cells were resuspended in 3-6ml of
freezing media (10% DMSO in 90% FCS). Cells were transferred to cryovials and
frozen stepwise (30min 4°C, l-2h -20°C, overnight -80°C) before transfer to a liquid
nitrogen tank.
Upon recovery, cells were defrosted in a 37°C waterbath for 1 min and
centrifuged as described above to obtain a cell pellet for resuspension in medium.
Cells were allowed to attach to the flask surface overnight before media was changed
to remove dead cells.
(iv) Cell counting
To determine appropriate cell numbers for experimental set up, cells were
trypsinized and centrifuged as above. The pellet was resuspended in 10ml media and
suspension syringed to break up any clumps. Cells were counted using a
haemocytometer and diluted appropriately for seeding.
211
Materials and Methods
(v) Dextran activation and charcoal stripping of serum
To remove enrichment factors from foetal calf serum for growth experiments, a
charcoal mix was prepared consisting of 5g charcoal and 25mg dextran T70 in 50ml
destilled H2O and stirred overnight at 4°C. On the following day, 1 litre of serum
was heat inactivated at 56°C for 30min. The serum was incubated with 2000U of
sulphatase at 37°C for 2h and the pH adjusted to 4.2 using 2M HC1. The charcoal
mix was added to the serum and left stirring overnight at 4°C. To remove the
charcoal, the mix was centrifuged at 10,000 rpm for 30min at 4°C, the supernatant
separated from the pellet and the pH readjusted to 4.2. A second prepared charcoal
mix was added to the serum for a further 24h incubation at 4°C. To remove the
charcoal, centrifugation as in the previous removal was carried out. A second
centrifugation was added to remove any residual charcoal from the serum. The pH
was adjusted to 7.2 using 2M NaOH. The serum was filter sterilised and aliquots
stored at -20°C.
(vi) Growth assays
To determine the effects of 17P-oestradiol and tamoxifen on cell proliferation,
cells were harvested by trypsinisation and plated in 6 well plates at a density of 2x104
cells per well. MCF-7 cells were seeded in DMEM containing 10% FCS for 24 h.
The media was changed to reduced DMEM with 5% DCC for 48 h. The media was
then replaced with experimental media with or without 10"9 M E2, 10"6 M tamoxifen
or both. This was designated Day O. LCC-1, LCC-2 and LCC-9 cells were seeded in
reduced DMEM containing 5% DCC FCS at the same density. Experimental media
was added after 24h, day 0 of the experiment. For all cells, media was changed every
two days. Cell counts were estimated using a Coulter Counter on Days 0,2,4 and 6.
Cells were washed in 1ml warm PBS pH7.3. PBS was removed from the cells and set
aside. Cells were harvested from wells in 200pl trypsin for 8min at 37°C. After
addition of 1ml of media to each well, the suspension was removed and added to the
PBS set aside previously. Cell pellets were collected by centrifugation for 4min at
1600rpm. Cells were resuspended in 1ml of growth media and syringed to break up
any aggregates before counting 200pl of the suspension in 9.8ml sodium chloride





MCF-7 cells were seeded in T175 flasks in normal DMEM with 10%FBS for 24
h. Cells were then washed twice in PBS and media added to reduced DMEM with
5% DCC for 48 h. The media was then replaced with experimental media with or
without 10"9 M E2, 10"6 M Tarn or both. LCC1,LCC2 and LCC9 cells were
immediately seeded in reduced DMEM with 5% DCC. Experimental media was
added after 24h. All cells were exposed to experimental media for 48h by which time
they had reached about 80-90% confluence.
(ii) RNA extraction
Extraction of total RNA from whole cells was performed using Tri-Reagent
(Sigma, Poole, Dorset) as per manufacturer instructions. Media was removed from
the culture flasks and Tri-Reagent added to the cells (1ml/ 25cm*" flask surface). Cell
lysates were triturated and transferred into 1.5ml Eppendorf tubes. Tri-Reagent was
added (125pl chloroform/ 1ml Tri-Reagent), samples thoroughly vortexed and then
centrifuged at 12 OOOrpm for 15min. The aqueous phase was carefully transferred to
a new Eppendorf and 200pl isopropanol/ml was added and the samples briefly
vortexed. After a 5min incubation at room temperature, the samples were centrifuged
at 12 OOOrpm for 8min at 4°C. The resulting pellet was washed with 75% ethanol by
vortexing and subsequent centrifugation at 7500rpm for 5min at RT, the pellet air
dried for several minutes and resuspended in 50pl ultrapure water. From this point,
samples were kept on ice throughout further processing. RNA concentration was
measured using 5pl of the suspension in 995pil of ultrapure water in a
spectrophotometer.
(iii) Reverse Transcription -Polymerase Chain Reaction
The QuantiTect™SYBR®Green system was used according to the manufacturers
instructions for one step RT-PCR in a total of 15pi reaction volumes including lOpM
each primer and 40ng RNA. Real Time cycler conditions were RT: 50°C for 30min;
PCR: initial activation 95°C for 15min; followed by 40 cycles of denaturation 94°C
for 15sec, annealing 57°C for 30sec, extension 72°C for 30sec; and a final extension
of 72°C for 60 sec. Primer sequences utilized in this experiment were designed using
Primer 3 (Whitehead Institute for Biomedical Research, http://www.genome.wi.mit.edu/cgi-
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bin/priiner/primer3_www.cgi) and synthesized by Cancer Research UK, Clare Hall,
South Mimms, UK. Product sizes were verified by visualisation on agarose gels
(figure 4.1). Sequences, NCBI accession codes and product sizes are listed in table
4.1.







SRC-3 AF012108 F5'CCC TTT TAT CTA CTC TGT CAT C3' 387bp
R5'CCA GAT GTA GAG GAG GAG AC3'
CTSD NM001909 F5'CCC GAG GTG CTC AAG AAC TA3' 195bp
R5TCA CGT AGG TGC TGG ACT TG3'
ERa NM000125 F5'CCA CCA ACC AGT GCA CCA TT3' 107bp
R5'GGT CTT TTC GTA TCC CAC CTT TC3'
ERP NM001437 F5'AGA GTC CCT GGT GTG AAG CAA G3' 143 bp
R5'GAC AGC GCA GAA GTG AGC ATC3'
MYC NM002467 F5TTC GGG TAG TGG AAA ACC AG3' 201 bp
R5'AGC AGC TCG AAT TTC TTC CA3'
NCoR NM006311 F5'AAA GTG TGG AGA CCC AGG TG3' 151 bp
R5"ACC CTC ACT TCA ACG TCC AC3'
p300 BC053889 F5'CTT TCC CAG CCA GCT GTA AAG3' 382bp
R5'CGG TAA AGT GCC TCC AAT GT3'
PR NM000926 F5'GTC AGT GGG CAG ATG CTG TA3' 193bp
R5'AGC CCT TCC AAA GGA ATT GT3'
pS2 NM003225 F5'TTG TGG TTT TCC TGG TGT CA3' 208
R5'CCG AGC TCT GGG ACT AAT CA3'
REA AF150962 F5'CGA AAA ATC TCC TCC CCT ACA3' 396bp
R5'CCT GCT TTG CTT TTT CTA CCA3'
RIP 140 NM003489 F5'CGG AAG AGG CTG TCT GAT TC3' 199bp
R5'AGG GCA TAT CCT TGC TCC TT3'
SMRT NM006312 F5'AAG TCC ATC CTC ACG TCC AC3' 200bp
R5'AAG CAC ACT GGG TCT CTG CT3'
SRC-1 NM147223 F5'CAT GCT TAT GAG GCA GCA AA3' 266bp
R5'ATT CCA GTG CCA AAC TGT C C 3'
SRC-2 NM006540 F5TCT GGA TAC CAG CAC CAT GA37 198bp
R5'GCA ACA AGA GTG CCA TCA GA3'
P-actin BC013835 F5'CTA CGT CGC CCT GGA CTT CGA GC3' 385 bp









lOObp ladder CTSD ERa pS2
(196 bp) (107 bp) (209 bp)
Figure 4.1: Size check for products of specific primers utilized in mRNA analysis. A
representative experiment is shown.
(iv) Statistical analysis
Statistical assistance for these studies was provided by Dr. Robert Rush of
Cancer Research UK. The following equation was used in all mRNA analysis






.x j I y J J
In this equation, z is the mean of the actin corrected sample value; x is the mean
sample value; y is the mean actin value; and Ax and Ay are the corresponding
standard deviations between the triplicate values that make up the means. This
calculation therefore takes both standard deviation of actin as well as the standard
deviation of the generated sample value into account. To determine statistically
significant variance between all treatment groups, the ANOVA test was employed in
all mRNA experiments. The overall p-value is noted on each graph. If a significant
variation had been established, a post hoc test, the Dunnet comparison test, was
employed to identify where differences occurred and compare each of the groups to
the matched untreated control group. This statistical significance was marked with
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asterisks. In some cases groups were compared with one another on an individual
basis using the Tukey/ Newman Keuls multiple comparison test.
4.2.3. Protein detection
(i) Protein extraction
Cells were grown and treated in T175 culture flasks as described under RNA cell
seeding. To isolate protein, cells were washed with ice cold PBS and lysed for 10
min on ice in 750pl/ flask lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150M
NaCl, 5mM EDTA, 1% Triton-X 100, 2 mM orthavanadate, 50mM sodium fluoride,
20mM phenylarsine oxide, ImM PMSF, lOpg/ml leupeptin, lOpg/ml aprotonin,
lOmM sodium molybdate. Cells were scraped from the surface of the flasks and
transferred into Eppendorf tubes, then spun for 6min at 13 OOOrpm at 4°C. The
protein content of the supernantant was determined using a standard Bio-Rad assay
according to manufactures guidelines. Protein extractions were stored at -20°C (or -
70°C for long term storage).
(ii) Western blotting
Protein lysates (lOOpg) were resolved on 7.5-12% SDS-PAGE. Aliquots of equal
concentration were made of protein samples, their volumes equalised and lx loading
buffer (5x buffer: 125mg Tris Base, 1.25g SDS, 6.25ml P-mercaptoethanol. 12.5ml
glycerol. 417pl bromophenol blue solution, made up to a total volume of 25ml with
H20) added. Samples were denatured for 6min at 95°C and loaded onto a 7.5-12%
polyacrylamide gel. Gels were run at 60mA for 35 min followed by 35mA for 4h.
Proteins were then electrophoretically transferred onto permeablised Immobilon-P
membranes at 30V, 4°C overnight. After transfer, membranes were blocked and
probed with primary antibody overnight at 4°C. Immunoreactive bands were detected
using chemiluminescent Western Blotting Kits (ECL or Super Signal West Femto
Maximum Sensitivity Substrate) and photographic paper. Standard molecular weight
markers were used to estimate protein size. Antibodies are listed in table 4.2.
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IgGl Mouse 1 pg/ml BD Biosciences
#610984


































MCF-7 cells were seeded in complete DMEM with 10% FCS for 24 h. Cells
were then washed twice in PBS and media added to reduced DMEM containing 5%
DCC for at least 48 h. LCC-1, LCC-2 and LCC-9 cells were immediately seeded in
reduced DMEM containing 5% DCC. All cells were plated into 92mm petri dishes
and grown to 85-90% confluence. Two dishes each containing approximately lxlO6
were set up for each timepoint. Following the treatment with 10~9 M E2 at various
intervals, cells were cross-linked with 1% formaldehyde for lOmin at 37°C and fixed
with 0.125M glycine on a rocker for lOmin at RT. Cells were then washed with ice-
cold PBS before collection into PBS (lml/plate) containing protease inhibitors
tablets (1 tablet/10ml buffer). Samples were kept on ice at all times from this point.
To prepare for lysis, samples were transferred into 1.5ml Eppendorf tubes and
centrifuged for 4min at 4°C and 2000rpm. The supernatant was carefully aspirated
and pellets resuspended in lysis buffer (50mM TrisHCl pH8.1, lOmM EDTA,
1%SDS), 200pl per dish containing protease inhibitor tablets as above. Duplicate
dishes of the same time point were now combined and left for 1 Omin. Samples were
then sonicated 3xl0sec at 4Ap to shear DNA to appoximately 500-1000bp fragments
followed by centrifugation for 15 min at 4°C and 13 OOOrpm. Supernatants were
collected into 4xl00pl aliquots, the equivalent of 4 immunoprecipitations and snap
frozen at -70°C until use for immunoprecipitation.
b. Verification of DNA fragment size
After sonication and centrifugation as described above, 5gl 4M NaCl was added
to 1 OOpl chromatin mixture (one aliquot of the sonicated sample) and heat treated at
65°C for 4h. To precipitate DNA fragments,lOOpl commercially available phenol-
chloroform solution was added, the sample vortexed for lOsec and spun at 13
OOOrpm for 5min at 4°C. The upper phase was transferred to a fresh tube and lOpl
3M NaAcetate/ 220jil ethanol added. The sample was vortexed and placed in the -
20°C freezer for a minimum of 3Omin. DNA fragments were then pelleted by
centrifugation for 5min at 13 OOOrpm and washed with 1ml of 70% ethanol at RT.
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The air dried pellet was resuspended in 50pl TE buffer. Fragments were visualized
on a 1.5% agarose gel.
c. Immunoprecipitation
One aliquot per time point was diluted lOfold in dilution buffer (16.7mM
TrisHCl pH8.1, 1.2mM EDTA, 167mM NaCl, l.l%Triton, 0.01%SDS). A portion
(3% of input) of this chromatin solution was set aside for quantification of DNA
amount present in each sample. To preclear the chromatin solution and reduce non¬
specific background, 50pl Protein G-Agarose Beads per sample were washed 3x in
lml dilution buffer. To the beads, lpg/reaction anti-rabbit IgG and 2pg/ reaction
salmon sperm DNA was added, the mixture made up to lOOpl with dilution buffer
and aliquoted into Eppendorf tubes. Samples were transferred to the bead mix and
rotated at 15rpm for at least 3h at 4°C. Beads were then pelleted briefly and the
supernatant transferred to newly prepared beads (also 50pl/reaction) containing
salmon sperm DNA and incubated with specific antibodies on a rotator at 12rpm at
4°C overnight. Antibodies are listed in table 4.4.
d. Recovery and PCR
After incubation, beads were washed sequentially with TSE I (20mM Tris HC1
ph8.1, 2mM EDTA, 150mM NaCl, 1% Triton X-100, 0.1% SDS), TSE II (20mM
Tris HC1 ph8.1, 2mM EDTA, 500mM NaCl, 1% Triton X-100, 0.1% SDS) and
Buffer III ( lOmM Tris HC1 ph8.1, ImM EDTA, 0.25M LiCl, 1% IgePal-CA630, 1%
deoxycholic Acid). Bead complexes were then eluted on a rotater at RT with 250pl
freshly prepared elution buffer (1%SDS,0.1M NaHC03) for 30min followed by
15min in 200pl and the supernatants collected into new Eppendorf tubes. To reverse
formaldehyde cross-linking, each sample (as well as input samples) was heat treated
at 65°C for 6h in 25 pi 4M NaCl and 45°C for lh with 32pl of a proteinase K cocktail
(lOpl 0.5M EDTA, 20pl 1M Tris-HCI pH6.5, 2pl lOmg/ml proteinase K). DNA
fragments were purified using QIAquick Spin Kit columns according to
manufacturers instructions and amplified using 2pl of each sample and the
QuantiTect™SYBR®Green system (Qiagen cat#204242) . PCR conditions were:
initial activation of 95°C for 15min followed by 45cycles of 94°C for 15sec, 55°C




(ii) ChIP assay using tumour material
The protocol for this assay is largely based upon a protocol published by Dr.
Peggy Farnham's laboratory at the UC Davis Genome Center in California, USA
(http://genomecenter.ucdavis.edu/farnham/protocol.html). Tumour tissue was thawed
and minced with a razor blade. The tissue was transferred into tubes with srcew cap
lids and a small amount of tissue culture media added. To cross-link, a final
concentration of 1% formaldehyde was added to each sample and the sample rotated
at RT for 15min. A final concentration of 0.125M glycine was added to stop the
cross-linking and rotated for a further 5min. All steps were carried out on ice from
here on forward. Samples were now centrifuged for 4min at 4000rpm, the media
decanted and ice-cold PBS added to wash the tissue. After subsequent centrifugation
and resuspension of the pellet in 1ml of ice-cold PBS, the tissue was liquified for 2x
lOsec using a dounce homogenizer. Tissue was pelleted at 5000rpm for 4min and
resuspended in 1ml lysis buffer (50mM TrisHCl pH8.1, lOmM EDTA, 1%SDS)
containing protease inhibitors ( 1 tablet/1 Oml). Samples were allowed to lyse for
15min on ice before sonication at 4Ap for 3xl0sec to fragment chromatin into 500-
lOOObp pieces. After centrifugation at 13,000rpm for 15min at 4°C, the supernatant
was aliquoted into new Eppendorf tubes containing approximately 0.03 tumour
tissue. Chromatin fractions were snap frozen at -70°C until use for
immunoprecipitation as described in in chapter 4.2.3: i. b and PCR in
chapter 4.2.3; i c.
Table 4.3 Primers used for ChIP PCR










NT030188 F5'CTT GCC TCT GCA TTC TCT CC3' 185bp
pS2 distal
reverse
R5'GAG TTT GGC CTC CCA CAT TA3'
pS2 promoter primers were designed and are published by Shang, Y. et al. 2000.
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Rabbit 5 pi/ rxn Upstate:
# 06-866
SRC-3 Polyclonal Goat 5pi/ rxn SANTA CRUZ











IgG Mouse 5 pi/ rxn Upstate
#05-490
SRC-1 IgGj/K Mouse 5 pi/ rxn Upstate:
#05-522
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